<SEC-DOCUMENT>0001731122-22-001301.txt : 20220809
<SEC-HEADER>0001731122-22-001301.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809163153
ACCESSION NUMBER:		0001731122-22-001301
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		221148849

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e3945_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:avxl="http://anavex.com/20220630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2022_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_avxl_anavex.com_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20211001_20220630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-06-30" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-09-30" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-10-01to2022-06-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012021-06-30" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2021-10-01to2022-06-30" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-10-01to2022-06-30" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:AccruedLicenseFeesPayables" contextRef="AsOf2021-09-30" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20220630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-10-01to2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>&#160;SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20211001__20220630_zm3by6IB47ib"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_909_edei--DocumentQuarterlyReport_c20211001__20220630_zcT5gjM6yyU2"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_907_edei--DocumentPeriodEndDate_c20211001__20220630_zhCi6PXLAXSh"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2022</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_90C_edei--DocumentTransitionReport_c20211001__20220630_z8VGxHe2qRfa"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_902_edei--EntityFileNumber_c20211001__20220630_zwoCkmiy0tIi"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20211001__20220630_zFUNJQHPfe3d"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20211001__20220630_zpcGMhtRDV7f"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
<td style="padding: 0; width: 50%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20211001__20220630_zN6uATFoCFBg"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
Employer</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
or organization)</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20211001__20220630_zBUwjE1qWcZ3"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20211001__20220630_zx8hZQLcAEd3"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20211001__20220630_zxjZJL0sQVY3"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20211001__20220630_zhAo9JJYHkY5"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressCountry_c20211001__20220630_zhu13IOkwRti"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A <span id="xdx_903_edei--EntityAddressPostalZipCode_c20211001__20220630_zvxa3AQoFMF5"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">1-<span id="xdx_90D_edei--CityAreaCode_c20211001__20220630_zsu0laTiikaa"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_900_edei--LocalPhoneNumber_c20211001__20220630_z48TP74y1h9a"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="border-bottom: black 1pt solid; padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Each Class</span></td>
<td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
Symbol</span></td>
<td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding: 0; width: 32%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20211001__20220630_zNIwuDsEbY45"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:Security12bTitle">Common
Stock Par Value $0.001</ix:nonNumeric></span></span></td>
<td style="padding: 0; width: 1%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 32%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20211001__20220630_zcY7VFh7QwV7"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
<td style="padding: 0; width: 1%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 34%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_902_edei--SecurityExchangeName_c20211001__20220630_zAzc6LyWJCR5"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;<b><span id="xdx_90F_edei--EntityCurrentReportingStatus_c20211001__20220630_zNqqzqX4Kuud"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;
No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<b><span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20211001__20220630_zDmL3S5fooc3"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0; width: 26%; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20211001__20220630_z74yFc6jzD5i"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
<td style="padding: 0; width: 2%; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
<td style="padding: 0; width: 44%; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 26%; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
<td style="padding: 0; width: 2%; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntitySmallBusiness_c20211001__20220630_zuEnpjUA2oM5"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20211001__20220630_zRDQmiNDFga9"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
<b>Yes &#9746; <span id="xdx_90A_edei--EntityShellCompany_c20211001__20220630_z9AnfjFMsrS8"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20220809_zSimjifcfZVa"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-08-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></span>
shares of common stock outstanding as of August 9, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I&#160;&#160;&#160;FINANCIAL
    INFORMATION</b></span></a></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 9%">&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002"><b>ITEM
1. FINANCIAL STATEMENTS</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003"><b>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004"><b>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005"><b>ITEM
4. CONTROLS AND PROCEDURES</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006"><b>PART II&#160;&#160;&#160;OTHER
    INFORMATION</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007"><b>ITEM
1. LEGAL PROCEEDINGS</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008"><b>ITEM
1A. RISK FACTORS</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009"><b>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010"><b>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011"><b>ITEM
4. MINE SAFETY DISCLOSURES</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012"><b>ITEM
5. OTHER INFORMATION</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013"><b>ITEM
6. EXHIBIT</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
<td style="padding: 0; line-height: 107%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014"><b>SIGNATURES</b></a></span></td>
<td style="padding: 0; line-height: 107%; text-indent: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
</table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I &#8211; FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Interim Condensed Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">June 30, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
    Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Condensed Consolidated Balance Sheets</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    at June 30, 2022 and September 30, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td></tr>
  </table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_z5YpDNBSisGi" summary="xdx: Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20220630_z7F4aNR3wNib" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210930_zlAOGxtnRJJ2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, <br />
    2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsAbstract_iB_zoyjlEBeRxAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Assets</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zMOaKboOu6zg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current assets</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzHO1_zUPPGnNY5R6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 62%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td>
    <td style="width: 5%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,199,352</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesReceivable_i02I_maCzHO1_zCY8fjD5NgB9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><b>&#160;</b></td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,559,829</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,136,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzHO1_zgbO39cwXfce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">461,963</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,914</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_mtCzHO1_zgtdRkQNVTXb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total assets</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,221,144</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zE4pS5gHOrmh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Liabilities and stockholders' equity</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zoV0wF9P8WV3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maCzEOX_zPbo28BiNke6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,126,892</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,739,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzEOX_zf6YzRcDEvw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities (Note 4)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><b>&#160;</b></td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,913,821</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,614,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeCurrent_i02I_maCzEOX_zA3KASnDFQ8g" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_mtCzEOX_maCz6f6_z0JncoJ55O7b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total liabilities</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,484,544</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,798,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommitmentsAndContingencies_i01I_zQoFbQU7exh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_z9dR8JHBiWXb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stockholders' equity</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20220630_zDmlNRsmsIYh" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930_zflKabY2KyZc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220630_ztQgubU7UxMk" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210930_z0YbPYQrS89d" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td id="xdx_988_eus-gaap--PreferredStockValue_pp0p0_maCzDEE_c20220630_zTmNYMsvpeY4" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">-</span>&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PreferredStockValue_c20210930_pp0p0" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span>&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20220630_zMpDLFsOw6tk" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210930_zybWlbwIsiQk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220630_zkKtEiJXe4if" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210930_zWCgkNx5EYb3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20220630_zv1nMXCEEvV8" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20220630_zykFmNnz5zo" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,568</ix:nonFraction></ix:nonFraction></span></span> common shares</td>
    <td>&#160;</td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt">(September 30, 2021 - <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20210930_zH57BmLdtdP" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20210930_zQLpGP4Ad3ee" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></ix:nonFraction></span></span>)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><b>&#160;</b></td><td id="xdx_989_eus-gaap--CommonStockValue_iI_pp0p0_maCzDEE_c20220630_zVPtxZ4uIWg" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,944</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CommonStockValue_iI_pp0p0_c20210930_zGi99HEaOOHd" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzDEE_zcj6LjDij0Kh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><b>&#160;</b></td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,932,039</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzDEE_zUlLfHO5ToI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">231,273,383</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_iTI_mtCzDEE_maCz6f6_zD7ICXdEprBi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total stockholders' equity</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,736,600</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCz6f6_zR7xBa2XLzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total liabilities and stockholders' equity</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,221,144</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Condensed Consolidated</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Operations and Comprehensive Loss</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three and nine months ended June 30, 2022 and 2021</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td></tr>
</table>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zY3CJlglvMt" summary="xdx: Statement - Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220401__20220630_z4RKT9ewylTd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20210401__20210630_z6wQ5N7ah317" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20211001__20220630_zVdbMx2xEn04" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20201001__20210630_zqsIWwTEw4Oe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">Three months ended June 30,</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zxO7HV9asnP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzcMf_z7yau3W6RNHb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,185,451</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,434,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,167,560</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,138,528</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzcMf_z98KFcAo3Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,273,269</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,964,528</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,534,297</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,610,888</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_iNT_di_mtCzcMf_msCzSwv_zsTXRQxRBBdg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,458,720</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,398,655</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,701,857</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,749,416</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zwUw12bqrN6e" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NonOperatingIncomeFromGrants_i01_maCzf26_z4nUbGTK46t4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,280</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzf26_zVfgFUyP3lb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,432</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,661</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,328,675</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,593,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_i01_maCzf26_z5EOJREW2vmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,917</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,405</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzf26_zgLOpMxpYe0d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange(loss) gain, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">732,549</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">160,880</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,541</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,191</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_iT_mtCzf26_maCzSwv_zsp5xd9V9tAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,800</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,257,514</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,162,539</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,684,257</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzSwv_maCz3eE_maNLACLzhp9_zCaUPl7xIxgi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,278,920</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,141,141</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,539,318</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,065,159</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCz3eE_msNLACLzhp9_zLHJQ8zjGVN4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Income tax expense, current</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,421</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,201</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,269</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--NetLossAndComprehensiveLoss_iT_mtNLACLzhp9_zXqd5rMVSOW1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossAndComprehensiveLoss" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--EarningPerShareBasicAndDilutedAbstract_iB_zrMkpKzl0Vo" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NetLossPerShareBasicAndDiluted_i01_zCqbTzB3kwJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zd8blihBxtBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_i01_zyjyBD75rZhb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,442,236</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,589,651</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,561,940</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,810,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed
Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span style="font-size: 10pt"><br /></span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
    Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Condensed Consolidated Statement of Changes in Stockholders' Equity</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the three months ended June 30, 2022 and 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_zJ7vklo4wMO1" summary="xdx: Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zAFdSQvHZGVl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVklJSPTAMw8" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zVHadGAdMcfe" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zuaM0fH4qpJl" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_4B4_z5oulmh1VT84" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proceeds</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par
Value</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_43B_c20220401__20220630_eus-gaap--StockholdersEquity_iS_z72W7noJUADa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; width: 40%; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
April 1, 2022</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqPSM0sA2oh2" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,161,688</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,163</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,437,616</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,906,042</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,205,041</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued under Sales Agreement</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued under Sales Agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">557,177</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,178,127</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,696</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,582,380</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--LessShareIssueCosts_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
share issue costs</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,361</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,361</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued pursuant to exercise of stock options</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98A_ecustom--SharesIssuedUponExerciseOfStockOptionsShares_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0HMNGnZLBg4" title="Shares issued upon exercise of stock options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptionsShares" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">223,703</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,043</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,267</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988,614</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988,614</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ProfitLoss_zKD66Tf6Wc4" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_437_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zxX2BPxewrC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
June 30, 2022</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTgkczuMkxT9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,568</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,932,039</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">231,273,383</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,736,600</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_438_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zvL3Ur0qGHVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
April 1, 2021</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVsPp2q0D4E7" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,030,620</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,032</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,427,781</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,687,517</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,810,296</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_iP3us-gaap--SharesOutstanding_zXeBTRaDBKu8" style="vertical-align: bottom; background-color: White">
  <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
  issued under Sales Agreement, net of share issue costs</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td id="xdx_98F_ecustom--SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares_iP3custom--SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKml45K0l8m1" title="Shares issued under Sales agreement, net of shareissue costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,082,263</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,082</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,282,225</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,284,307</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
</tr>
<tr id="xdx_40C_ecustom--LessShareIssueCosts_z9rhm7ilFJS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
share issue costs</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,302,826</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,302,826</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_407_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_iP3custom--LessShareIssueCosts_zZe4uC8TG9Wi" style="vertical-align: bottom; background-color: White">
  <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
  issued pursuant to registered direct offering, net of share issuance costs</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td id="xdx_981_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4wldJkd5h3f" title="Shares issued pursuant to registered direct offering, net of share issuance costs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,381</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,997,619</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
</tr>
<tr id="xdx_409_ecustom--LessShareIssueCosts1_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_z751GQnn1twb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
share issue costs</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,095,938</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,095,938</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zGDvvtL6rg9" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued upon exercise of options</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_981_ecustom--SharesIssuedUponExerciseOfStockOptionsShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNYyKAeWAP8e" title="Shares issued upon exercise of stock options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptionsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">305,997</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,300</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,606</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--SharesIssuedPursuantToExerciseOfWarrants_iP3custom--SharesIssuedUponExerciseOfStockOptionsShares_zGuKBTC3dhDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued pursuant to exercise of warrants</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98F_ecustom--SharesIssuedPursuantToExerciseOfWarrantsShares_iP3custom--SharesIssuedPursuantToExerciseOfWarrants_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZtUbfpkfpXf" title="Shares issued pursuant to exercise of warrants, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrantsShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,150</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--ShareBasedCompensation_zEaiIulIf4pk" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,925</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,925</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--ProfitLoss_zYiQjNKEkZr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,180,141</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_435_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zT0vTzlRlk35" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
June 30, 2021</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvBjcPKAT1Vc" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,149,833</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,151</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,938,236</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,867,658</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,145,729</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed
Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
Condensed Consolidated Statement of Changes in Stockholders' Equity</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended June 30, 2022 and 2021</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z60oG6alChNe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zg7zJ9VZlEF4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zFWj0UpZM7Fk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_z9CHUZhT0noi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Additional</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Paid-in</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr id="xdx_431_c20211001__20220630_eus-gaap--StockholdersEquity_iS_z86fxh5Hes76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt">Balance, October 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXvkvu8k18F5" title="Beginning balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueOther_zhI6T0kxczn2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfzyBXAPgz8" title="Shares issued under Sales Agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,980,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,982,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LessShareIssueCosts_za6GAXM2OuEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Less: share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,167</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,167</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zkhlPTgRsUf6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued upon exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedUponExerciseOfStockOptionsShares_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRJpzU271MAf" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptionsShares" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_zKdLej0PwU8l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,336,844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,336,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_zBcRYkT7LK3l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20211001__20220630_eus-gaap--StockholdersEquity_iE_zvEDmyBbs3v6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, June 30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8dQ9cjKXxh9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,932,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">231,273,383</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,736,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20201001__20210630_eus-gaap--StockholdersEquity_iS_zxgqgYWyk4Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, October 1, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0ViBOCAE6Cg" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_ztAaTHYqgk05" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_iP3us-gaap--SharesOutstanding_zjE0TeWvRcel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_iP3us-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPmR7m696D5d" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,107,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,111,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommitmentSharesValue_iP3us-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_zUcMkpjqS5Ec" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--CommitmentSharesShares_iP3custom--CommitmentSharesValue_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmsfBfSTYBbj" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_z0ozIW4wAIU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued under Sales Agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,101,914</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,107,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LessShareIssueCosts_zYfaAQ6CKGmc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Less: share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,437,523</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,437,523</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
  <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to registered direct offering, net of share issuance costs</td>
  <td>&#160; &#160;</td>
  <td style="text-align: left">&#160; &#160;</td>
  <td id="xdx_988_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued pursuant to registered direct offering, net of share issuance costs, shares" style="text-align: right">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,953</ix:nonFraction></td>
  <td style="text-align: left">&#160; &#160;</td>
  <td>&#160; &#160;</td>
  <td style="text-align: left">&#160; &#160;</td>
  <td style="text-align: right">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,381</ix:nonFraction></td>
  <td style="text-align: left">&#160; &#160;</td>
  <td>&#160; &#160;</td>
  <td style="text-align: left">&#160; &#160;</td>
  <td style="text-align: right">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,997,619</ix:nonFraction></td>
  <td style="text-align: left">&#160; &#160;</td>
  <td>&#160; &#160;</td>
  <td style="text-align: left">&#160; &#160;</td>
  <td style="text-align: right">&#160; <span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td>
  <td style="text-align: left">&#160; &#160;</td>
  <td>&#160; &#160;</td>
  <td style="text-align: left">&#160; &#160;</td>
  <td style="text-align: right">&#160; <ix:nonFraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></td>
  <td style="text-align: left">&#160; &#160;</td>
</tr>
<tr id="xdx_404_ecustom--LessShareIssueCosts1_zJz06Y07aUFf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Less: share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,095,938</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:LessShareIssueCosts1" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,095,938</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zhZL4ElGklk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesIssuedUponExerciseOfStockOptionsShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmsX5tv8CGUj" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptionsShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,867,755</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,868,408</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedPursuantToExerciseOfWarrants_zbWtTHy5i7I1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued pursuant to exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesIssuedPursuantToExerciseOfWarrantsShares_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued pursuant to exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrantsShares" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfWarrants" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_zK54cs0nGIkl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_zXyGBt4yKVY" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20201001__20210630_eus-gaap--StockholdersEquity_iE_zg6uMOQhr155" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20201001__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2c2EAHaDlj3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,149,833</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,938,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,867,658</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,145,729</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed
Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
    Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Condensed Consolidated Statements of Cash Flows</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the nine months ended June 30, 2022 and 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zJb0XnwhG0ii" summary="xdx: Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20211001__20220630_ziMk3RJyUgMi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20201001__20210630_zcQBCal2K4yi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zSoPGUMPFmwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_maCzuLj_z5voTNCQsEWl" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,190,428</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_znFpQ88qtpqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_maCzuLj_zGeTI2VAfEO1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,336,844</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,079,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zI4iZxLUrFU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Changes in working capital balances:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzuLj_zGSdSNPp3hak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,577,002</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,751,918</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzuLj_zJD3NjJn9TAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,414</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzuLj_zULEBTU3UPV1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,612,889</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,653</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzuLj_zmfW4pfejaye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,047</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,336,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IncreaseDecreaseInDeferredGrantIncome_i02_maCzuLj_znwj8X7cjjSi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzuLj_maCzdH9_z4JGBmeLg75d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,193,929</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,709,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_z17ZgOo6J28c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash flows provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCz4oB_zwXZ2O9ZoWbk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,982,148</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,218,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCz4oB_zZBzlVekcxxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,802</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,533,461</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromWarrantExercises_i01_maCz4oB_zK5rH0kjFyad" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Proceeds from exercise of warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,466,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCz4oB_zOchq1tPXjse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,868,408</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCz4oB_maCzdH9_ztugZnW9Pzkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,285,536</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,020,193</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzdH9_zCQemzNxxHWf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Increase in cash and cash equivalents during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,091,607</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,311,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zwGh5SJNiJG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, beginning of
    period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zYfTDJJ5aNEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,199,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,560,045</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zW0V65pNqEPb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zNjgOHee7kFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Cash paid for state and local minimum
    income taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">See Accompanying Notes to Condensed
Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLgoFKzLxsKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1 &#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_823_z3PTuESTS5q3">Description
of Business and Basis of Presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
of Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with
high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound
ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central
nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations
in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements
in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the
disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2021 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2021 filed with the SEC on November 24, 2021. The Company follows the same accounting policies in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.</span></p>

<ix:exclude><p id="xdx_23E_z0guco3NnCql" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_233_zj3Hignr4Wqb" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_z8FBh0zYXKEb" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_239_zz8cmOdmxgc3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zoYCI4qwIo8j" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zz2kDvKl6rj2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:exclude><p id="xdx_238_z4v8VMMTthQ" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zs3EVh3aXvgd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_z3eFlhKODzz3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zo5LsLa23sId" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited</span></p></ix:exclude>
<ix:exclude><p id="xdx_230_zko4x2dQ0xx8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:exclude><p id="xdx_23E_zEcBI4MxJNQb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Description of Business and Basis of Presentation</span> &#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zps28Y5f5S9j" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zsGfuletlcD2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
&#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond
the next 12 months after the date that these interim condensed consolidated financial statements are issued. The process of drug development
can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary
depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress
of the Company&#8217;s research and development programs and the level of financial resources available. The Company has the ability
to adjust its operating plan spending levels based on the timing of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the Sales Agreement (as defined below in Note 5), there can be no assurance that additional financing will
be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able
to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all
of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in
the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors, including
the potential future effects of COVID-19, that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates.
To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_236_znYELqVxqR27" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zsLI615kHwKj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_237_zPR9elJwoQyb" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zhEqTAG1ZY75" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zqvbmstDsNdj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zn4biP5Vv9lc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zaTUTiilad3a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z9230eoKRgfh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z3qtxQfkdUo" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_ziyi5sDaTiVg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><p id="xdx_23A_zjlaBBhXZen2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Description of Business and Basis of Presentation</span> &#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles
of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia
Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated
under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
that may be used to measure fair value which are the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - &#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - &#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022 and September 30, 2021, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Basic
and Diluted Loss per Share</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number
of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available
to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive
effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities
and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,194,616</ix:nonFraction></span> (September 30, 2021 &#8211; <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,540,903</ix:nonFraction></span>) potentially dilutive common shares related
to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

<ix:exclude><p id="xdx_239_z0DTEjktxpI6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_231_zVhjijJn2Ss9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zFhehdjgWbb1" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_239_zNpRwojviYQj" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zlWiNamxO7U4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zxf1cXQuMite" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:exclude><p id="xdx_237_zHh3aWpkUJTl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_z9ZTWbnRKGCl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zryLxAXYRH2j" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zHlfi38ImTzi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>
<ix:exclude><p id="xdx_230_z7NPEJQB8EI4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_z2OGcTOgGf47" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z7xuxYhTmh61" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2&#9;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82E_zAeS4gxOqSyc">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrnSjxk9FKFh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_znxLYpWZ61af">Recently
Adopted Accounting Pronouncements</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740 and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s
operations, financial condition, or cash flows.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_803_ecustom--OtherIncomeDisclosureTextBlock_zzZm1O5SAftb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_822_z4X41tOnbOO2">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;&#160;&#160;Grant Income</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2021, the Company received $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_MichaelJFoxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> of a $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_ParkinsonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">995,862</ix:nonFraction></span> research grant awarded by the Michael J. Fox Foundation
for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73
related to Parkinson&#8217;s disease.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2022, the Company did <span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20220401__20220630_zOb9sGlxU7Kh" title="Grant income"><span id="xdx_90D_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20211001__20220630_zDDYDoUqL1vg" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-04-012022-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-01to2022-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t recognize any of this grant on its statements of operations
(2021: $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,280</ix:nonFraction></span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,100</ix:nonFraction></span> respectively). At June 30, 2022, an amount of $<span id="xdx_90A_ecustom--DeferredGrantIncome_c20220630_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span> (September 30, 2021: $<span id="xdx_90C_ecustom--DeferredGrantIncome_c20210930_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded
as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize
this income on its statement of operations as the relating expenditures are incurred to offset the income.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit,
(the &#8220;R&amp;D Incentive Credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended June 30, 2022 the Company recorded research and development incentive income of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">682,432</ix:nonFraction></span> (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-04-012022-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">954,986</ix:nonFraction></span>)
and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,328,675</ix:nonFraction></span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,218,303</ix:nonFraction></span>) (2021: $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,363,661</ix:nonFraction></span> (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-04-012021-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,770,444</ix:nonFraction></span>) and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,593,856</ix:nonFraction></span> (AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,750,539</ix:nonFraction></span>)), respectively, related to the R&amp;D
Incentive Credit for eligible research and development expenses incurred during the period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zEbnwKkJkcY1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4&#9; &#9; &#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82A_zEf0nvcC1Im">Accrued liabilities</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
principal components of accrued liabilities consists of:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zofAQJYzLUP3" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zJFGzxI2vDD2" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20220630_zJmxZ22azvp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210930_zgjOArYxjdS9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">June 30,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_40B_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maCzJSg_maALCzSaG_zRac5IN3zXEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,138,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,035,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedBonusesCurrent_iI_maCzJSg_maALCzSaG_zNBXJ800tLe8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">889,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,201,903</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FixedContractAccruals_iI_maCzJSg_maALCzSaG_zhyBwY25iGi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">649,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedLicenseFeesPayables_iI_maCzJSg_maALCzSaG_zy7280LISuQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued license fees payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:AccruedLicenseFeesPayables" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maCzJSg_maALCzSaG_zRHuQh5sgOCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,050,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,727,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzSaG_znXYB0qE5qgb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: White; text-indent: -10pt">Total accrued liabilities </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,913,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,614,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p id="xdx_8A3_zJy5wECD7XTc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-indent: 0.75in">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_23F_zCaPJplnhYwb" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_z9uB8PAjIWbc" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_231_zZY8V934C8qb" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zytkgD1WrlC1" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zSimQHHImww6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zuMr2H7Vvfr9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zJnz4XsHLvsa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zsB3gup1X8Ic" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z77IKEcytlFa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>
<ix:exclude><p id="xdx_23D_zpk0EHEQ42G9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="avxl:EquityOfferingTextBlock"><p id="xdx_805_ecustom--EquityOfferingTextBlock_zI3gvjmJbt24" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline"><span id="xdx_82D_zrXqiavVlsY4">Equity Offerings</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
shares are voting and are entitled to dividends as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the
&#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant
to which the Company may offer and sell shares of common stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement,
the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted
by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon notice
to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on a commercially reasonable efforts basis
consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of
Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_907_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zPhXlmfMizje" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares
pursuant to the Sales Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution
rights. During the nine months ended June 30, 2022, <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,566</ix:nonFraction></span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_906_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztZUZfpJGtNc" title="Gross proceeds from Issuance Public Offering"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,982,148</ix:nonFraction></span>
(net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z0N81rBaPW0g"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,258,981</ix:nonFraction></span> after deducting offering expenses) (2021: <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,634,576</ix:nonFraction></span> shares were sold for gross proceeds of $<span id="xdx_90D_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjH13dysxIXd"><ix:nonFraction name="avxl:GrossProceedsFromIssuancePublicOffering" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,107,548</ix:nonFraction> </span>(net
proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z8i8iutnnCX" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,670,025</ix:nonFraction></span> after deducting offering expenses)). At June 30, 2022, an amount of $<span id="xdx_908_ecustom--SalesOfAgreementAmount_c20220630_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,410,402</ix:nonFraction></span> (September 30, 2021: $<span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,392,550</ix:nonFraction></span>)
was registered pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.</span></p>

<ix:exclude><p id="xdx_234_z2czfRBsmMm" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_23B_zU0JyENxkNNe" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zgAFRecgJ2e9" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_230_z2ZD0WeCDt4c" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zFSQr9xXUl6" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zTt41ONoeFM1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p><ix:exclude><p id="xdx_231_zrlx9aCHRPzk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
                                            Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zrUktjIJ8yVi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zZH7341anzXh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zxZQ9gTsAwkc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zrO0vp5QAuLj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zPXliYeO4rd5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Equity Offerings</span> &#8211; (continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park,
as amended on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated
to purchase, up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment
fee during the year ended September 30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased,
at the Company&#8217;s discretion, the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022 and September 30, 2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the nine months
ended June 30, 2021, the Company issued to Lincoln Park an aggregate of 4,086,209 shares of common stock including<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Shares issued under Sales Agreement, net of shares issue costs, shares"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,007,996</ix:nonFraction> </span>shares of
common stock for an aggregate purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,198</ix:nonFraction></span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,213</ix:nonFraction></span> commitment shares.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zUkmgXtOrZV" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 &#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline"><span id="xdx_824_zBzixcaVAMh5">Commitments and Contingencies </span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Leases
                                            </i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2022, the Company incurred office lease expense of $<span id="xdx_90C_ecustom--OperatingLeasesRentExpense_pp0p0_c20220401__20220630_zVXelDSDtp78" title="Operating Leases, Rent Expense"><ix:nonFraction name="avxl:OperatingLeasesRentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,015</ix:nonFraction></span> and $<span id="xdx_909_ecustom--OperatingLeasesRentExpense_pp0p0_c20211001__20220630_z1mqR2uyz4Gh" title="Operating Leases, Rent Expense"><ix:nonFraction name="avxl:OperatingLeasesRentExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,348</ix:nonFraction></span> (2021: $<span id="xdx_901_ecustom--OperatingLeasesRentExpense_pp0p0_c20210401__20210630_zaD4miPJIuv" title="Operating Leases, Rent Expense"><ix:nonFraction name="avxl:OperatingLeasesRentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,994</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pp0p0_c20201001__20210630_zQ93tVUH60Rk" title="Operating Leases, Rent Expense"><ix:nonFraction name="avxl:OperatingLeasesRentExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,284</ix:nonFraction></span>),
respectively.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            401(k) Benefit Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States
based employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits
under the Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf
of contributing employees. During the three and nine months ended June 30, 2022, the Company made $<span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,358</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,979</ix:nonFraction></span> (2021: $<span id="xdx_90D_eus-gaap--PensionContributions_c20210401__20210630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,221</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--PensionContributions_c20201001__20210630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,261</ix:nonFraction></span>), respectively, in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Litigation</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of
any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company does not believe
that any of</span> <span style="font-family: Times New Roman, Times, Serif">such pending claims and legal proceedings will have a material
adverse effect on its consolidated financial statements.</span></p>

<ix:exclude><p id="xdx_235_zWwkjIoNVnzc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_235_zEyiDp464GU4" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zLZoDfgIvkXl" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_237_zTl0iwADXWzh" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zH3KouVhzMzf" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zNSBGqyXZJyf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p><ix:exclude><p id="xdx_23C_ztsRGBAtsSV6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
                                            Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z8d0XHZAtU46" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z9ZotYzRo0v8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zqde38o4OCgc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zHxtOrfr1Qc7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><p id="xdx_23F_zH2GNotFAwv3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6&#9;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Share
                                            Purchase Warrants</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zK5wHvBHg8sc" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_z70YmB198CNl" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbGMSNhIGru3" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 1pt solid; width: 26%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3fTEuyi5mV9" title="Weighted Average Exercise Price Balance, at beginning" style="border-bottom: Black 1pt solid; width: 26%; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Share Purchase Warrants Granted" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5RcCHtEpdA8" title="Share Purchase Warrants Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2021</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5eiDf3kky1j" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8Su0NIbLQfb" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.69</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmDf35Q0VM65" title="Share Purchase Warrants Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2021-10-012022-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" contextRef="From2021-10-012022-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zNv0ptqaCx2h" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z4jkyl37RxKb" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AD_zXr7NlRY7Wk9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, the Company had share purchase warrants outstanding as follows</span>&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zMsYB5MDcFyg" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B1_z404gnhCoY16" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9VHEbdWG2S4" title="Exercise Price" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" title="Expiry Date" style="text-align: right; width: 43%"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z8NbKxtdZnuh" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" title="Expiry Date" style="text-align: right"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630_pdd" title="Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_zngh7yVOQCQf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock&#8211;based
                                            Compensation Plan</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2015, the Company&#8217;s Board approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for
the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction> </span>shares, subject to adjustment in the event of a change
of the Company&#8217;s capitalization.</span></p>

<ix:exclude><p id="xdx_23F_zEUhAB2vqe1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_z5mfLCIU6ATj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div id="xdx_230_z1lUz7gXq7G9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zDyMEf0nz3cc" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_230_zqsuKeUNRThf" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zbdx9qCtJYV8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zTFXETqDSzrc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zAJAYQCzzPci" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zy7Bojvv0mWb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zfA0yRAr3Ie9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zx1n7G04tiMh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zKGbkhClGMg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zhXKQRY8DvF" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6&#9;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zDgucKv0jlCi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_235_zGMlLI3IHtHi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock-based
                                            Compensation Plan &#8211; (Continued)</i></span></td></tr></table></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock
options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change
of the Company&#8217;s capitalization.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended June 30, 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span> options previously available under the 2019 Plan and the 2015 Plan became available under
the 2022 Plan (as defined below).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2022, the Board approved the 2022 Omnibus Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders
on May 24, 2022. Under the terms of the 2022 Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction> </span>additional shares of Common Stock will be available for issuance under
the plan, in addition to the shares available under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option
plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2022 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise
price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee
is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s
shares of common stock on the grant date. Stock options may be granted under the 2022 Plan for an exercise period of up to ten years
from the date of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance
with the terms of the 2022 Plan. At June 30, 2022, <span id="xdx_903_ecustom--OptionIssued_c20211001__20220630_zCy7QikHbqnc" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,298,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-06-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,108,453</ix:nonFraction></span> options were available
</span><span style="font-family: Times New Roman, Times, Serif">for issue under the 2022 Plan, subject to stockholder approval.</span></p>

<ix:exclude><p id="xdx_23C_zFlUoYoNhPcf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div id="xdx_234_zA0Bxcx6H5ol" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_z9OFRW5ln3Xi" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23E_zGzbdSsYJWsg" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zctmxWVRd1ri" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zJ0sPLf7hKPg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zQFDKC1ro7Df" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zdcvJtxHBrli" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zs5uaFyrwSZ8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zM8IupaRCOUk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z13qhlLgOEu4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><p id="xdx_236_zlsPRj4NtIA6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zpSoNrAJkxcd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_231_zeoGQIqdL8I2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock-based
                                            Compensation Plan &#8211; (Continued)</i></span></td></tr></table></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of Company&#8217;s outstanding stock options is presented below:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z3RpVtIMXVxj" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_zXcHLOesnPX6" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2020</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW7csxuW2u4k" title="Options Outstanding at beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7S42xtkyY9e" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDovu43sShld" title="Aggregate intrinsic value Outstanding at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,982,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,732,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWo7Hm1SFE7g" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,834</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh40HCrd7f7j" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,421,529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,446,305</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhKCOuPfuv9" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwNcCePmjql" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z43nyzVsP9Kb" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,208,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDW302EiwCWj" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqoNCG0pvAe9" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbd22WklfOO4" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,034,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zba3DJqh9KD6" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6XyoAO0I9b6" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,809,090</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options Exercisable at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,562,530</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.11</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,439,132</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_8A8_zxAdCEvk0cRl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes information about stock options at June 30, 2022 by a range of exercise prices:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPysIElXurS2" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B6_zJpjIQXnZA67" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
    prices</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">life (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of outstanding options" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,903,762</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znyQxmLkyTTf" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.38</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,868,762</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,078,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zW9HrtBWztBi" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.59</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.30</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,058,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.04</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,957,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2E2p7T6fm9i" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.32</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,356,221</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.30</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.09</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,798,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zS4voK6pDsU" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.38</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.05</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,997</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.11</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.58</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,297,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zpfoLjFBhYRb" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.08</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.39</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,750</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.03</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,034,616</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,562,530</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zU2ipszcQbD8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of options vested during the three and nine months ended June 30, 2022 was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220401__20220630_pdd" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.83</ix:nonFraction></span> (2021: $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.16</ix:nonFraction></span>).
At June 30, 2022, the weighted average contractual life of options outstanding was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_z0M2wwhieNDd" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.62</ix:nonNumeric></span> years (September 30, 2021: <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zmCILppq5ra3" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.65</ix:nonNumeric></span> years) and for
options exercisable was <span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_zUpcE52yDoOa" title="Options exercisable"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.21</ix:nonNumeric></span> years (September 30, 2021: <span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zgs3PZs6pVf9" title="Options exercisable"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.80</ix:nonNumeric></span> years).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price
of the Company&#8217;s stock for the options that were in-the-money at June 30, 2022.</span></p>

<ix:exclude><p id="xdx_23B_zaTXEvWTuuV7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div id="xdx_234_zA05mCGfxf4h" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zOrlhayPv1H" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_237_zzEtH7DvMDRd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zHvA88XgRIG4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zSBbwAm7xb5e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p><ix:exclude><p id="xdx_23D_zaDxxdI21M1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
                                            Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zVPmvn0Byfd3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Interim Condensed Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zqTNwlMjYWn4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2022</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zykyTaq9w7b3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zQn9P0Q7Ho6e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:exclude><p id="xdx_239_zIq6tb4MzNGg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6&#9;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zyPwp7ClDhu3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_233_z0qMTWCrfEJc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock-based
                                            Compensation Plan &#8211; (Continued)</i></span></td></tr></table></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended June 30, 2022, the Company recognized stock-based compensation expense of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,988,614</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,336,844</ix:nonFraction></span>
(2021: $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,925</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,079,395</ix:nonFraction></span>), respectively, in connection with the issuance and vesting &#9;of stock options and warrants in exchange
for services. These amounts have been included in general and &#9;administrative expenses and research and development expenses on the
Company&#8217;s statement of &#9;operations as follows:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ6OMAf8vqW8" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zxQqWg1gJINh" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months
    ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine months
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,490,267</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,048,606</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,739,021</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,265,387</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,498,347</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,245,319</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,597,823</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,814,008</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,988,614</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,925</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,336,844</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,079,395</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zTZt5sDBAkK8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
amount of approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630_pp0p0" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,276,312</ix:nonFraction> </span>in stock-based compensation is expected to be recorded over the remaining term &#9;of such options
through fiscal 2025.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award granted during the three and nine months ended June 30, 2022 and 2021 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2021-10-01to2022-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9doc0ils37e" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zbUynMVHmZqd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zc2QyWVE6FZ1" title="Risk-free interest rate" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.10</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210630_ze8xOE24DzWj" title="Risk-free interest rate" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.71</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zSPFF48pCIg1" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-01to2022-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.51</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_z42JGOJBRUka" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2020-10-012021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.66</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_zIyV5jZrco1d" title="Annualized volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.12</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210630_zksKYXLCc5me" title="Annualized volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.87</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_zXC4piOcNug2" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-01to2022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210630_zNJdFZDYkbQc" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-012021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AA_zbiVlCUIx3wg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock compensation charges recognized during the three and nine months ended June 30, 2022 and 2021 was determined with
reference to the quoted market price of the Company&#8217;s shares on the grant date.&#160;</span></p>

</ix:nonNumeric><p id="xdx_814_zVr0kHBfZq7h" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forward-Looking
Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained
in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone events,
future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements.
The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221; and
similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
in our stock and in the markets in general;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to successfully conduct clinical and preclinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to generate any revenue or to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to execute our research and development plan on time and on budget; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
products&#8217;&#8217; ability to demonstrate efficacy or an acceptable safety profile of our product candidates; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain the support of qualified scientific collaborators; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved
for sale; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to identify and obtain additional product candidates; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
reliance on third parties in non-clinical and clinical studies; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to defend against product liability claims; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to safeguard against security breaches; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain and maintain sufficient intellectual property protection for our product candidates; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to comply with our intellectual property licensing agreements; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to defend against claims of intellectual property infringement; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to comply with the maintenance requirements of the government patent agencies; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to protect our intellectual property rights throughout the world; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition;
</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
anticipated start dates, durations and completion dates of our ongoing and future clinical studies; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
anticipated designs of our future clinical studies; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of fast track designation on receipt of actual FDA approval; </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates,
including any orphan drug or fast track designations; and </span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
anticipated future cash position.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about future events, including the responses
we expect from the U.S. Food and Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and financial trends that
we believe may affect our financial condition, results of operations, business strategy, preclinical and clinical trials, and financial
needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation
the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and
Exchange Commission on November 24, 2021. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include
additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and
rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk
factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as
required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Anavex&#8221;
mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Current Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying
precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data from clinical
studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative
and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead compound, ANAVEX<sup>&#174;</sup>2-73, is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially
other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder
caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two core programs and two seed programs. Our core programs are at various stages of clinical and preclinical development,
in neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes key information about our programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><img src="image_001.jpg" alt="" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*
= Orphan Drug Designation by the FDA; Dashed lines indicate planned clinical studies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is
an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional regulation
at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability
of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron
Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor
occupancy (RO) with S1R in the brain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Source:
Reyes S et al., Sci Rep. 2021 Aug 25; 11(1):17150</i>s</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cellular
Homeostasis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like
Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In
neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated
buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic finding in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking,
folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible to imbalances that
result in aggregation and degeneration in nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence
of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases
known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73,
our approach is to restore cellular balance, i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the
potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific
Biomarkers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
full genomic analysis of Alzheimer&#8217;s disease (AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification
of actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. It is expected that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant improved
functional and cognitive scores.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73, which are considered independent of AD pathology,
as well as multiple endpoints and time-points, provides support for precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73
by using genetic biomarkers identified within the study population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73
treatment in AD as well as indications like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>&#174;</sup>2-73
is currently studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Studies Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alzheimer&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73
in mild-to-moderate Alzheimer&#8217;s patients. This open-label randomized trial met both primary and secondary endpoints and was designed
to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1
and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular
homeostasis and to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic
(PK) and pharmacodynamic (PD) data from the Phase 2a study, which established a concentration-effect relationship between ANAVEX<sup>&#174;</sup>2-73
and study measurements. These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive
and functional scores as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>&#174;</sup>2-73
activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately
twice as long as the parent molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
consecutive trial extensions for the Phase 2a trial have allowed participants who completed the 52-week PART B of the study to continue
taking ANAVEX<sup>&#174;</sup>2-73, providing an opportunity to gather extended safety data for a cumulative time period of five years.
In August 2020, patients completing these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73
through the Australian Government Department of Health &#8211; Therapeutic Goods Administration (TGA) compassionate use Special Access
Scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August
2018. The Phase 2b/3 study enrolled 509 patients for 48 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or
placebo. The trial commenced in Australia; and during fiscal 2020 additional regions were added in the United Kingdom, The Netherlands,
Germany and Canada. The ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified
in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. Primary and secondary endpoints will assess safety and both cognitive and functional
efficacy, measured through Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating
&#8211; Sum of Boxes for cognition and function (CDR-SB). The study completed enrollment in June 2021, exceeding the 450 patient enrollment
target at 52 sites across North America, Europe and Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, we initiated a long-term open label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD study, for
patients who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years
and will give patients the opportunity to continue their treatment. Upon request by patients, caretakers and investigators, this extension
study was extended by one further year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rett
Syndrome </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease.
The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017, we were awarded
a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial
of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly instalments which commenced during
fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment
of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions, utilizing a convenient
oral liquid once-daily formulation of ANAVEX<sup>&#174;</sup>2-73.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first Phase 2 study, (ANAVEX&#174;2-73-RS-001), which took place in the United States, was completed in December 2020. This trial was
a randomized double-blind, placebo-controlled safety, tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>&#174;</sup>2-73
formulation in 25 adult female patients with Rett syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific
genomic precision medicine biomarkers. The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was
well-tolerated and demonstrated dose-proportional PK (pharmacokinetics). All secondary efficacy endpoints of the trial showed statistically
significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire (RSBQ AUC) Total scores, when compared to
placebo, in the ITT cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically
significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants, p = 0.011).
ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement (CGI-I) scores throughout
the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73
clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements
in the prespecified efficacy endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second, international study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR study, commenced in June
2019. This study took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 study for Rett syndrome.
The study was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Following
the successful completion of the U.S. Phase 2 Rett syndrome study (ANAVEX&#174;2-73-RS-001), and the knowledge gained from it, the endpoints
for the AVATAR study (ANAVEX&#174;2-73-RS-002) were appropriately updated according to ICH guidelines and were approved by the U.K. Medicines
and Healthcare products Regulatory Agency (MHRA) and in Australia by the Human Research Ethics Committees (HREC), where the AVATAR study
was conducted. Subsequently the AVATAR study was updated from a Phase 2 to a Phase 3 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data of the AVATAR study was released in February 2022. The study met all primary and secondary efficacy and safety endpoints, with consistent
improvements in primary efficacy endpoint, RSBQ AUC (p = 0.037) response, and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I
(p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome
symptoms. Convenient once daily oral liquid doses of up to 30mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the study are eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol, which is currently ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we commenced the third study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE study.
This Phase 2/3 study in pediatric patients with Rett syndrome will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in
approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>&#174;</sup>2-73 specific
precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under
a voluntary open label extension protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Parkinson&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease,
which demonstrated significant improvements on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by
the Michael J. Fox Foundation. Additional data announced in October 2017 indicates that ANAVEX<sup>&#174;</sup>2-73 induces robust neurorestoration
in experimental Parkinsonism. The encouraging results we have gathered in this model, coupled with the favorable profile of this compound
in the Alzheimer&#8217;s disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for
Parkinson&#8217;s disease dementia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s
disease. The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
this study ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful,
dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis.
Treatment with ANAVEX<sup>&#174;</sup>2-73 also resulted in clinically meaningful improvements as measured by the global composite score
of Parkinson&#8217;s disease symptom severity, MDS-UPDRS Total score on top of standard of care including dopaminergic therapy, levodopa
and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential global capability
of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. The study confirmed the precision medicine approach of
targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, we announced we were awarded a research grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s
Research&#160;(MJFF) to develop ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson&#8217;s disease. The award will explore utilization
of PET imaging biomarkers to enable measurement of target engagement and pathway activation of the sigma-1 receptor (SIGMAR1) with clinically
relevant doses in people with Parkinson&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Frontotemporal
Dementia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we commenced the First-in-Human Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously
granted orphan drug designation for the treatment of Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally
administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
In preclinical studies, ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s
disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial
dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 1 clinical trial was a prospective double-blind, randomized, placebo-controlled study. A total of 36 healthy male and female subjects
were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability,
and pharmacokinetics (PK) of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study met its primary and secondary endpoints of safety, with no serious adverse events (SAEs) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the study, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
pharmacokinetics. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug
and food had no effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The study also met the secondary objective of characterizing
the effect of ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (ECG) parameters. There were no clinically significant ECG parameters throughout
the study. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into
a biomarker-driven clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer&#8217;s disease, evaluating
longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of these studies could serve as the basis for
advancing into respective registration studies in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical study indications, and several
other compounds in different stages of clinical and pre-clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary SIGMACEPTOR&#8482; Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding
of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature,
including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands,
sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development)
of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related
cellular processes, in order to ensure survival and replication. Hence, it is possible that S1R could play a role in modulating the cellular
response to viral infection and ameliorate pathogenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compounds
that have been subjects of our research include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73
<i>(blarcamesine)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related improvements in an array of
behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org,
ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced
pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73
for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic oral
dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease
mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the core
deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related improvements
in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and
infantile spasms, respectively. In November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation
for the treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments
for rare pediatric diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in February 2020, the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment
of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address
unmet medical needs in the treatment of serious and life-threatening conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Parkinson&#8217;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal model
of Parkinson&#8217;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory
endpoints. In October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s
disease. The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study found that ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically
meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system
analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after
submitting the results of the study to the FDA to obtain regulatory guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Alzheimer&#8217;s disease (AD) animal models, ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral evidence
as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1
receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual
mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic AD animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73
induced a statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as
significantly increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It
also statistically alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of
spatial working memory and long-term spatial reference memory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG)
parameters. ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and
reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease.
The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients
with mild-to-moderate Alzheimer&#8217;s disease. ANAVEX<sup>&#174;</sup>2-73 is an orally available drug candidate that restores cellular
homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the
course of Alzheimer&#8217;s. The Phase 2a study met both primary and secondary objectives of the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes
were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data in
patients exposed to ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that study participants
with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population worldwide, demonstrated improved cognitive
(MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have been used to establish a precision medicine approach
in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in clinical studies with
ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the Human
Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week
safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in
Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates inclusion of genomic
precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The Phase 2b/3 study, which commenced in October
2018, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo, completed enrollment in June 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data also validates ANAVEX<sup>&#174;</sup>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s
disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome,
multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant improvements
in all of these indications in the respective preclinical animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development
of audiogenic seizures. The results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in
many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses.
ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental
and neurodegenerative disorders like Angelman and Fragile X syndromes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes during
pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data on ANAVEX<sup>&#174;</sup>2-73 related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons
in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;).
TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence
of seizures. The preclinical data demonstrates that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly increases survival and reduces
seizures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX<sup>&#174;</sup>3-71</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71
is a clinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation,
which has been shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable
potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses against the major Alzheimer&#8217;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on
inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation
and M1 muscarinic allosteric modulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant reduction
in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the
FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of Frontotemporal dementia (FTD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
pathological conditions ANAVEX<sup>&#174;</sup>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis) without
causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s
disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that in addition to reducing
oxidative stress, ANAVEX<sup>&#174;</sup>3-71 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions,
which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, we commenced the first Phase 1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The study took place in Australia and was
a double-blind, randomized, placebo-controlled, Phase 1 trial to evaluate safety and tolerability, and pharmacokinetics (PK) of oral
escalating doses of ANAVEX<sup>&#174;</sup>3-71 including effects of food and gender in healthy volunteers The study met its primary and
secondary endpoints of safety, respectively with no serious adverse events (SAEs) or dose-limiting toxicities observed, as more fully
described above under <i>Clinical Studies Overview &#8211; Frontotemporal Dementia</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into
a biomarker-driven clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer&#8217;s disease, evaluating
longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. Anavex believes the results of these studies, could serve as the basis
for advancing into respective registration studies in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX<sup>&#174;</sup>1-41</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>1-41
is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration
or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.
In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis
(programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory. These
activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes during
pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX<sup>&#174;</sup>1066</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>1066,
a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction
injury model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive
threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained
significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory
agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control
levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit
with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX<sup>&#174;</sup>1037
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<sup>&#174;</sup>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity
for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced
pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without
affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications
highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma
receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an
important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body),
angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our programs
and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license, or otherwise
transfer our intellectual property to further our goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Target Indications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed compounds with potential application to two broad categories and several specific indications. including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central
Nervous System Diseases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
    disease &#8211; In 2022, an estimated 6.5 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s
    Association<sup>&#174; </sup>estimates that by 2050, this number will rise to 12.7 million Americans. Medications on the market today
    treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. There is an
    urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>

<tr style="vertical-align: top">
    <td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&#8217;s
    disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and
    slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter
    dopamine. Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically middle-aged and elderly people. The
    Parkinson&#8217;s disease market is expected to expand to $11.5 billion by 2029, according to business intelligence provider GBI
    Research.</span></td></tr>

<tr style="vertical-align: top">
    <td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rett
    syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain
    develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis.
    It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males
    have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways.
    Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting
    nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping problems,
    seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depression
&#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for depression
is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately 75% of total sales. However,
the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epilepsy
&#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient
signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control
and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication
that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers
in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic
drugs.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of
the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications.
Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="padding: 0; width: 28px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; width: 24px; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malignant
Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment,
chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected
to grow to $6.4 billion by 2027.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system.
The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics
for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of pancreatic
cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according to the American
Cancer Society. Sales predictions by FutureWise forecast that the market for the global pharmaceutical treatment of pancreatic cancer
will increase to $4.7 billion by 2027.</span></td></tr>
</table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents,
Trademarks and Intellectual Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold ownership or exclusive rights to fifteen U.S. patents, sixteen U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73 and certain anticholinesterase inhibitors composition and method
for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73 directed to a novel and synergistic neuroprotective
compound combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire in June 2034, absent any patent
term extension for regulatory delays. We own three issued U.S. patents each with claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73.
The first of these three patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms and compositions containing crystalline
ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using them. This patent is expected to expire in July
2036, absent any patent term extension for regulatory delays. The second of these three patents claims pharmaceutical compositions containing
a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using the compositions. This
patent is expected to expire in June 2037, absent any patent term extension for regulatory delays. The third of these three patents claims
pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s
disease using the compositions. This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays.
We also own two issued U.S. patents for seizure treatment. The first of these two patents claims methods and dosage forms for treating
seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active
metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. The second of these two patents further claims a combination
seizure treatment involving administration of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;
</sup>and ANAVEX 2-73<sup>&#174;</sup>. Both patents are expected to expire in October 2035, absent any patent term extension for regulatory
delays. We also own two issued U.S. patents with claims directed to treating neurodevelopmental disorders. These patents claim methods
for treating a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. Both
patents are expected to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued
U.S. Patent with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is
expected to expire in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims
crystalline forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays. Further, we own one issued U.S. Patent with claims directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73
.. This patent is expected to expire in July 2038, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own two issued U.S. patents related to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or
preventing pain using (+) ANAVEX<sup>&#174;</sup>1066 isomer. The second patent claims methods for treating or preventing pain using (-)
ANAVEX<sup>&#174;</sup>1066 isomer. Both patents are expected to expire in November 2036, absent any patent term extension for regulatory
delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted
or pending applications in Australia, Canada, China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to ANAVEX<sup>&#174;</sup>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71
compound and methods of treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in
April 2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South
Africa, which are expected to expire in January 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own other patent applications directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide
additional protection for one or more of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual property
rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and confidential information
by means of carefully considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure
agreements and provisions for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements
provide some form of recourse in the event of disclosure, or anticipated disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on
November 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating costs consist primarily of research and development activities including the cost of clinical studies and clinical supplies
as well as clinical drug manufacturing and formulation. Research and development expenses also include personnel related costs such as
salaries and wages, and third-party contract research organization (CRO) expenses in support of these clinical studies. Personnel costs
include salaries and wages, benefits, and non-cash stock-based compensation charges associated with options and other equity awards granted
to employees and consultants who are directly engaged in support of our research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of personnel costs, expenses for outside professional services and expenses associated with operating
as a public company. Personnel costs consist of salaries and wages, benefits and stock-based compensation for general and administrative
personnel. Outside professional services and public company expenses include expenses related to compliance and reporting, additional
insurance expenses, audit and SOX compliance, expenses associated with patent research, applications and filings, investor and shareholder
relations activities and other administrative expenses and professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the three and nine months ended June 30, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended June 30, 2022, we continued to advance enrollment of our EXCELLENCE international Phase 2/3 pediatric
Rett syndrome clinical trial at new clinical sites in the United Kingdom and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our double blind, placebo-controlled Phase 2b/3 study for the treatment of Alzheimer&#8217;s disease the last patient visit
was completed end of June 2022. We expect to announce top line data from that study in the second half of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also recently completed this quarter the last patient visit with respect to the 48-week open label extension of the Phase 2 clinical
trial in Parkinsons Disease Dementia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we continued to run open label extensions of our recently completed AVATAR study and the Phase 2b/3 Alzheimer&#8217;s disease study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the third quarter of
fiscal 2022 were $12.5 million, compared to $11.4 million for the comparable third quarter of fiscal 2021. Total operating expenses for
the nine-month period ended June 30, 2022 were $35.7 million compared to $29.7 million for the same period in fiscal 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $3.2 million for the three months ended June 30, 2022, as compared to $2.4 million for the third quarter
of fiscal 2021. Similarly, general and administrative expenses were $9.2 million for the nine months ended June 30, 2022, as compared
to $6.1 million for the nine months ended June 30, 2021. The increase in general and administrative expense is primarily related to (i)
an increase in non-cash stock option compensation charges of $0.4 million and $2.5 million, in the three and nine month periods respectively,
in connection with the vesting of stock options to an expanding team, (ii) an increase in corporate insurance costs and (iii) an increase
in intellectual property professional fees to maintain our strong patent positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses for the three months ended June 30, 2022 were $9.3 million, as compared to $9.0 million for the three
months ended June 30, 2021. Our research and development expenses were $26.5 million for the nine-month period ended June 30, 2022, as
compared to $23.6 million for the comparable nine-month period in 2021. The increase in research and development expenses is primarily
driven by an increase in non-cash stock option compensation charges of $1.3 million and $4.8 million in the three and nine month periods
respectively, associated with an expanding team directly engaged in support of ongoing research and development activities. For the nine-month
period ended June 30, 2022, this increase was partially offset by a decrease in clinical trial expenditures over the comparable period,
associated with the completion of the enrollment and recruitment activities for our Phase 2b/3 trial in Alzheimer&#8217;s disease, and
manufacturing activities in the comparable period associated with the Rett syndrome program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
income (net)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of other income for the three months ended June 30, 2022 was $0.2 million as compared to $1.3 million for the comparable three
months ended June 30, 2021 and $2.2 million for the nine-month period as compared to $3.7 million for the comparable nine-month period
in fiscal 2021. The decrease in other income for the three-month period is partially related to differences in foreign exchange fluctuations
of the Australian dollar against the US dollar as they relate to incentive and tax receivables denominated in Australian Dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
well, the decrease in other income for the three and nine-month periods is attributable to a decrease in Australian research and development
incentive income in connection with the decrease in eligible clinical activities in Australia over the comparable period such as the
completion of the ANAVEX<sup>&#174;</sup>3-71 Phase 1 clinical study and other Australian arms of ongoing clinical programs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss for the third quarter of fiscal 2022 was $12.4 million, or $0.16 per share, as compared to $10.2 million, or $0.14 per share in
the comparative third quarter of fiscal 2021 and $33.7 million, or $0.44 per share, for the nine-month period ended June 30, 2022, as
compared to $26.2 million, or $0.39 per share in the comparative nine-month period ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working
Capital</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June
                                            30,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">160,221,144</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">161,616,490</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,484,544</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,798,386</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,736,600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,818,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, we held $153.2 million in cash and cash equivalents, an increase of $1.1 million from September 30, 2021. Cash used in
operations was $20.2 million for the nine-month period ended June 30, 2022, compared to $22.7 million in the comparable nine-month period
ended June 30, 2021. We received cash from financing activities of $21.3 million, primarily from the issuance of shares of common stock
under the Sales Agreement (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71,
and to perform work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Nine months ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(20,193,929</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(22,709,166</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,285,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,020,193</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,091,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,311,027</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
flow used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the nine months ended June 30, 2022 was $20.2 million, compared to $22.7 million during the comparable
nine months ended June 30, 2021. The principal reason for this decrease in net cash used in operating activities in the current period
is due to the receipt of research and development incentive tax refunds during the period, as compared to no such receipts during the
comparable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
flow provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the nine months ended June 30, 2022 was $21.3 million, primarily attributable to cash received from
the issuance of common shares at various market prices under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the nine months ended June 30, 2021 was $151.0 million, net of financing costs, attributable to
cash received from the issuance of common shares at various market prices under the 2019 Purchase Agreement, the Sales Agreement and
a direct registered offering that was completed for net proceeds of $46.9 million, after deducting expenses associated with the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controlled
Equity Offering Sales Agreement </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, we entered into an Amended and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp;
Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell shares of common stock registered under
an effective registration statement from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents
may sell shares of common stock by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law,
including negotiated transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales
Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain
conditions. The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales
practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the Sales Agents commissions for their services of 3.0% of the gross proceeds from the sale of the shares pursuant
to the Sales Agreement. We have also agreed to provide the Sales Agents with customary indemnification and contribution rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended June 30, 2022, 1,623,566 shares were sold pursuant to the At-the-Market Offering for gross proceeds of $21.0 million
(net proceeds of $20.3 million after deducting commissions and offering expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that
are material to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CRITICAL
ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United
States of America, and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses,
and the related disclosures of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe
are reasonable in the circumstances. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the
year ended September 30, 2021 as filed with the SEC on November 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Note 2 &#8220;Recent Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements included
in this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be
disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods
specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated
to our management, our chief executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer
and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined
in Rule 13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation,
our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective
as of June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended June 30, 2022, there were no changes to our internal control over financial reporting identified in management&#8217;s
evaluation pursuant to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>PART
II &#8211; OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company
or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors, officers
or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or has a material
interest adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes to the risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on
Form 10-K for the fiscal year ended September 30, 2021 filed with the SEC on November 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities
Act of 1933 that were not previously reported in a Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>ITEM
6. EXHIBIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: black 1pt solid; width: 11%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
</b><br /> <b>Number </b></span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 89%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br /><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)
</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles
of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed
on November 24, 2021)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws
(incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31)
</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3945_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3945_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32)
</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3945_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 100%; font-weight: normal; text-align: center; font-family: Calibri Light; color: #2F5496"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext"><b><span id="a_014"></span>SIGNATURES</b></span></td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: center; text-indent: -36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX
LIFE SCIENCES CORP. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0; width: 50%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Christopher
Missling, PhD</span></td>
<td style="padding: 0; width: 50%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling,
PhD</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
Officer)</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">Date: August 9, 2022</td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0; width: 50%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/Sandra
Boenisch</span></td>
<td style="padding: 0; width: 50%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA,
CGA</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial
Officer</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial
and Accounting Officer)</span></td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">Date: August 9, 2022</td>
<td style="padding: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e3945_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I, Christopher
Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three and nine months ended June 30, 2022 of Anavex Life Sciences Corp.
(the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding: 0; text-indent: 0">Date: August 9, 2022</TD>
<TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher Missling, PhD</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Secretary</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e3945_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
31.2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three and nine months ended June 30, 2022 of Anavex Life Sciences Corp.
(the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding: 0; text-indent: 0">Date: August 9, 2022</TD>
<TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra Boenisch</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e3945_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three and
nine months ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; text-align: justify; padding: 0; text-indent: 0">Dated: August 9, 2022</TD>
<TD STYLE="width: 50%; border-bottom: black 1pt solid; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher Missling, PhD </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer) </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 50%; border-bottom: black 1pt solid; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %. G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"M0!9HJOYMS_S[+_W\_P#K4>;<_P#/LO\ W\_^M0!8HJOYMS_S[+_W\_\
MK4>;<_\ /LO_ '\_^M0!8HJOYMS_ ,^R_P#?S_ZU'FW/_/LO_?S_ .M0!8HJ
MOYMS_P ^R_\ ?S_ZU'FW/_/LO_?S_P"M0!8HJOYMS_S[+_W\_P#K4>;<_P#/
MLO\ W\_^M0!8HJOYMS_S[+_W\_\ K4>;<_\ /LO_ '\_^M0!8HJOYMS_ ,^R
M_P#?S_ZU'FW/_/LO_?S_ .M0!8HJOYMS_P ^R_\ ?S_ZU'FW/_/LO_?S_P"M
M0!4NM>M;.YD@D$A>,J#C&.?Q]_Q[9-$6NV\P+1Q3E%+!F"#"@'&3SW/XU))
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M_P#K4 6**K^;<_\ /LO_ '\_^M1YMS_S[+_W\_\ K4 6**K^;<_\^R_]_/\
MZU'FW/\ S[+_ -_/_K4 5[O6K6QO!;W#,AV!RW&T MM&><]?;%,_M^R(4HSN
M#Y?0=GZ'_/J/6IF21Y"[62%SMRWF<_*<CMV/-5FTN!SDZ9%G.21)@M[$CJ..
MAXH L6VJPW<%M+&DNRX8JA*],9ZX/'2KU9JV>U(5%H=L#;XP;EC@_P!?I5KS
M;G_GV7_OY_\ 6H L457\VY_Y]E_[^?\ UJ/-N?\ GV7_ +^?_6H L457\VY_
MY]E_[^?_ %J/-N?^?9?^_G_UJ +%%5_-N?\ GV7_ +^?_6H\VY_Y]E_[^?\
MUJ +%%5_-N?^?9?^_G_UJ/-N?^?9?^_G_P!:@"Q66GB*P:4QL[(WF&,!@/F.
M0.,'U/UJYYMS_P ^R_\ ?S_ZU5VM0T9C-A'L(((\SU.3V]: (9/$EE'&),2L
MI7<"%'/S[,<GUJ^ETKW;V^R1650^XC@@^AK/.E0'[NFQIZ".8H >#D 8P>!R
M*LQPO%<R3I:8EE #GSR<XZ<=* +U%5_-N?\ GV7_ +^?_6H\VY_Y]E_[^?\
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M,B2\@JBX((W=&YR,?6CZK2[?B_\ ,/;S[_@CHO['F_Z"E[_WT/\ "C^QYO\
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MTY,-VC^!ESXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\
MH%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_
M /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG
M^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_O
MFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\
MH%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_
M /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG
M^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_O
MFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\
MH%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_
M /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG
M^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_O
MFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\
MH%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_
M /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_OFCDPW:/X!SXGO+\2]_PG
M^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\ H%W/_?-'_"+:W_T"[G_O
MFCDPW:/X!SXGO+\2]_PG^O\ _/U%_P!^5H_X3_7_ /GZB_[\K5'_ (1;6_\
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MTB183'Y:H(_NC(/!SG/'>J'_  BVM_\ 0+N?^^:J,*'51_ B4\1]ER_$O?\
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M?Q'YOY4?[/WC^ ?[1VE^(R^\0Z[8W:)_;$[NBC(P@'0'D?CWQ50>*M=",O\
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M+-*<R2-QGT '8"N3%.ARKDW\CKPBK\SY]O,TZ***X#T HHHH **** "BBB@
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MJIPV/E,9_P#9:0Z=,%!_MO6.>P"?_$U/'?ZM$NU?#S@9S_Q]Q5$UQJC2;_\
MA'YLYSQ>Q@?SIOV]M&O_ "4%[&^J?_DPATV<?\QO6#] G_Q-*=*G '_$\U8Y
M]/+_ /B::9=3/_, N/\ P/3_ !H\W4_^@!<?^!R?XTO]H[Q^^(_W':7W2%_L
MV?&?[;UC'/:/_P")I/[.F_Z#>L?7"?\ Q-.,^J%=O]@3XP!_Q_1]OQIOFZGS
M_P 2"X_\#D_QH_VCO'[X@O8=I?=(/[.G R=;UC\H_P#XFN-U_7=8TK6[BS@U
M:Z:.(KM+[=W*@\\>]=M%=ZK$Q*^'Y2<8YO8S_6N1UWPKKVL:S<7R:<(EF((0
MSH2,*!US[5V8.ZF_;N-K>1QXQ7@O8J5[^9C?\);KO_04G_\ '?\ "C_A+==_
MZ"D__CO^%6?^$#\0?\^2?]_D_P :/^$#\0?\^2?]_D_QKT>;#?W?P/.Y<3_>
M_$K?\);KO_04G_\ '?\ "C_A+==_Z"D__CO^%6?^$#\0?\^2?]_D_P :/^$#
M\0?\^2?]_D_QHYL-_=_ .7$_WOQ*W_"6Z[_T%)__ !W_  H_X2W7?^@I/_X[
M_A5G_A _$'_/DG_?Y/\ &C_A _$'_/DG_?Y/\:.;#?W?P#EQ/][\1;/7O$5\
ML[1:I,/)3=R!\Q]!QUX/Y5<^V>)?,5?[9?:S ;\# !7)/3MC!]Z@A\'>)[=0
ML-N$ </Q,GWAT[U*WA?Q8T4L1B^25MS@3(,GCWXZ#I4-T;Z./X&B5:VJE^(D
M6H>))'*MJ\B +U('WLD%>G4;320ZMKLJ)(VO-'$[% S  [@,E<8],?F*<?"_
MBPD$P@X8N 98\9(P3U]*C?P?XGDA,+6J>5Q\@EC"C!SP,\=32O1[Q_ +5NTO
MQ&S:WKR+*T&M2W'ER>60BCGKTXYZ<TZ+6-=F\G;KDH:96959 #@<>GUIK>"_
M$CP)"UG&8TSM'F1Y&>O.<T]/"7BA'5UMDW*H53YD9V@=,>E.]"V\?P"U>^TO
MQ%M-2\2742N=7EA+,5"R*!Z>W^UQ]*$U37WCCD77'V2N(XR5ZMSP>..5_6F1
M^#?$T7E;+91Y3^8G[Y/E;CGK["I1X7\5@ "!0!RH$D?RGGD>AY/3UI-T>CC^
M )5NJE^(VUU+Q)<[%.K2Q2.'94=1G:OWCT_SBHIM<UZ*U:<:U(Z!48 +@E6S
M@]/8U+!X3\56R!(8 @!)&)H\C.,\Y[X%#^$O%$D;HUK&4< $>9'T'0>V/:G>
MC?>/X!:M;:7XF;_PENN_]!2?_P =_P */^$MUW_H*3_^._X59_X0/Q!_SY)_
MW^3_ !H_X0/Q!_SY)_W^3_&KYL-_=_ SY<3_ 'OQ*W_"6Z[_ -!2?_QW_"G)
MXPUU'#?VE,<=B%(_E4__  @?B#_GR3_O\G^-.3P#K[.JM:HBD\L9E./?K0Y8
M;^[^ U'%?WOQ-NS\2WM_9!H=0F5U/SY6/<#Z?=QC\*?)X@U592XOGQC&S8FW
MIC^[GWZT6OAN]LK5HX-/E^7J2\>Z0^OWOYXI)-!U9MF+"0[^O[Q/E^OS?RS7
M'_LU]+'7_M-M;E23Q)K*1E!J,F<YW>7'GZ?=Q5=_%VN+(K"_.% &TQ)AOKQF
MK4GAC66:0"P;Y<X/F)AOI\W\\54E\):X45AIS$L3\OFQY'U^:M(_5>MC.7UK
MI<K-XSU]0R_VBQW'[QACR/I\M/7QGKQ9"=0/R]1Y4?S?7Y?Y8I'\$Z^9646'
M"Y.[SDP?ISFA?!NOK'N.G-G.-OG1Y^OWL5I_L?\ =,_]L_O$Z>+M<._.H-\W
M3]U'\OT^7^>:E7Q3K3*@_M!_EZD11Y;Z_+_*HU\'ZX)0AL>,9W^:F.GUS^E2
M)X6UL1ECIS@@XV^;'D^_WL4G]4\BE];\R=?$NL,[M]O?# @+Y:87Z?+_ #S6
MUX?\32M/'9ZBSRF0G9<$ 8/96  Q[&L9/#.L!T4V+88 EO,3"_7YOY9K9T'P
MNY<7&K0E#&^8H2X(;'\38R.O09^M<]?ZMR/EM?R.C#_6>=<U[>9UM%%%>6>H
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ^+O%
M^J:/K\EI9O"(5C5@&CR<GKS7?5YGXXT;4KWQ-)-:V%S-$8D >.,D9Q79@HPE
M4M/:W4X\;*<:=X;WZ"/XM\5QG#Q1@[0W^I'0@D=_8_E3/^$R\3Y<;8,H,L/+
M7Y?KSQ5*VL_$$$;I)I5],'(!+HV=H!&!Z=:2XT[6IY+E_P"Q;T&XCV$%"=O(
M/''M7H^SHWVC^!YOM*UMY?B7CXS\3B7RRL._;NV^4.GKU]Q0?&?BA4D<QQA8
M_OGR/N]/?W'YU0&FZS]N%R=&O?\ 5JA14(!  '/'(..E3+;Z\@0+HMT B>6%
M\MMN-^[&/3'R_2G[.CVC^ >TK=Y?B6SXO\5*0#%&"3C'D#_'V--_X3+Q1@G9
M%Q_TQ'IGCGGCGBHV36C=_:5T"[60KL^ZQ&W<6].N3^E1&VUMI()6T.[,T .Q
MMA R0 21CVSBI4*7\L?P'SU?YI?B6E\8^*6EDB6*,R1D!U\CE<],\U7?X@:_
M&2&DM@1_TR!_K4JG7A*9/["N<DY;Y&RV"",\=@,5CS>'M9ED9AI5\-W]Z,D_
MR%5&G1?Q*/X$RJ5U\+E^)T5QXPUFW.#>Q2!54RO%8LRQDC.TG/) ZXK235]7
MD *Z]IFTJ'5C;, P(!X_ BJME=W=F59/#.J*S1JDZ(V(YB%VY9=OI4C7LA*[
M?!MVH4!5 R,   #ITP*X'"=](K_R4])3I6UD_P 2Y%>:[.F^/7=+*\G)MV'3
MZTXW.OAE4ZWIF6SC_1VJG_:=U@ >$[X $' )['Z4XZM=EBQ\)7VX]\GKC'IZ
M5FXU_P"6/_DH<]/^9_\ DQ;,^OC.=;TOC_IW:EED\1Q0/)_;.E-M0MM$)R>,
M^M4_[7O"NP^$KTKG=WZYSGIZU7N+NYF5]OA2_21@?G!.>^.W3)IQC6O[T8_^
M2@YT[?$__)C&'Q#UT@'S+?\ [\__ %Z7_A86N_\ /2W_ ._/_P!>LH>&]9
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MW^)J_P#"PM=_YZ6__?G_ .O1_P +"UW_ )Z6_P#WY_\ KUE?\(WK/_0*O/\
MOT:/^$;UG_H%7G_?HT>RPW9?@'M<3W?XFK_PL+7?^>EO_P!^?_KT?\+"UW_G
MI;_]^?\ Z]97_"-ZS_T"KS_OT:/^$;UG_H%7G_?HT>RPW9?@'M<3W?XFK_PL
M+7?^>EO_ -^?_KT?\+"UW_GI;_\ ?G_Z]97_  C>L_\ 0*O/^_1H_P"$;UG_
M *!5Y_WZ-'LL-V7X![7$]W^)J_\ "PM=_P">EO\ ]^?_ *]'_"PM=_YZ6_\
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M7/BJ>&5-O1/R.C"U,2ZB6K7F=Y1117C'M!1110 4444 %%%% !1110 4444
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MWPW_ ,57.?V3J/\ T#[S_OPW^%']DZC_ - ^\_[\-_A1]7P_9!]8Q'=G1_\
M"RM8_P">-E_WPW_Q5'_"RM8_YXV7_?#?_%5SG]DZC_T#[S_OPW^%']DZC_T#
M[S_OPW^%'U?#]D'UC$=V='_PLK6/^>-E_P!\-_\ %4?\+*UC_GC9?]\-_P#%
M5SG]DZC_ - ^\_[\-_A1_9.H_P#0/O/^_#?X4?5\/V0?6,1W9T?_  LK6/\
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MN3_SS/\ A1]FG_YX3?\ ?L_X5ZWU/#_R_BSR_KF(_F_!?Y'<?\+1D_Z!:_\
M?_\ ^QH_X6C)_P! M?\ O_\ _8UP_P!FG_YX3?\ ?L_X4?9I_P#GA-_W[/\
MA1]3P_\ +^+#ZYB/YOP1W'_"T9/^@6O_ '__ /L:/^%HR?\ 0+7_ +__ /V-
M</\ 9I_^>$W_ '[/^%'V:?\ YX3?]^S_ (4?4\/_ "_BP^N8C^;\$=Q_PM&3
M_H%K_P!__P#[&C_A:,G_ $"U_P"__P#]C7#_ &:?_GA-_P!^S_A1]FG_ .>$
MW_?L_P"%'U/#_P OXL/KF(_F_!'<?\+1D_Z!:_\ ?_\ ^QH_X6C)_P! M?\
MO_\ _8UP_P!FG_YX3?\ ?L_X4?9I_P#GA-_W[/\ A1]3P_\ +^+#ZYB/YOP1
MW'_"T9/^@6O_ '__ /L:/^%HR?\ 0+7_ +__ /V-</\ 9I_^>$W_ '[/^%'V
M:?\ YX3?]^S_ (4?4\/_ "_BP^N8C^;\$=Q_PM&3_H%K_P!__P#[&C_A:,G_
M $"U_P"__P#]C7#_ &:?_GA-_P!^S_A1]FG_ .>$W_?L_P"%'U/#_P OXL/K
MF(_F_!'<?\+1D_Z!:_\ ?_\ ^QH_X6C)_P! M?\ O_\ _8UP_P!FG_YX3?\
M?L_X4?9I_P#GA-_W[/\ A1]3P_\ +^+#ZYB/YOP1W'_"T9/^@6O_ '__ /L:
M/^%HR?\ 0+7_ +__ /V-</\ 9I_^>$W_ '[/^%'V:?\ YX3?]^S_ (4?4\/_
M "_BP^N8C^;\$=Q_PM&3_H%K_P!__P#[&C_A:,G_ $"U_P"__P#]C7#_ &:?
M_GA-_P!^S_A1]FG_ .>$W_?L_P"%'U/#_P OXL/KF(_F_!'<?\+1D_Z!:_\
M?_\ ^QH_X6C)_P! M?\ O_\ _8UP_P!FG_YX3?\ ?L_X4?9I_P#GA-_W[/\
MA1]3P_\ +^+#ZYB/YOP1W'_"T9/^@6O_ '__ /L:<?B;<#&='ZXQ^]/.>G\-
M<,MM+O7?;S[<_-B,YQ6T=6=WWMI\^5!\L!3A2#F,_P# <D5,L)06T?Q*CBZ[
MWE^'_ .@7XE73<+HK$]>)"?_ &6@?$NY8@#1B2<X E/..O\ #7-MJ+MY>+*Z
M A5DC.TYVLFWG\>?Q-/BU1HH1&-/N#Y4>R'*$\$#=N^I&>*GZK2_D_'_ ()7
MUJM_/^'_  #?'Q.F.<:2#MZ_OCQ]?EI?^%F7&<?V.<Y(QYI[=?X:YN&],37
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M '[/^%'V:?\ YX3?]^S_ (57U/#_ ,OXLGZYB/YOP1W'_"T9/^@6O_?_ /\
ML:Z7PQXEM->M2L2+;SQ#YK?/0=B/45Y%]FG_ .>$W_?L_P"%=EX%\+7,EW'J
MMR9+>*(YB495I#[_ .S_ #KGQ.&H0IMK1F^&Q6(G42>J/16B1W1F4%D.5)['
M&/Y&GT45XY[(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<_\ /M/_ -^F_P */L=S_P ^T_\ WZ;_  H^J8?M^+#ZYB/YOP1VO_"T9_\
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ML,-V0>WQ/=G1?\+-U3_GSL_R;_&C_A9NJ?\ /G9_DW^-<[_PC^K_ /0+O?\
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M*CE'812[4QN/EMQ^E2!)!Y>8I?WGW/W;?-SCCBCZOANR^_\ X(_K.)[O[O\
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MW^3_ !H_X0+Q!_SYI_W^3_&B^%_N_@'^U_WOQ&_\)UX@_P"?X?\ ?E/\*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI]W_ %\QWJ=E_7R-3^TK+_G\M_\ OZO^-']I67_/Y;_]_5_QK+_X0GP[_P!
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M 4444 %%%% !1110 4444 <SXJ_Y#7AO_K^_]E-=-7,^*O\ D->&_P#K^_\
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MY^KC_OZW^-4E/R^[_@DN4%T?W_\  .AN?#GB6ZM$@DTB4;7W9!4# 4*% SP
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MN=\5IIPM;==<S<(TF(D2 D[L>Q]*YK[)X3_Z!=W_ . DO_Q5=,:;G!:/[O\
M@G-*IR3>J^__ (!Z/Y\7_/5/^^A1Y\7_ #U3_OH5YQ]D\)_] N[_ / 27_XJ
MC[)X3_Z!=W_X"2__ !5/ZL^S^[_@B^L>:^__ (!Z/Y\7_/5/^^A5*UTW2K2Q
M^QQ16_V?<6V/A@3GW_3T %<+]D\)_P#0+N__  $E_P#BJ/LGA/\ Z!=W_P"
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M_P!>@"Q15?RKG_GY7_OW_P#7H\JY_P"?E?\ OW_]>@"Q15?RKG_GY7_OW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTR!\Q)/3IDDUC?\ "=:+_P ]I_\ P'?_  H_X3K1?^>T_P#X#O\ X4?5ZO\
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M6TVI72LR:C.H5E3+W#C);./Y4^:?=!RPVLQG]A:M_P! R]_\!W_PH_L+5O\
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M ]C[3SZ7.GHHHKQ3V@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ G # 2(  A$! Q$!_\0
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M+DD# DY#<<'!KG?B#8^,K/0=&M1J=_/)L:2YN8-P1K@DL5?8,A #M0>W/.*
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M_P _-C_X"BO,** /3_\ A?OCK_GYL?\ P%%'_"_?'7_/S8_^ HKS"B@#T_\
MX7[XZ_Y^;'_P%%'_  OWQU_S\V/_ ("BO,** /3_ /A?OCK_ )^;'_P%%'_"
M_?'7_/S8_P#@**\PHH ]/_X7[XZ_Y^;'_P !11_POWQU_P _-C_X"BO,** /
M3_\ A?OCK_GYL?\ P%%'_"_?'7_/S8_^ HKS"B@#T_\ X7[XZ_Y^;'_P%%'_
M  OWQU_S\V/_ ("BO,** /3_ /A?OCK_ )^;'_P%%'_"_?'7_/S8_P#@**\P
MHH ]/_X7[XZ_Y^;'_P !11_POWQU_P _-C_X"BO,** /3_\ A?OCK_GYL?\
MP%%'_"_?'7_/S8_^ HKS"B@#T_\ X7[XZ_Y^;'_P%%'_  OWQU_S\V/_ ("B
MO,** /3_ /A?OCK_ )^;'_P%%'_"_?'7_/S8_P#@**\PHH ]/_X7[XZ_Y^;'
M_P !11_POWQU_P _-C_X"BO,** /3_\ A?OCK_GYL?\ P%%'_"_?'7_/S8_^
M HKS"B@#T_\ X7[XZ_Y^;'_P%%'_  OWQU_S\V/_ ("BO,*4#--)O8#T[_A?
MOCK_ )^;'_P%%'_"_?'7_/S8_P#@**\S$1-#1E:T]A4M>PKH],_X7[XZ_P"?
MFQ_\!11_POWQU_S\V/\ X"BO,**R&>G_ /"_?'7_ #\V/_@**/\ A?OCK_GY
ML?\ P%%>844 >G_\+]\=?\_-C_X"BC_A?OCK_GYL?_ 45YA10!Z?_P +]\=?
M\_-C_P" HH_X7[XZ_P"?FQ_\!17F%% 'I_\ POWQU_S\V/\ X"BC_A?OCK_G
MYL?_  %%>844 >G_ /"_?'7_ #\V/_@**/\ A?OCK_GYL?\ P%%>844 >G_\
M+]\=?\_-C_X"BC_A?OCK_GYL?_ 45YA10!Z?_P +]\=?\_-C_P" HH_X7[XZ
M_P"?FQ_\!17F&*7%-1; ]._X7[XZ_P"?FQ_\!11_POWQU_S\V/\ X"BO,**0
M'I__  OWQU_S\V/_ ("BC_A?OCK_ )^;'_P%%>844 >G_P#"_?'7_/S8_P#@
M**^C/ .M7GB+P+I.KWY0W5S"6D,:[5)#$<#\*^)*^R_A)_R2KP__ ->Y_P#0
MVH [2BBB@#X/US_D8-2_Z^I?_0S5"K^N?\C!J7_7U+_Z&:H4 %%%% !1110
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M6AW;ESP:XOJ]&JI.A-2Y=['HX7-:&(GR1>IS=%*1BDKSVK,],****0!1110
M4444 %+24HIH J1%W-BFA2QP!73>&/#%UJU_$/)819R6(KOPM!SE=[&%>O"C
M!SF[)%W0O"SWL(E<?*:LZIX,DCB9X5)QZ"O6K'2;>QM4A1!P.N*G6&WDC*%5
M.:[UF6&E%J"YDM#XJIGM7VKE'8^9KFW>WE9'&&!P14%>D^._"SPSM=V\7R'K
M@5YRZ%#@BN#&8;D?/#X6?88+%PQ-)3B,HHHKSSL"BBB@ HHHH **** "BBB@
M I0":<B%V 4$D]A70:?X4U.Y D-K(L9YR179A\).J]-C&K7ITE>;L84<+.<
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MC!DF7[LDF%_>,,\%LUEW>LZC?V,5G=W3SPQ2R31B3#%7?!<[NO)&2,XSSUH
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M!\=*\"O)C+.[D\DU^B4O=P6M]6]SV.&J;Y93*II*6DKRYH^M$HHHK(84444
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MS#E78?YK>OZ4A=CUIM%)U9O=A9!FBBBLQA1110 4444 %.5RO3%-HJHR<7=
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M7_(>U'_KYD_]"-4: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ^BHVD=1DQ_^/4NZ3_GG_P"/4 /HIFZ3_GG_ ./4;I/^>?\ X]0 ^BF;I/\
MGG_X]1ND_P">?_CU #Z*9ND_YY_^/4BR.P!$?!_VJ )**122.1C\:6@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KE_$'B>Z\/:Q&L]G%+IT\(\I_M4,+B8,=R_O77<,;>G3
M\:ZBO.?$>J0?\)7=_9!')<I:+;W"7VCW%PBKN<@QLB\YR<CHV%YX- 'H5O(T
MUO'*\30NZAC&Q!*$CH2"1^1J2LSP["+?PWID*BX 2UC4"X39)@*/O+V/MVK3
MH BGM8+H1B>))/+D$B;AG:PZ$>XJF- TD7-W<?V=;>;=J4N&,8/F*?O _7 S
MZXYK1HH JV&G6>EVHMK&WC@A#%MJ#&2>I/J?>I7_ ./F+_=;^E2U$_\ Q\Q?
M[K?TH EHHHH **** "F2_P"K/U'\Z?3)?]6?J/YT /HHHH **** "BBB@!D/
M^J%/ID/^J%/H **** "BBB@!B?ZR3ZC^5/IB?ZR3ZC^5/H **** "BBB@!C?
MZQ/QI],;_6)^-/H **** "BBB@!DO^K/U'\Z?3)?]6?J/YT^@ HHHH ****
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MW_[Z-'E)[_\ ?1H )?\ 5GZC^=/J&2-0AZ]1W/K3_*3W_P"^C0 ^BF>4GO\
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M[[%-^WVO_/4'Z FK  '0 ?2EHM4[K[O^"%X]OZ^XJ)>V^]SO8Y(Z(WI]*?\
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M-Y_YYM^E&\_\\V_2GT4 ,WG_ )YM^E-E<E/N-U'IZU+3)?\ 5GZC^= !O/\
MSS;]*-Y_YYM^E)+,D";G;'8#J2?0#O4.R:YYD)AB_N*?F;ZGM]!^=1*=G9:L
MI1OJ]A7O ',<<3RR#JJXX^IZ"F[+B;_7,R+_ '(CC\VZ_EBK,<:1($C4*HZ
M#%.J>1R^-_+I_P '^M!\R7PD,4<<(Q' 5SU( R?K4F\_W&_2G5'-!%<1&*9
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MX(-.K@K&_O\ 1=6U.:[NH)X/[8C@O9ECV81[:(1L><*0VP'MSGBMVUOM6O\
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MW;]T[OE._P"7'%=1JD<_A;X?);65TR-900VYNS'N,295'EV]/E7<V.G'I6;
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M$DE9$-W#R_\ ;?\ .CR_]M_SI]%,!GE_[;_G1Y?^V_YT^B@!GE_[;_G1Y?\
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MT:V5Y)<37$CK$\:DA& //S 9Y/ QUKH-(OGU/1K*_DMWMGN($E:%^J$C.#0
MDNEQ3:E8W\DDAGLXY(TZ -OVY)&.ORCIBC4[";4(!'%?SVG4,8D1@ZD8((=2
M*O44 <_#X4ALI(&T[4+RR1+>*VD2(H?-2/A,EE)!P2,C&1^&$L?"5O8W]M<)
M?7;16LTTUO;,4V(TN[=DA=S?>.,DXKH:* ,BT\.VEG%H\<<DQ&E*RP[B/FRA
M3YN.>#VQ3=0\/B\OY+VWU&\L9IH1!.;8I^]0$D9W*<,-S888//TK9HH S;+0
M[/3[V.XM@Z"*S2S2//RK&A)'OGGUK2HHH **** "BBB@ HHHH **** "N UV
MRU0^*KF+2[S79Y9+=)I(H[Z&"&)2S@!-R$DY!SZ<<\BN_KS7XA/9+XBL/[2M
MK!(2BQI<7-@UP7W;]P##IL(0[>K;O:@#OM+MS;:1:6SHZF.%4999?-8$#!!;
M^(^_>DLM'TS39))+#3K2U>7_ %C00*A?ZD#FH] :5O#VG--:+:2FVCW6ZJ5$
M1VCY0#R,>AZ5HT %%%<3JOBO5](OKF&2&QG81.ZPQ;LVV9%2$RMG!WELX !&
M#C.": .VJ)_^/F+_ '6_I6;H>HW=W+J-G?"$W5C<")I(%*I("BNI ))!PV",
MGI6C(<7$7!/RMT_"@"MK'_(,?_?C_P#0UJQ/,RL(80&F8<9Z*/4^W\ZP?%%[
M<1+##&"D;?,WJ2#Q6GI#RMIZ33Q/Y\G+L>K>GZ5P+&1JXB6%BFG'=_Y?>=#H
M.%)57LR]#"L";0223EF/5CZFI*9YA_YYO^E'F'_GF_Z5W)**LC!MMW8^F2_Z
ML_4?SH\P_P#/-_TIDKDH?D;J/3UIB)J*9YA_YYO^E'F'_GF_Z4 /HIGF'_GF
M_P"E'F'_ )YO^E #Z*9YA_YYO^E'F'_GF_Z4 $/^J%/J&)R(Q\C?I3_,/_/-
M_P!* 'T4SS#_ ,\W_2CS#_SS?]* 'T4SS#_SS?\ 2CS#_P \W_2@ 3_62?4?
MRI]0JYWO\C=1Z>E/\P_\\W_2@!]%,\P_\\W_ $H\P_\ /-_TH ?13/,/_/-_
MTH\P_P#/-_TH &_UB?C3ZA9SYB?(W?TI_F'_ )YO^E #Z*9YA_YYO^E'F'_G
MF_Z4 /HIGF'_ )YO^E'F'_GF_P"E !+_ *L_4?SI]0R.2GW&ZCT]:?YA_P">
M;_I0 ^BF>8?^>;_I1YA_YYO^E #Z*9YA_P">;_I1YA_YYO\ I0 ^F1?ZI:/,
M/_/-_P!*9$Y$:_(WZ4 344@.1T(^M+0 4444 1SF46\IMPAFV'RPYPI;'&?;
M-<C:^"I]/AT>>WU*XEO[&=99!-,3$^_(GPN.-P=R/?%=E10!PNH>"+VX\,VM
MK;7%O%J4$DBM(<[)())M[(>,]-I''#*.V:N7O@MM8DUJ:_O[F*2_;RXUMIV5
M$B5<1Y&.2#EC[M7744 <G/X<U*]U72[RXFM@C11#5HUS^]DA.^,IQTWELYQQ
MBGOHU]!XKOM3CTS3;R*Y:%DEGF*2P[%VG'[MOJ.174T4 <LWA[43K/\ ;XGA
M_M07&Q4W-Y?V+./)^O\ RTSC[^!TKIQ%&)3*$42$8+8Y(],TZB@#E](T[6EU
MBYO-7M+)Y+D-&9X;MR881G;&B&,8[$G=DGGL +M_HCCP_<Z9I4K0-<G8TLTS
MR%$8@.5+$G.W.!TSBMNB@#$U73Y6LK:RM-&TV^LHTV>1=OM"8&%Q\C C&1VJ
MSH&G3:3H-G87%P;B:",*TF21]!GG Z#/. *TJ* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *XW7[JZ3Q//;V\7V_S=-"&T-^;7R@SL"X['. -
MP^9=HQ]ZNRKSCX@-"-?L#?6=O]EV*BSOI0NR^[?N&[:=NW"$+QNW'TH [K2(
M+FVT:R@O+G[3<QP(LLV<^8P R<]\^M7:S]!\\^'].^TVJ6L_V:/S((TVK&VT
M94+V ].U:% !7-Q>"M.C-^&NM0EAOF=YX9+C*,[<[NF01@8.>,#'2NDHH H:
M7I,&DPRI"\TLDTAEFFG?>\C8 R3]  /8"K$SK',CL<*J,2?;BIZI7_+0Q]I#
ML/TR,_H#4SERQ;0XJ[2*M]&?[)DFD'[V5XV;/8;UP/P']:UZHZG;75W;B&W>
M%06!8R GH01C'TJW%YGE+YVSS,?-LSC/MFB$5%6!N[N/HHHJA!3)?]6?J/YT
M^F2_ZL_4?SH ?1110 4444 %%%% #(?]4*?3(?\ 5"GT %%%% !1110 Q/\
M62?4?RI],3_62?4?RI] !1110 4444 ,;_6)^-/IC?ZQ/QI] !1110 4444
M,E_U9^H_G3Z9+_JS]1_.GT %%%% !1110 4R+_5+3Z9%_JEH ?1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N8OO$UU;:U/$EI$VGVES;VMQ(SD2%YMN"HQC WIG/7)].>GK$NO#-I=ZO\
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9qJZs7xRiXgOn8uMb3VcSaCOWaP9zJFxOZkhtmR0fZnavygh/0S72iltfSymobUM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20220630" elementFormDefault="qualified" targetNamespace="http://anavex.com/20220630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Description of Business and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000010 - Disclosure - Accrued liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000014 - Disclosure - Accrued liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" id="DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
	  <link:definition>00000018 - Disclosure - Accrued liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="avxl_ShareProceedsReceivableMember" name="ShareProceedsReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ParkinsonMember" name="ParkinsonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossAndComprehensiveLoss" name="NetLossAndComprehensiveLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EarningPerShareBasicAndDilutedAbstract" name="EarningPerShareBasicAndDilutedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesValue" name="CommitmentSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" name="SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" name="SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessShareIssueCosts" name="LessShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" name="SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" name="SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessShareIssueCosts1" name="LessShareIssueCosts1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfStockOptionsShares" name="SharesIssuedUponExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfWarrants" name="SharesIssuedPursuantToExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" name="SharesIssuedPursuantToExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInDeferredGrantIncome" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalSiteCostsAndPatientVisits" name="ClinicalSiteCostsAndPatientVisits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedLicenseFeesPayables" name="AccruedLicenseFeesPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromIssuancePublicOffering" name="GrossProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLeasesRentExpense" name="OperatingLeasesRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="loc_avxlNetLossAndComprehensiveLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_avxlNetLossAndComprehensiveLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_avxlNetLossAndComprehensiveLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_AccruedLicenseFeesPayables" xlink:label="loc_avxlAccruedLicenseFeesPayables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlAccruedLicenseFeesPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlShareProceedsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareissueCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareissueCostsShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts1" xlink:label="loc_avxlLessShareIssueCosts1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts1_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrants_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsShares_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OperatingLeasesRentExpense" xlink:label="loc_avxlOperatingLeasesRentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOperatingLeasesRentExpense_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_110" xlink:type="arc" order="11" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="avxl_ShareProceedsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivableMember" xlink:to="avxl_ShareProceedsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivableMember_lbl" xml:lang="en-US">Share Proceeds Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ParkinsonMember" xlink:label="avxl_ParkinsonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ParkinsonMember" xlink:to="avxl_ParkinsonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ParkinsonMember_lbl" xml:lang="en-US">Parkinson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange(loss) gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="avxl_NetLossAndComprehensiveLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossAndComprehensiveLoss" xlink:to="avxl_NetLossAndComprehensiveLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avxl_NetLossAndComprehensiveLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EarningPerShareBasicAndDilutedAbstract" xlink:to="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="avxl_NetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossPerShareBasicAndDiluted" xlink:to="avxl_NetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesValue" xlink:label="avxl_CommitmentSharesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesValue" xlink:to="avxl_CommitmentSharesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesValue_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:to="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" xlink:to="avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares_lbl" xml:lang="en-US">Shares issued under Sales agreement, net of shareissue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts" xlink:label="avxl_LessShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts" xlink:to="avxl_LessShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessShareIssueCosts_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:to="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares_lbl" xml:lang="en-US">Shares issued pursuant to registered direct offering, net of share issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts1" xlink:label="avxl_LessShareIssueCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts1" xlink:to="avxl_LessShareIssueCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_LessShareIssueCosts1_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedUponExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrantsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share-based Payment Arrangement, Option, Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalSiteCostsAndPatientVisits" xlink:to="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xml:lang="en-US">Clinical site costs and patient visits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_AccruedLicenseFeesPayables" xlink:label="avxl_AccruedLicenseFeesPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedLicenseFeesPayables" xlink:to="avxl_AccruedLicenseFeesPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedLicenseFeesPayables_lbl" xml:lang="en-US">Accrued license fees payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromIssuancePublicOffering" xlink:to="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Gross proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share Purchase Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Share Purchase Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OperatingLeasesRentExpense" xlink:label="avxl_OperatingLeasesRentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLeasesRentExpense" xlink:to="avxl_OperatingLeasesRentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLeasesRentExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossAndComprehensiveLoss" xlink:to="avxl_NetLossAndComprehensiveLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossAndComprehensiveLoss_2_lbl" xml:lang="en-US">NetLossAndComprehensiveLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts1" xlink:to="avxl_LessShareIssueCosts1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessShareIssueCosts1_2_lbl" xml:lang="en-US">LessShareIssueCosts1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_2_lbl" xml:lang="en-US">IncreaseDecreaseInDeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20220630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20220630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20220630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20220630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20220630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20220630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20220630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20220630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20220630.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20220630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20220630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20220630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20220630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NetLossAndComprehensiveLoss" xlink:label="loc_avxlNetLossAndComprehensiveLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlNetLossAndComprehensiveLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="loc_avxlEarningPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="loc_avxlNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:to="loc_avxlNetLossPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlShareProceedsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementNetOfShareissueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:label="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LessShareIssueCosts1" xlink:label="loc_avxlLessShareIssueCosts1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrants" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_AccruedLicenseFeesPayables" xlink:label="loc_avxlAccruedLicenseFeesPayables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlAccruedLicenseFeesPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_GrossProceedsFromIssuancePublicOffering" xlink:label="loc_avxlGrossProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OperatingLeasesRentExpense" xlink:label="loc_avxlOperatingLeasesRentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOperatingLeasesRentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20220630.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831177999872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831181079952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 153,199,352<span></span>
</td>
<td class="nump">$ 152,107,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">6,559,829<span></span>
</td>
<td class="nump">9,136,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">461,963<span></span>
</td>
<td class="nump">371,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">160,221,144<span></span>
</td>
<td class="nump">161,616,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,126,892<span></span>
</td>
<td class="nump">4,739,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities (Note 4)</a></td>
<td class="nump">5,913,821<span></span>
</td>
<td class="nump">5,614,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total liabilities</a></td>
<td class="nump">9,484,544<span></span>
</td>
<td class="nump">10,798,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)</a></td>
<td class="nump">77,944<span></span>
</td>
<td class="nump">75,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">381,932,039<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(231,273,383)<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">150,736,600<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 160,221,144<span></span>
</td>
<td class="nump">$ 161,616,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831177977920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831180609328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 3,185,451<span></span>
</td>
<td class="nump">$ 2,434,127<span></span>
</td>
<td class="nump">$ 9,167,560<span></span>
</td>
<td class="nump">$ 6,138,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,273,269<span></span>
</td>
<td class="nump">8,964,528<span></span>
</td>
<td class="nump">26,534,297<span></span>
</td>
<td class="nump">23,610,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(12,458,720)<span></span>
</td>
<td class="num">(11,398,655)<span></span>
</td>
<td class="num">(35,701,857)<span></span>
</td>
<td class="num">(29,749,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43,280<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">54,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">682,432<span></span>
</td>
<td class="nump">1,363,661<span></span>
</td>
<td class="nump">2,328,675<span></span>
</td>
<td class="nump">3,593,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">229,917<span></span>
</td>
<td class="nump">11,453<span></span>
</td>
<td class="nump">242,405<span></span>
</td>
<td class="nump">19,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange(loss) gain, net</a></td>
<td class="num">(732,549)<span></span>
</td>
<td class="num">(160,880)<span></span>
</td>
<td class="num">(408,541)<span></span>
</td>
<td class="nump">17,191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">179,800<span></span>
</td>
<td class="nump">1,257,514<span></span>
</td>
<td class="nump">2,162,539<span></span>
</td>
<td class="nump">3,684,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(12,278,920)<span></span>
</td>
<td class="num">(10,141,141)<span></span>
</td>
<td class="num">(33,539,318)<span></span>
</td>
<td class="num">(26,065,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(88,421)<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
<td class="num">(148,201)<span></span>
</td>
<td class="num">(125,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NetLossAndComprehensiveLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (12,367,341)<span></span>
</td>
<td class="num">$ (10,180,141)<span></span>
</td>
<td class="num">$ (33,687,519)<span></span>
</td>
<td class="num">$ (26,190,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NetLossPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">77,442,236<span></span>
</td>
<td class="nump">70,589,651<span></span>
</td>
<td class="nump">76,561,940<span></span>
</td>
<td class="nump">67,810,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossAndComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossAndComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831175814672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Share Proceeds Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">$ 186,851,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (159,677,230)<span></span>
</td>
<td class="nump">$ 27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 4,008<span></span>
</td>
<td class="nump">24,107,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,111,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares, shares</a></td>
<td class="nump">4,007,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">78,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 5,634<span></span>
</td>
<td class="nump">79,101,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,107,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">5,634,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,437,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,437,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts', window );">Shares issued pursuant to registered direct offering, net of share issuance costs</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">49,997,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares', window );">Shares issued pursuant to registered direct offering, net of share issuance costs, shares</a></td>
<td class="nump">2,380,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts1', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,095,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,095,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">1,867,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,868,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">652,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrants', window );">Shares issued pursuant to exercise of warrants</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">1,466,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsShares', window );">Shares issued pursuant to exercise of warrants, shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,190,428)<span></span>
</td>
<td class="num">(26,190,428)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 75,151<span></span>
</td>
<td class="nump">342,938,236<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(185,867,658)<span></span>
</td>
<td class="nump">157,145,729<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">251,427,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(175,687,517)<span></span>
</td>
<td class="nump">75,810,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="nump">70,030,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts', window );">Shares issued under Sales Agreement, net of share issue costs</a></td>
<td class="nump">$ 2,082<span></span>
</td>
<td class="nump">41,282,225<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">41,284,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares', window );">Shares issued under Sales agreement, net of shareissue costs, shares</a></td>
<td class="nump">2,082,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,302,826)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,302,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts', window );">Shares issued pursuant to registered direct offering, net of share issuance costs</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="nump">49,997,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares', window );">Shares issued pursuant to registered direct offering, net of share issuance costs, shares</a></td>
<td class="nump">2,380,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts1', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,095,938)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,095,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">869,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">869,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">305,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrants', window );">Shares issued pursuant to exercise of warrants</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">1,466,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsShares', window );">Shares issued pursuant to exercise of warrants, shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,293,925<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,293,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,180,141)<span></span>
</td>
<td class="num">(10,180,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 75,151<span></span>
</td>
<td class="nump">342,938,236<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(185,867,658)<span></span>
</td>
<td class="nump">157,145,729<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">75,149,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">20,980,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,982,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">1,623,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(723,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(723,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">1,009,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,010,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">400,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,336,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,336,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,687,519)<span></span>
</td>
<td class="num">(33,687,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">381,932,039<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(231,273,383)<span></span>
</td>
<td class="nump">150,736,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 77,163<span></span>
</td>
<td class="nump">371,437,616<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="num">(218,906,042)<span></span>
</td>
<td class="nump">152,205,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">77,161,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">6,178,127<span></span>
</td>
<td class="nump">403,696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,582,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">557,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(185,361)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(185,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of options</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">513,043<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">513,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">223,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,988,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,988,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,367,341)<span></span>
</td>
<td class="num">(12,367,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">$ 381,932,039<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (231,273,383)<span></span>
</td>
<td class="nump">$ 150,736,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessShareIssueCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessShareIssueCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831180986112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,687,519)<span></span>
</td>
<td class="num">$ (26,190,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,336,844<span></span>
</td>
<td class="nump">5,079,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">2,577,002<span></span>
</td>
<td class="num">(3,751,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(106,414)<span></span>
</td>
<td class="nump">185,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,612,889)<span></span>
</td>
<td class="nump">187,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">299,047<span></span>
</td>
<td class="nump">1,336,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,193,929)<span></span>
</td>
<td class="num">(22,709,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows provided by financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">20,982,148<span></span>
</td>
<td class="nump">153,218,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(706,802)<span></span>
</td>
<td class="num">(5,533,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,466,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,010,190<span></span>
</td>
<td class="nump">1,868,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,285,536<span></span>
</td>
<td class="nump">151,020,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">1,091,607<span></span>
</td>
<td class="nump">128,311,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">152,107,745<span></span>
</td>
<td class="nump">29,249,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">153,199,352<span></span>
</td>
<td class="nump">157,560,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 141,374<span></span>
</td>
<td class="nump">$ 98,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831183675184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLgoFKzLxsKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1 	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_823_z3PTuESTS5q3">Description
of Business and Basis of Presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
of Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with
high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound
ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central
nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations
in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements
in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the
disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2021 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September
30, 2021 filed with the SEC on November 24, 2021. The Company follows the same accounting policies in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>





<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>







<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond
the next 12 months after the date that these interim condensed consolidated financial statements are issued. The process of drug development
can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary
depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress
of the Company&#8217;s research and development programs and the level of financial resources available. The Company has the ability
to adjust its operating plan spending levels based on the timing of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the Sales Agreement (as defined below in Note 5), there can be no assurance that additional financing will
be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able
to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all
of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in
the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors, including
the potential future effects of COVID-19, that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates.
To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>















<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles
of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia
Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated
under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
that may be used to measure fair value which are the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022 and September 30, 2021, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Basic
and Diluted Loss per Share</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number
of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available
to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive
effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities
and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares">13,194,616</span> (September 30, 2021 &#8211; <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_pdd" title="Loss per share for potentially dilutive common shares">11,540,903</span>) potentially dilutive common shares related
to outstanding options and warrants, as their effect was anti-dilutive.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>





<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>












<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831185915040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z7xuxYhTmh61" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2	&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82E_zAeS4gxOqSyc">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrnSjxk9FKFh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_znxLYpWZ61af">Recently
Adopted Accounting Pronouncements</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740 and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s
operations, financial condition, or cash flows.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831183901920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_803_ecustom--OtherIncomeDisclosureTextBlock_zzZm1O5SAftb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_822_z4X41tOnbOO2">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;&#160;&#160;Grant Income</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended September 30, 2021, the Company received $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income">497,931</span> of a $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income">995,862</span> research grant awarded by the Michael J. Fox Foundation
for Parkinson&#8217;s Research. The grant will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73
related to Parkinson&#8217;s disease.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2022, the Company did <span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20220401__20220630_zOb9sGlxU7Kh" title="Grant income"><span id="xdx_90D_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20211001__20220630_zDDYDoUqL1vg" title="Grant income">no</span></span>t recognize any of this grant on its statements of operations
(2021: $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income">43,280</span> and $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income">54,100</span> respectively). At June 30, 2022, an amount of $<span id="xdx_90A_ecustom--DeferredGrantIncome_c20220630_pp0p0" title="Deferred grant income">443,831</span> (September 30, 2021: $<span id="xdx_90C_ecustom--DeferredGrantIncome_c20210930_pp0p0" title="Deferred grant income">443,831</span>) of this grant is recorded
as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize
this income on its statement of operations as the relating expenditures are incurred to offset the income.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit,
(the &#8220;R&amp;D Incentive Credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended June 30, 2022 the Company recorded research and development incentive income of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income">682,432</span> (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">954,986</span>)
and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income">2,328,675</span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">3,218,303</span>) (2021: $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income">1,363,661</span> (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">1,770,444</span>) and $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income">3,593,856</span> (AUD <span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">4,750,539</span>)), respectively, related to the R&amp;D
Incentive Credit for eligible research and development expenses incurred during the period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831268020128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued liabilities</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zEbnwKkJkcY1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4	 	 &#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82A_zEf0nvcC1Im">Accrued liabilities</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
principal components of accrued liabilities consists of:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"/>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zofAQJYzLUP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zJFGzxI2vDD2" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20220630_zJmxZ22azvp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210930_zgjOArYxjdS9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">June 30,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_40B_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maCzJSg_maALCzSaG_zRac5IN3zXEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,138,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,035,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedBonusesCurrent_iI_maCzJSg_maALCzSaG_zNBXJ800tLe8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">889,616</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,201,903</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FixedContractAccruals_iI_maCzJSg_maALCzSaG_zhyBwY25iGi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">649,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedLicenseFeesPayables_iI_maCzJSg_maALCzSaG_zy7280LISuQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued license fees payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maCzJSg_maALCzSaG_zRHuQh5sgOCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,050,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,727,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzSaG_znXYB0qE5qgb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: White; text-indent: -10pt">Total accrued liabilities </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,913,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,614,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A3_zJy5wECD7XTc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-indent: 0.75in">&#160;</p>














<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831185783408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_805_ecustom--EquityOfferingTextBlock_zI3gvjmJbt24" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5&#160;&#160;&#160;&#160;&#160;&#160;	<span style="text-decoration: underline"><span id="xdx_82D_zrXqiavVlsY4">Equity Offerings</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
shares are voting and are entitled to dividends as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
Stock</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the
&#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant
to which the Company may offer and sell shares of common stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement,
the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted
by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon notice
to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on a commercially reasonable efforts basis
consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of
Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_907_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zPhXlmfMizje" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares
pursuant to the Sales Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution
rights. During the nine months ended June 30, 2022, <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold">1,623,566</span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_906_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztZUZfpJGtNc" title="Gross proceeds from Issuance Public Offering">20,982,148</span>
(net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z0N81rBaPW0g">20,258,981</span> after deducting offering expenses) (2021: <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold">5,634,576</span> shares were sold for gross proceeds of $<span id="xdx_90D_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjH13dysxIXd">79,107,548 </span>(net
proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z8i8iutnnCX" title="Proceeds from Issuance Public Offering">76,670,025</span> after deducting offering expenses)). At June 30, 2022, an amount of $<span id="xdx_908_ecustom--SalesOfAgreementAmount_c20220630_pp0p0" title="Sales of agreement amount">142,410,402</span> (September 30, 2021: $<span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount">163,392,550</span>)
was registered pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>





<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park,
as amended on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated
to purchase, up to $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment
fee during the year ended September 30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchased,
at the Company&#8217;s discretion, the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">50,000,000</span> aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022 and September 30, 2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the nine months
ended June 30, 2021, the Company issued to Lincoln Park an aggregate of 4,086,209 shares of common stock including<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Shares issued under Sales Agreement, net of shares issue costs, shares"> 4,007,996 </span>shares of
common stock for an aggregate purchase price of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">24,111,198</span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment">78,213</span> commitment shares.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831185783408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zUkmgXtOrZV" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 &#160;&#160;&#160;&#160;&#160;	<span style="text-decoration: underline"><span id="xdx_824_zBzixcaVAMh5">Commitments and Contingencies </span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Leases
                                            </i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2022, the Company incurred office lease expense of $<span id="xdx_90C_ecustom--OperatingLeasesRentExpense_pp0p0_c20220401__20220630_zVXelDSDtp78" title="Operating Leases, Rent Expense">21,015</span> and $<span id="xdx_909_ecustom--OperatingLeasesRentExpense_pp0p0_c20211001__20220630_z1mqR2uyz4Gh" title="Operating Leases, Rent Expense">42,348</span> (2021: $<span id="xdx_901_ecustom--OperatingLeasesRentExpense_pp0p0_c20210401__20210630_zaD4miPJIuv" title="Operating Leases, Rent Expense">18,994</span> and $<span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pp0p0_c20201001__20210630_zQ93tVUH60Rk" title="Operating Leases, Rent Expense">117,284</span>),
respectively.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            401(k) Benefit Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States
based employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits
under the Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf
of contributing employees. During the three and nine months ended June 30, 2022, the Company made $<span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount">27,358</span> and $<span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount">120,979</span> (2021: $<span id="xdx_90D_eus-gaap--PensionContributions_c20210401__20210630_pp0p0" title="Contribution amount">28,221</span>
and $<span id="xdx_909_eus-gaap--PensionContributions_c20201001__20210630_pp0p0" title="Contribution amount">102,261</span>), respectively, in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Litigation</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of
any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company does not believe
that any of</span> <span style="font-family: Times New Roman, Times, Serif">such pending claims and legal proceedings will have a material
adverse effect on its consolidated financial statements.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"/>




<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Share
                                            Purchase Warrants</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zK5wHvBHg8sc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_z70YmB198CNl" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbGMSNhIGru3" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning">500,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3fTEuyi5mV9" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">3.88</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5RcCHtEpdA8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">4.19</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2021</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5eiDf3kky1j" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning">210,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8Su0NIbLQfb" style="border-bottom: Black 1pt solid; text-align: right">5.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmDf35Q0VM65" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zNv0ptqaCx2h" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z4jkyl37RxKb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AD_zXr7NlRY7Wk9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2022, the Company had share purchase warrants outstanding as follows</span>&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zMsYB5MDcFyg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B1_z404gnhCoY16" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number">150,000</span></td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9VHEbdWG2S4" style="width: 15%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="text-align: right; width: 43%" title="Expiry Date">May 6, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number">10,000</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z8NbKxtdZnuh" style="text-align: right" title="Exercise Price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date">April 21, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630_pdd" title="Number">160,000</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  </table>


<p id="xdx_8A1_zngh7yVOQCQf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Stock&#8211;based
                                            Compensation Plan</i></span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2015, the Company&#8217;s Board approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for
the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance">6,050,553 </span>shares, subject to adjustment in the event of a change
of the Company&#8217;s capitalization.</span></p>

























<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock
options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change
of the Company&#8217;s capitalization.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended June 30, 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted">406,453</span> options previously available under the 2019 Plan and the 2015 Plan became available under
the 2022 Plan (as defined below).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2022, the Board approved the 2022 Omnibus Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders
on May 24, 2022. Under the terms of the 2022 Plan, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance">10,000,000 </span>additional shares of Common Stock will be available for issuance under
the plan, in addition to the shares available under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option
plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2022 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise
price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee
is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s
shares of common stock on the grant date. Stock options may be granted under the 2022 Plan for an exercise period of up to ten years
from the date of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance
with the terms of the 2022 Plan. At June 30, 2022, <span id="xdx_903_ecustom--OptionIssued_c20211001__20220630_zCy7QikHbqnc" title="Option issued">1,298,000</span> options had been issued under the 2022 Plan and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">9,108,453</span> options were available
</span><span style="font-family: Times New Roman, Times, Serif">for issue under the 2022 Plan, subject to stockholder approval.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"/>















<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>







<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of Company&#8217;s outstanding stock options is presented below:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z3RpVtIMXVxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_zXcHLOesnPX6" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2020</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW7csxuW2u4k" style="width: 16%; text-align: right" title="Options Outstanding at beginning">10,076,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7S42xtkyY9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDovu43sShld" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">14,982,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted">2,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted">12.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">9.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWo7Hm1SFE7g" style="text-align: right" title="Options Forfeited">(55,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh40HCrd7f7j" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(1,421,529</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">24,446,305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhKCOuPfuv9" style="text-align: right">11,330,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwNcCePmjql" style="text-align: right">5.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z43nyzVsP9Kb" style="text-align: right">140,132,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted">2,208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted">10.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">6.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDW302EiwCWj" style="text-align: right" title="Options Forfeited">(103,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">5.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">4.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqoNCG0pvAe9" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbd22WklfOO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">13,034,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zba3DJqh9KD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6XyoAO0I9b6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">58,809,090</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable at ending">8,562,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercisable at ending">52,439,132</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p id="xdx_8A8_zxAdCEvk0cRl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes information about stock options at June 30, 2022 by a range of exercise prices:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPysIElXurS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B6_zJpjIQXnZA67" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
    prices</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">life (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,903,762</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znyQxmLkyTTf" title="Weighted average remaining contractual life (in years)">5.38</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,868,762</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,078,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zW9HrtBWztBi" title="Weighted average remaining contractual life (in years)">5.59</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,058,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,957,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2E2p7T6fm9i" title="Weighted average remaining contractual life (in years)">6.32</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,356,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,798,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zS4voK6pDsU" title="Weighted average remaining contractual life (in years)">9.38</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.11</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.58</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,297,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zpfoLjFBhYRb" title="Weighted average remaining contractual life (in years)">9.08</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.39</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,750</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.03</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,034,616</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,562,530</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p id="xdx_8A3_zU2ipszcQbD8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of options vested during the three and nine months ended June 30, 2022 was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220401__20220630_pdd" title="Weighted average grant date fair value of options vested">3.83</span> (2021: $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested">3.16</span>).
At June 30, 2022, the weighted average contractual life of options outstanding was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_z0M2wwhieNDd" title="Weighted average contractual life of options outstanding">6.62</span> years (September 30, 2021: <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zmCILppq5ra3" title="Weighted average contractual life of options outstanding">6.65</span> years) and for
options exercisable was <span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_zUpcE52yDoOa" title="Options exercisable">5.21</span> years (September 30, 2021: <span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zgs3PZs6pVf9" title="Options exercisable">5.80</span> years).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price
of the Company&#8217;s stock for the options that were in-the-money at June 30, 2022.</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>





<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>







<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended June 30, 2022, the Company recognized stock-based compensation expense of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation">3,988,614</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation">12,336,844</span>
(2021: $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" title="Share based compensation">2,293,925</span> and $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" title="Share based compensation">5,079,395</span>), respectively, in connection with the issuance and vesting 	of stock options and warrants in exchange
for services. These amounts have been included in general and 	administrative expenses and research and development expenses on the
Company&#8217;s statement of 	operations as follows:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ6OMAf8vqW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zxQqWg1gJINh" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months
    ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine months
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,490,267</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048,606</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,739,021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,265,387</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,498,347</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,245,319</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,597,823</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,814,008</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,988,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,293,925</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,336,844</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,079,395</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p id="xdx_8A5_zTZt5sDBAkK8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
amount of approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630_pp0p0" title="Remaining stock based compensation">24,276,312 </span>in stock-based compensation is expected to be recorded over the remaining term 	of such options
through fiscal 2025.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award granted during the three and nine months ended June 30, 2022 and 2021 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9doc0ils37e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zbUynMVHmZqd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zc2QyWVE6FZ1" style="width: 12%; text-align: right" title="Risk-free interest rate">3.10</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210630_ze8xOE24DzWj" style="width: 12%; text-align: right" title="Risk-free interest rate">0.71</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zSPFF48pCIg1" title="Expected life of options (years)">5.51</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_z42JGOJBRUka" title="Expected life of options (years)">5.66</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_zIyV5jZrco1d" style="text-align: right" title="Annualized volatility">84.12</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210630_zksKYXLCc5me" style="text-align: right" title="Annualized volatility">95.87</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_zXC4piOcNug2" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210630_zNJdFZDYkbQc" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td></tr>
  </table>


<p id="xdx_8AA_zbiVlCUIx3wg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock compensation charges recognized during the three and nine months ended June 30, 2022 and 2021 was determined with
reference to the quoted market price of the Company&#8217;s shares on the grant date.&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831185834512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrnSjxk9FKFh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_znxLYpWZ61af">Recently
Adopted Accounting Pronouncements</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740 and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s
operations, financial condition, or cash flows.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831185886464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zofAQJYzLUP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zJFGzxI2vDD2" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20220630_zJmxZ22azvp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210930_zgjOArYxjdS9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">June 30,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_40B_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maCzJSg_maALCzSaG_zRac5IN3zXEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,138,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,035,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedBonusesCurrent_iI_maCzJSg_maALCzSaG_zNBXJ800tLe8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">889,616</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,201,903</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FixedContractAccruals_iI_maCzJSg_maALCzSaG_zhyBwY25iGi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">649,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedLicenseFeesPayables_iI_maCzJSg_maALCzSaG_zy7280LISuQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued license fees payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maCzJSg_maALCzSaG_zRHuQh5sgOCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,050,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,727,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzSaG_znXYB0qE5qgb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; color: White; text-indent: -10pt">Total accrued liabilities </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,913,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,614,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831181082432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zK5wHvBHg8sc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_z70YmB198CNl" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbGMSNhIGru3" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning">500,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3fTEuyi5mV9" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">3.88</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5RcCHtEpdA8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">4.19</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2021</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5eiDf3kky1j" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning">210,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8Su0NIbLQfb" style="border-bottom: Black 1pt solid; text-align: right">5.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmDf35Q0VM65" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zNv0ptqaCx2h" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z4jkyl37RxKb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zMsYB5MDcFyg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B1_z404gnhCoY16" style="display: none">Schedule of share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number">150,000</span></td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9VHEbdWG2S4" style="width: 15%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="text-align: right; width: 43%" title="Expiry Date">May 6, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number">10,000</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z8NbKxtdZnuh" style="text-align: right" title="Exercise Price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date">April 21, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630_pdd" title="Number">160,000</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z3RpVtIMXVxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_zXcHLOesnPX6" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2020</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW7csxuW2u4k" style="width: 16%; text-align: right" title="Options Outstanding at beginning">10,076,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7S42xtkyY9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDovu43sShld" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">14,982,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted">2,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted">12.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">9.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWo7Hm1SFE7g" style="text-align: right" title="Options Forfeited">(55,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh40HCrd7f7j" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(1,421,529</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">24,446,305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    September 30, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhKCOuPfuv9" style="text-align: right">11,330,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwNcCePmjql" style="text-align: right">5.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z43nyzVsP9Kb" style="text-align: right">140,132,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted">2,208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted">10.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">6.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDW302EiwCWj" style="text-align: right" title="Options Forfeited">(103,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited">5.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">4.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqoNCG0pvAe9" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(400,537</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.52</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">1.88</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbd22WklfOO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">13,034,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zba3DJqh9KD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">6.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6XyoAO0I9b6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">58,809,090</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable,
    June 30, 2022</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable at ending">8,562,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">4.11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercisable at ending">52,439,132</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPysIElXurS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><span id="xdx_8B6_zJpjIQXnZA67" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercise
    prices</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">life (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">options</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,903,762</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znyQxmLkyTTf" title="Weighted average remaining contractual life (in years)">5.38</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,868,762</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,078,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zW9HrtBWztBi" title="Weighted average remaining contractual life (in years)">5.59</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,058,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,957,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2E2p7T6fm9i" title="Weighted average remaining contractual life (in years)">6.32</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,356,221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,798,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zS4voK6pDsU" title="Weighted average remaining contractual life (in years)">9.38</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">209,997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.11</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.58</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,297,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zpfoLjFBhYRb" title="Weighted average remaining contractual life (in years)">9.08</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.39</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,750</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.03</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,034,616</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,562,530</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ6OMAf8vqW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BF_zxQqWg1gJINh" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months
    ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine months
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,490,267</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,048,606</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,739,021</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,265,387</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,498,347</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,245,319</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,597,823</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,814,008</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,988,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,293,925</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,336,844</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,079,395</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9doc0ils37e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zbUynMVHmZqd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zc2QyWVE6FZ1" style="width: 12%; text-align: right" title="Risk-free interest rate">3.10</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210630_ze8xOE24DzWj" style="width: 12%; text-align: right" title="Risk-free interest rate">0.71</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zSPFF48pCIg1" title="Expected life of options (years)">5.51</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_z42JGOJBRUka" title="Expected life of options (years)">5.66</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_zIyV5jZrco1d" style="text-align: right" title="Annualized volatility">84.12</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210630_zksKYXLCc5me" style="text-align: right" title="Annualized volatility">95.87</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_zXC4piOcNug2" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210630_zNJdFZDYkbQc" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831177878320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">13,194,616<span></span>
</td>
<td class="nump">11,540,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831175734400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 682,432<span></span>
</td>
<td class="nump">$ 1,363,661<span></span>
</td>
<td class="nump">$ 2,328,675<span></span>
</td>
<td class="nump">$ 3,593,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 954,986<span></span>
</td>
<td class="nump">$ 1,770,444<span></span>
</td>
<td class="nump">$ 3,218,303<span></span>
</td>
<td class="nump">$ 4,750,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember', window );">Parkinson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 995,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831175796400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ClinicalSiteCostsAndPatientVisits', window );">Clinical site costs and patient visits</a></td>
<td class="nump">$ 2,138,505<span></span>
</td>
<td class="nump">$ 2,035,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">889,616<span></span>
</td>
<td class="nump">1,201,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">334,887<span></span>
</td>
<td class="nump">649,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AccruedLicenseFeesPayables', window );">Accrued license fees payables</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">2,050,813<span></span>
</td>
<td class="nump">1,727,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 5,913,821<span></span>
</td>
<td class="nump">$ 5,614,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedLicenseFeesPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedLicenseFeesPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ClinicalSiteCostsAndPatientVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ClinicalSiteCostsAndPatientVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831178030448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,410,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,392,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,623,566<span></span>
</td>
<td class="nump">5,634,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromIssuancePublicOffering', window );">Gross proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,982,148<span></span>
</td>
<td class="nump">$ 79,107,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,258,981<span></span>
</td>
<td class="nump">$ 76,670,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,007,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,111,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues1', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831178676240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning</a></td>
<td class="nump">$ 5.69<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share Purchase Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Share Purchase Warrants Forfeited</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 5.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831177923616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831180426688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">11,330,903<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 140,132,451<span></span>
</td>
<td class="nump">$ 14,982,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">2,208,000<span></span>
</td>
<td class="nump">2,732,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 10.07<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 6.99<span></span>
</td>
<td class="nump">$ 9.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(103,750)<span></span>
</td>
<td class="num">(55,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 5.39<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(400,537)<span></span>
</td>
<td class="num">(1,421,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,446,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">13,034,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 6.57<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 58,809,090<span></span>
</td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">8,562,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 52,439,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831178890320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">13,034,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.57<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">8,562,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,903,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,868,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,078,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,058,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,957,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,356,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">10.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 17.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 11.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">209,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">18.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 24.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 19.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 24.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831175737184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 3,988,614<span></span>
</td>
<td class="nump">$ 2,293,925<span></span>
</td>
<td class="nump">$ 12,336,844<span></span>
</td>
<td class="nump">$ 5,079,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,490,267<span></span>
</td>
<td class="nump">1,048,606<span></span>
</td>
<td class="nump">4,739,021<span></span>
</td>
<td class="nump">2,265,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,498,347<span></span>
</td>
<td class="nump">$ 1,245,319<span></span>
</td>
<td class="nump">$ 7,597,823<span></span>
</td>
<td class="nump">$ 2,814,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831184191760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">84.12%<span></span>
</td>
<td class="nump">95.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831173768624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OperatingLeasesRentExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 21,015<span></span>
</td>
<td class="nump">$ 18,994<span></span>
</td>
<td class="nump">$ 42,348<span></span>
</td>
<td class="nump">$ 117,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 27,358<span></span>
</td>
<td class="nump">28,221<span></span>
</td>
<td class="nump">$ 120,979<span></span>
</td>
<td class="nump">102,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 3,988,614<span></span>
</td>
<td class="nump">$ 2,293,925<span></span>
</td>
<td class="nump">$ 12,336,844<span></span>
</td>
<td class="nump">$ 5,079,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 24,276,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,276,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">9,108,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,108,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLeasesRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLeasesRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>e3945_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20220630"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20220630.xsd" xlink:type="simple"/>
    <context id="From2021-10-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_ParkinsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-01to2022-06-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-01to2022-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-10-01to2022-06-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-10-01to2022-06-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-10-01to2022-06-30">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-06-30"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-10-01to2022-06-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts1
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts1
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts1
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012021-06-30"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts1
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts1
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2021-10-01to2022-06-30"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-10-01to2022-06-30"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:AccruedLicenseFeesPayables
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-10-01to2022-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-10-01to2022-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-01to2022-06-30">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-10-01to2022-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-10-01to2022-06-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-10-01to2022-06-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-01to2022-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-01to2022-06-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-01to2022-06-30">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-10-01to2022-06-30">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-01to2022-06-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-01to2022-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2021-10-01to2022-06-30">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-01to2022-06-30">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-01to2022-06-30">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-01to2022-06-30">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-10-01to2022-06-30">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-10-01to2022-06-30">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-10-01to2022-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-10-01to2022-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-10-01to2022-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-10-01to2022-06-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-10-01to2022-06-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-01to2022-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-10-01to2022-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-08-09" decimals="INF" unitRef="Shares">77942815</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">153199352</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">6559829</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9136831</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">461963</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">371914</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">160221144</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">3126892</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4739781</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">5913821</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">9484544</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10798386</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">77942568</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">77942568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">77944</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">75920</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">381932039</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">348328048</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-231273383</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-197585864</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">150736600</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">160221144</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3185451</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2434127</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">9167560</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">6138528</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">9273269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">8964528</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">26534297</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">23610888</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">12458720</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">11398655</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">35701857</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">29749416</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">43280</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">682432</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1363661</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">2328675</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">3593856</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">229917</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">11453</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">242405</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">19110</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-732549</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-160880</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-408541</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">17191</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">179800</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1257514</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">2162539</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">3684257</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12278920</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10141141</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-33539318</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-26065159</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">88421</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">39000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">148201</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">125269</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12367341</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10180141</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-33687519</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossAndComprehensiveLoss
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-26190428</avxl:NetLossAndComprehensiveLoss>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.16</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.14</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.44</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2020-10-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.39</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">77442236</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">70589651</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">76561940</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2020-10-012021-06-30"
      decimals="INF"
      unitRef="Shares">67810774</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77161688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">371437616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-218906042</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">152205041</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">557177</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">557</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6178127</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">403696</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">6582380</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-185361</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-185361</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedUponExerciseOfStockOptionsShares
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">223703</avxl:SharesIssuedUponExerciseOfStockOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">224</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">513043</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">513267</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3988614</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12367341</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12367341</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942568</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">381932039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-231273383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">150736600</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">70030620</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">70032</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">251427781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-175687517</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">75810296</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2082263</avxl:SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2082</avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">41282225</avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts>
    <avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">41284307</avxl:SharesIssuedUnderSalesAgreementNetOfShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1302826</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-1302826</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2380953</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2381</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">49997619</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">50000000</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:LessShareIssueCosts1
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-3095938</avxl:LessShareIssueCosts1>
    <avxl:LessShareIssueCosts1
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3095938</avxl:LessShareIssueCosts1>
    <avxl:SharesIssuedUponExerciseOfStockOptionsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">305997</avxl:SharesIssuedUponExerciseOfStockOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">306</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">869300</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">869606</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <avxl:SharesIssuedPursuantToExerciseOfWarrantsShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</avxl:SharesIssuedPursuantToExerciseOfWarrantsShares>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">350</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1466150</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1466500</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2293925</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10180141</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-10180141</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75149833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">342938236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185867658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157145729</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1623566</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1623</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20980525</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">20982148</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-723167</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-723167</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedUponExerciseOfStockOptionsShares
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">400537</avxl:SharesIssuedUponExerciseOfStockOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">401</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1009789</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">1010190</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12336844</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942568</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">381932039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-231273383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">150736600</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4007996</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4008</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">24107190</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">24111198</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:CommitmentSharesShares>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">78</avxl:CommitmentSharesValue>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-78</avxl:CommitmentSharesValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5634576</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5634</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">79101914</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">79107548</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-2437523</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-2437523</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2380953</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2381</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">49997619</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">50000000</avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts>
    <avxl:LessShareIssueCosts1
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-3095938</avxl:LessShareIssueCosts1>
    <avxl:LessShareIssueCosts1
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-3095938</avxl:LessShareIssueCosts1>
    <avxl:SharesIssuedUponExerciseOfStockOptionsShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">652897</avxl:SharesIssuedUponExerciseOfStockOptionsShares>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">653</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1867755</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">1868408</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <avxl:SharesIssuedPursuantToExerciseOfWarrantsShares
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350000</avxl:SharesIssuedPursuantToExerciseOfWarrantsShares>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">350</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1466150</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">1466500</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5079395</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75149833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">342938236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-185867658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157145729</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-26190428</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-2577002</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">3751918</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">106414</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-185641</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-1612889</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">187653</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">299047</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">1336660</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">443831</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">-20193929</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">-22709166</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">20982148</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">153218746</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">706802</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">5533461</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">1466500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">1010190</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">1868408</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">21285536</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">151020193</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">1091607</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">128311027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">153199352</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">157560045</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">141374</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">98281</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLgoFKzLxsKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;Note 1 	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_823_z3PTuESTS5q3"&gt;Description
of Business and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Description
of Business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anavex
Life Sciences Corp. (&#x201c;Anavex&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the
development of differentiated therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with
high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#x2019;s lead compound
ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central
nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations
in the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements
in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the
disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments,
which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance
sheet as of September 30, 2021 was derived from the audited annual financial statements but does not include all disclosures required
by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September
30, 2021 filed with the SEC on November 24, 2021. The Company follows the same accounting policies in the preparation of interim reports.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research
and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business
to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business
might become profitable.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;





&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;







&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital requirements beyond
the next 12 months after the date that these interim condensed consolidated financial statements are issued. The process of drug development
can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its
estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary
depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress
of the Company&#x2019;s research and development programs and the level of financial resources available. The Company has the ability
to adjust its operating plan spending levels based on the timing of future clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
than our rights related to the Sales Agreement (as defined below in Note 5), there can be no assurance that additional financing will
be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able
to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all
of its research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in
the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors, including
the potential future effects of COVID-19, that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates.
To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;















&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia
Pty Limited. (&#x201c;Anavex Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated
under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
that may be used to measure fair value which are the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose
significant value drivers are observable; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2022 and September 30, 2021, the Company did not have any Level 3 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Basic
and Diluted Loss per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number
of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available
to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive
effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities
and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2022, loss per share excludes &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,194,616&lt;/span&gt; (September 30, 2021 &#x2013; &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,540,903&lt;/span&gt;) potentially dilutive common shares related
to outstanding options and warrants, as their effect was anti-dilutive.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;





&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;












</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">13194616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Shares">11540903</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_804_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_z7xuxYhTmh61" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
2	&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82E_zAeS4gxOqSyc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrnSjxk9FKFh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_znxLYpWZ61af"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 1, 2021, the Company adopted ASU 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740 and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s
operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrnSjxk9FKFh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_znxLYpWZ61af"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 1, 2021, the Company adopted ASU 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740 and clarifying and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s
operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_803_ecustom--OtherIncomeDisclosureTextBlock_zzZm1O5SAftb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_822_z4X41tOnbOO2"&gt;Other Income&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&#160;&#160;&#160;Grant Income&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended September 30, 2021, the Company received $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"&gt;497,931&lt;/span&gt; of a $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_pp0p0" title="Research and development incentive income"&gt;995,862&lt;/span&gt; research grant awarded by the Michael J. Fox Foundation
for Parkinson&#x2019;s Research. The grant will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73
related to Parkinson&#x2019;s disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the three and nine months ended June 30, 2022, the Company did &lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20220401__20220630_zOb9sGlxU7Kh" title="Grant income"&gt;&lt;span id="xdx_90D_ecustom--NonOperatingIncomeFromGrant_pp0p0_do_c20211001__20220630_zDDYDoUqL1vg" title="Grant income"&gt;no&lt;/span&gt;&lt;/span&gt;t recognize any of this grant on its statements of operations
(2021: $&lt;span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20210401__20210630_pp0p0" title="Grant income"&gt;43,280&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20201001__20210630_pp0p0" title="Grant income"&gt;54,100&lt;/span&gt; respectively). At June 30, 2022, an amount of $&lt;span id="xdx_90A_ecustom--DeferredGrantIncome_c20220630_pp0p0" title="Deferred grant income"&gt;443,831&lt;/span&gt; (September 30, 2021: $&lt;span id="xdx_90C_ecustom--DeferredGrantIncome_c20210930_pp0p0" title="Deferred grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded
as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize
this income on its statement of operations as the relating expenditures are incurred to offset the income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development incentive income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit,
(the &#x201c;R&amp;amp;D Incentive Credit&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine months ended June 30, 2022 the Company recorded research and development incentive income of $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income"&gt;682,432&lt;/span&gt; (AUD &lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;954,986&lt;/span&gt;)
and $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income"&gt;2,328,675&lt;/span&gt; (AUD &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;3,218,303&lt;/span&gt;) (2021: $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630_pp0p0" title="Research and development incentive income"&gt;1,363,661&lt;/span&gt; (AUD &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20210401__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;1,770,444&lt;/span&gt;) and $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630_pp0p0" title="Research and development incentive income"&gt;3,593,856&lt;/span&gt; (AUD &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;4,750,539&lt;/span&gt;)), respectively, related to the R&amp;amp;D
Incentive Credit for eligible research and development expenses incurred during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_MichaelJFoxMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_ParkinsonMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">43280</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">54100</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">682432</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-04-012022-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">954986</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">2328675</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">3218303</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1363661</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-04-012021-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">1770444</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">3593856</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">4750539</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zEbnwKkJkcY1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
4	 	 &#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_zEf0nvcC1Im"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
principal components of accrued liabilities consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.75in"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zofAQJYzLUP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zJFGzxI2vDD2" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20220630_zJmxZ22azvp4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210930_zgjOArYxjdS9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maCzJSg_maALCzSaG_zRac5IN3zXEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Clinical site costs and patient visits&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,138,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,035,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedBonusesCurrent_iI_maCzJSg_maALCzSaG_zNBXJ800tLe8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889,616&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FixedContractAccruals_iI_maCzJSg_maALCzSaG_zhyBwY25iGi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;649,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedLicenseFeesPayables_iI_maCzJSg_maALCzSaG_zy7280LISuQ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued license fees payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0606"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maCzJSg_maALCzSaG_zRHuQh5sgOCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,050,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,727,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzSaG_znXYB0qE5qgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; color: White; text-indent: -10pt"&gt;Total accrued liabilities &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,913,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,614,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zJy5wECD7XTc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-indent: 0.75in"&gt;&#160;&lt;/p&gt;














</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zofAQJYzLUP3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zJFGzxI2vDD2" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20220630_zJmxZ22azvp4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210930_zgjOArYxjdS9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maCzJSg_maALCzSaG_zRac5IN3zXEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Clinical site costs and patient visits&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,138,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,035,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedBonusesCurrent_iI_maCzJSg_maALCzSaG_zNBXJ800tLe8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889,616&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FixedContractAccruals_iI_maCzJSg_maALCzSaG_zhyBwY25iGi8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;649,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedLicenseFeesPayables_iI_maCzJSg_maALCzSaG_zy7280LISuQ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued license fees payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0606"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maCzJSg_maALCzSaG_zRHuQh5sgOCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,050,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,727,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzSaG_znXYB0qE5qgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; color: White; text-indent: -10pt"&gt;Total accrued liabilities &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,913,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,614,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">2138505</avxl:ClinicalSiteCostsAndPatientVisits>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2035800</avxl:ClinicalSiteCostsAndPatientVisits>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">889616</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1201903</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">334887</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">649649</avxl:FixedContractAccruals>
    <avxl:AccruedLicenseFeesPayables contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">500000</avxl:AccruedLicenseFeesPayables>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">2050813</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1727422</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">5913821</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:EquityOfferingTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_805_ecustom--EquityOfferingTextBlock_zI3gvjmJbt24" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
5&#160;&#160;&#160;&#160;&#160;&#160;	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82D_zrXqiavVlsY4"&gt;Equity Offerings&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
shares are voting and are entitled to dividends as declared at the discretion of the Board of Directors (the &#x201c;Board&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preferred
Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Board has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the
&#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant
to which the Company may offer and sell shares of common stock registered under an effective registration statement from time to time
through the Sales Agents (the &#x201c;Offering&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
delivery of a placement notice based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales Agreement,
the Sales Agents may sell the Shares by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted
by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon notice
to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on a commercially reasonable efforts basis
consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of
Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has agreed to pay the Sales Agents commissions for their services of up to &lt;span id="xdx_907_ecustom--PercentageOfGrossProceedsFromSales_dp_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zPhXlmfMizje" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares
pursuant to the Sales Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution
rights. During the nine months ended June 30, 2022, &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"&gt;1,623,566&lt;/span&gt; shares were sold pursuant to the Offering for gross proceeds of $&lt;span id="xdx_906_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztZUZfpJGtNc" title="Gross proceeds from Issuance Public Offering"&gt;20,982,148&lt;/span&gt;
(net proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z0N81rBaPW0g"&gt;20,258,981&lt;/span&gt; after deducting offering expenses) (2021: &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"&gt;5,634,576&lt;/span&gt; shares were sold for gross proceeds of $&lt;span id="xdx_90D_ecustom--GrossProceedsFromIssuancePublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zjH13dysxIXd"&gt;79,107,548 &lt;/span&gt;(net
proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20201001__20210630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z8i8iutnnCX" title="Proceeds from Issuance Public Offering"&gt;76,670,025&lt;/span&gt; after deducting offering expenses)). At June 30, 2022, an amount of $&lt;span id="xdx_908_ecustom--SalesOfAgreementAmount_c20220630_pp0p0" title="Sales of agreement amount"&gt;142,410,402&lt;/span&gt; (September 30, 2021: $&lt;span id="xdx_90A_ecustom--SalesOfAgreementAmount_c20210930_pp0p0" title="Sales of agreement amount"&gt;163,392,550&lt;/span&gt;)
was registered pursuant to an effective registration statement and remained available to be sold under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;





&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2019
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln Park,
as amended on July 1, 2020, pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated
to purchase, up to $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Value of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; in value of its shares of common stock from time to time over a three-year period until July 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment
fee during the year ended September 30, 2019 and agreed to issue up to &lt;span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased,
at the Company&#x2019;s discretion, the $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"&gt;50,000,000&lt;/span&gt; aggregate commitment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2022 and September 30, 2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the nine months
ended June 30, 2021, the Company issued to Lincoln Park an aggregate of 4,086,209 shares of common stock including&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Shares issued under Sales Agreement, net of shares issue costs, shares"&gt; 4,007,996 &lt;/span&gt;shares of
common stock for an aggregate purchase price of $&lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodValueNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;24,111,198&lt;/span&gt; and &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"&gt;78,213&lt;/span&gt; commitment shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1623566</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20982148</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20258981</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">5634576</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:GrossProceedsFromIssuancePublicOffering
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">79107548</avxl:GrossProceedsFromIssuancePublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-10-012021-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">76670025</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">142410402</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">163392550</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4007996</us-gaap:StockIssuedDuringPeriodSharesOther>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111198</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <avxl:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">78213</avxl:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2021-10-01to2022-06-30">&lt;p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zUkmgXtOrZV" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
6 &#160;&#160;&#160;&#160;&#160;	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_824_zBzixcaVAMh5"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Leases
                                            &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended June 30, 2022, the Company incurred office lease expense of $&lt;span id="xdx_90C_ecustom--OperatingLeasesRentExpense_pp0p0_c20220401__20220630_zVXelDSDtp78" title="Operating Leases, Rent Expense"&gt;21,015&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--OperatingLeasesRentExpense_pp0p0_c20211001__20220630_z1mqR2uyz4Gh" title="Operating Leases, Rent Expense"&gt;42,348&lt;/span&gt; (2021: $&lt;span id="xdx_901_ecustom--OperatingLeasesRentExpense_pp0p0_c20210401__20210630_zaD4miPJIuv" title="Operating Leases, Rent Expense"&gt;18,994&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pp0p0_c20201001__20210630_zQ93tVUH60Rk" title="Operating Leases, Rent Expense"&gt;117,284&lt;/span&gt;),
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
                                            401(k) Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States
based employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits
under the Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf
of contributing employees. During the three and nine months ended June 30, 2022, the Company made $&lt;span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount"&gt;27,358&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount"&gt;120,979&lt;/span&gt; (2021: $&lt;span id="xdx_90D_eus-gaap--PensionContributions_c20210401__20210630_pp0p0" title="Contribution amount"&gt;28,221&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--PensionContributions_c20201001__20210630_pp0p0" title="Contribution amount"&gt;102,261&lt;/span&gt;), respectively, in matching contributions under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of
any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company does not believe
that any of&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;such pending claims and legal proceedings will have a material
adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"/&gt;




&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Share
                                            Purchase Warrants&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;A
summary of the status of the Company&#x2019;s outstanding share purchase warrants is presented below:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zK5wHvBHg8sc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_z70YmB198CNl" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbGMSNhIGru3" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3fTEuyi5mV9" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5RcCHtEpdA8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5eiDf3kky1j" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8Su0NIbLQfb" style="border-bottom: Black 1pt solid; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmDf35Q0VM65" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zNv0ptqaCx2h" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z4jkyl37RxKb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zXr7NlRY7Wk9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2022, the Company had share purchase warrants outstanding as follows&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zMsYB5MDcFyg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z404gnhCoY16" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9VHEbdWG2S4" style="width: 15%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="text-align: right; width: 43%" title="Expiry Date"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z8NbKxtdZnuh" style="text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date"&gt;April 21, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630_pdd" title="Number"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_zngh7yVOQCQf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Stock&#x2013;based
                                            Compensation Plan&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2015
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 18, 2015, the Company&#x2019;s Board approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for
the grant of stock options and restricted stock awards to directors, officers, employees and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
maximum number of our common shares reserved for issue under the plan was &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553 &lt;/span&gt;shares, subject to adjustment in the event of a change
of the Company&#x2019;s capitalization.&lt;/span&gt;&lt;/p&gt;

























&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2019
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock
options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
maximum number of our common shares reserved for issue under the plan was &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change
of the Company&#x2019;s capitalization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended June 30, 2022, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"&gt;406,453&lt;/span&gt; options previously available under the 2019 Plan and the 2015 Plan became available under
the 2022 Plan (as defined below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 25, 2022, the Board approved the 2022 Omnibus Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders
on May 24, 2022. Under the terms of the 2022 Plan, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"&gt;10,000,000 &lt;/span&gt;additional shares of Common Stock will be available for issuance under
the plan, in addition to the shares available under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option
plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2022 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2022 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise
price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date. If the grantee
is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s
shares of common stock on the grant date. Stock options may be granted under the 2022 Plan for an exercise period of up to ten years
from the date of grant of the option or such lesser periods as may be determined by the Board, subject to earlier termination in accordance
with the terms of the 2022 Plan. At June 30, 2022, &lt;span id="xdx_903_ecustom--OptionIssued_c20211001__20220630_zCy7QikHbqnc" title="Option issued"&gt;1,298,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"&gt;9,108,453&lt;/span&gt; options were available
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;for issue under the 2022 Plan, subject to stockholder approval.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"/&gt;















&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;







&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the status of Company&#x2019;s outstanding stock options is presented below:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z3RpVtIMXVxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zXcHLOesnPX6" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW7csxuW2u4k" style="width: 16%; text-align: right" title="Options Outstanding at beginning"&gt;10,076,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7S42xtkyY9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDovu43sShld" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;14,982,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;2,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;9.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWo7Hm1SFE7g" style="text-align: right" title="Options Forfeited"&gt;(55,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh40HCrd7f7j" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(1,421,529&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;24,446,305&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhKCOuPfuv9" style="text-align: right"&gt;11,330,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwNcCePmjql" style="text-align: right"&gt;5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z43nyzVsP9Kb" style="text-align: right"&gt;140,132,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;2,208,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;6.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDW302EiwCWj" style="text-align: right" title="Options Forfeited"&gt;(103,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;5.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;4.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqoNCG0pvAe9" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbd22WklfOO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;13,034,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zba3DJqh9KD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6XyoAO0I9b6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;58,809,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable at ending"&gt;8,562,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;52,439,132&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A8_zxAdCEvk0cRl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes information about stock options at June 30, 2022 by a range of exercise prices:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPysIElXurS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zJpjIQXnZA67" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercise
    prices&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,903,762&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znyQxmLkyTTf" title="Weighted average remaining contractual life (in years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,868,762&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,078,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zW9HrtBWztBi" title="Weighted average remaining contractual life (in years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,058,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,957,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2E2p7T6fm9i" title="Weighted average remaining contractual life (in years)"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,356,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,798,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zS4voK6pDsU" title="Weighted average remaining contractual life (in years)"&gt;9.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;209,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zpfoLjFBhYRb" title="Weighted average remaining contractual life (in years)"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68,750&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,034,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,562,530&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zU2ipszcQbD8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of options vested during the three and nine months ended June 30, 2022 was $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220401__20220630_pdd" title="Weighted average grant date fair value of options vested"&gt;3.83&lt;/span&gt; (2021: $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested"&gt;3.16&lt;/span&gt;).
At June 30, 2022, the weighted average contractual life of options outstanding was &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_z0M2wwhieNDd" title="Weighted average contractual life of options outstanding"&gt;6.62&lt;/span&gt; years (September 30, 2021: &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zmCILppq5ra3" title="Weighted average contractual life of options outstanding"&gt;6.65&lt;/span&gt; years) and for
options exercisable was &lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630_zUpcE52yDoOa" title="Options exercisable"&gt;5.21&lt;/span&gt; years (September 30, 2021: &lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zgs3PZs6pVf9" title="Options exercisable"&gt;5.80&lt;/span&gt; years).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price
of the Company&#x2019;s stock for the options that were in-the-money at June 30, 2022.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;





&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;







&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine months ended June 30, 2022, the Company recognized stock-based compensation expense of $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation"&gt;3,988,614&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation"&gt;12,336,844&lt;/span&gt;
(2021: $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" title="Share based compensation"&gt;2,293,925&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" title="Share based compensation"&gt;5,079,395&lt;/span&gt;), respectively, in connection with the issuance and vesting 	of stock options and warrants in exchange
for services. These amounts have been included in general and 	administrative expenses and research and development expenses on the
Company&#x2019;s statement of 	operations as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ6OMAf8vqW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zxQqWg1gJINh" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three months
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine months
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,490,267&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,048,606&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,739,021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,265,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,498,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,245,319&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,597,823&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,814,008&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,988,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,293,925&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,336,844&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,079,395&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zTZt5sDBAkK8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
amount of approximately $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20220630_pp0p0" title="Remaining stock based compensation"&gt;24,276,312 &lt;/span&gt;in stock-based compensation is expected to be recorded over the remaining term 	of such options
through fiscal 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each option award granted during the three and nine months ended June 30, 2022 and 2021 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9doc0ils37e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zbUynMVHmZqd" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zc2QyWVE6FZ1" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;3.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210630_ze8xOE24DzWj" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;0.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zSPFF48pCIg1" title="Expected life of options (years)"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_z42JGOJBRUka" title="Expected life of options (years)"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_zIyV5jZrco1d" style="text-align: right" title="Annualized volatility"&gt;84.12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210630_zksKYXLCc5me" style="text-align: right" title="Annualized volatility"&gt;95.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_zXC4piOcNug2" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210630_zNJdFZDYkbQc" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AA_zbiVlCUIx3wg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock compensation charges recognized during the three and nine months ended June 30, 2022 and 2021 was determined with
reference to the quoted market price of the Company&#x2019;s shares on the grant date.&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <avxl:OperatingLeasesRentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">21015</avxl:OperatingLeasesRentExpense>
    <avxl:OperatingLeasesRentExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">42348</avxl:OperatingLeasesRentExpense>
    <avxl:OperatingLeasesRentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">18994</avxl:OperatingLeasesRentExpense>
    <avxl:OperatingLeasesRentExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">117284</avxl:OperatingLeasesRentExpense>
    <us-gaap:PensionContributions
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">27358</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">120979</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">28221</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">102261</us-gaap:PensionContributions>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zK5wHvBHg8sc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_z70YmB198CNl" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zbGMSNhIGru3" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3fTEuyi5mV9" style="border-bottom: Black 1pt solid; width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5RcCHtEpdA8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z5eiDf3kky1j" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8Su0NIbLQfb" style="border-bottom: Black 1pt solid; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmDf35Q0VM65" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zNv0ptqaCx2h" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z4jkyl37RxKb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">60000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.69</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2021-10-012022-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited
      contextRef="From2021-10-012022-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zMsYB5MDcFyg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z404gnhCoY16" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9VHEbdWG2S4" style="width: 15%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="text-align: right; width: 43%" title="Expiry Date"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_z8NbKxtdZnuh" style="text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20220630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date"&gt;April 21, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20220630_pdd" title="Number"&gt;160,000&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-06-30_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-06-30_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2022-06-30" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-10-012022-06-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Shares">1298000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-06-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">9108453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z3RpVtIMXVxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zXcHLOesnPX6" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW7csxuW2u4k" style="width: 16%; text-align: right" title="Options Outstanding at beginning"&gt;10,076,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7S42xtkyY9e" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDovu43sShld" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;14,982,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;2,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;9.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWo7Hm1SFE7g" style="text-align: right" title="Options Forfeited"&gt;(55,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh40HCrd7f7j" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(1,421,529&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;24,446,305&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIhKCOuPfuv9" style="text-align: right"&gt;11,330,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwNcCePmjql" style="text-align: right"&gt;5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z43nyzVsP9Kb" style="text-align: right"&gt;140,132,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;2,208,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;10.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;6.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDW302EiwCWj" style="text-align: right" title="Options Forfeited"&gt;(103,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;5.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;4.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqoNCG0pvAe9" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(400,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zbd22WklfOO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;13,034,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zba3DJqh9KD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6XyoAO0I9b6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;58,809,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable,
    June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable at ending"&gt;8,562,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;4.11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;52,439,132&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2732000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">55834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.43</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1421529</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.43</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-10-012021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">24446305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">103750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.04</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">400537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.88</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13034616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">58809090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8562530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">52439132</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zPysIElXurS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zJpjIQXnZA67" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercise
    prices&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,903,762&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znyQxmLkyTTf" title="Weighted average remaining contractual life (in years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,868,762&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,078,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zW9HrtBWztBi" title="Weighted average remaining contractual life (in years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,058,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,957,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z2E2p7T6fm9i" title="Weighted average remaining contractual life (in years)"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,356,221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,798,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zS4voK6pDsU" title="Weighted average remaining contractual life (in years)"&gt;9.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;209,997&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,297,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zpfoLjFBhYRb" title="Weighted average remaining contractual life (in years)"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68,750&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,034,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,562,530&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3903762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3868762</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2078800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2058800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3957054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">P6Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">2356221</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">10.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">17.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">1798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">P9Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">11.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">209997</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">14.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1297000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">P9Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">19.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">68750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13034616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012022-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8562530</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="USDPShares">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2022-06-30">P6Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P6Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2022-06-30">P5Y2M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zQ6OMAf8vqW8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zxQqWg1gJINh" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three months
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine months
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,490,267&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,048,606&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,739,021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,265,387&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,498,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,245,319&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,597,823&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,814,008&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,988,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,293,925&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,336,844&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,079,395&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1490267</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1048606</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">4739021</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2265387</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2498347</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1245319</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">7597823</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2814008</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2293925</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012021-06-30"
      decimals="0"
      unitRef="USD">5079395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">24276312</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-10-01to2022-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9doc0ils37e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zbUynMVHmZqd" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zc2QyWVE6FZ1" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;3.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210630_ze8xOE24DzWj" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;0.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zSPFF48pCIg1" title="Expected life of options (years)"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210630_z42JGOJBRUka" title="Expected life of options (years)"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_zIyV5jZrco1d" style="text-align: right" title="Annualized volatility"&gt;84.12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210630_zksKYXLCc5me" style="text-align: right" title="Annualized volatility"&gt;95.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_zXC4piOcNug2" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210630_zNJdFZDYkbQc" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Pure">0.0310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-012021-06-30"
      decimals="INF"
      unitRef="Pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-01to2022-06-30">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-012021-06-30">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Pure">0.8412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-012021-06-30"
      decimals="INF"
      unitRef="Pure">0.9587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-01to2022-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-012021-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!)&0NYOT[D&+JKF,+H6&JVVSW# *X(T O%\)( _M@[G?=O_/F/T'4$L#!!0
M   ( /B#"56[Q8,1T (  *L(   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULK99=;]HP%(;_BI5-4RMUY ,":0>16J9JG30)%76[F'9AD@.QZMB9[4"W
M7[_C)$30IA2D<0'^..?-<]XXG(PW4CWJ#,"0IYP+/7$R8XHKU]5)!CG5/5F
MP)VE5#DU.%4K5Q<*:%HEY=P-/&_HYI0))QY7:S,5CV5I.!,P4T27>4[5GQO@
M<C-Q?&>[<,]6F;$+;CPNZ KF8!Z*F<*9VZJD+ >AF11$P7+B7/M7T\C&5P'?
M&6STSIC82A92/MK)73IQ/ L$'!)C%2C^K&$*G%LAQ/C=:#KM)6WB[GBK?EO5
MCK4LJ(:IY#]8:K*)$SDDA24MN;F7FR_0U!-:O41R77V331/K.20IM9%YDXP$
M.1/U+WUJ?-A)\ >O) 1-0G!L0K])Z%>%UF1569^IH?%8R0U1-AK5[*#RILK&
M:IBP=W%N%.XRS#/QG3"@6$ZF4J1X;R"U(RTY2ZG!R0WE5"1 YO8"FIP]"%JF
M#'?.R=F,*A F \,2RL_)1_*>N$1GN*K'KD$V>P4W:3AN:H[@%8ZOI>B1OG=!
M B\(.M*GA]/G4+3I_GZZBXZTM@2M+4&EUW]-SV#Y>%@-D4MRRP2:P"@G,ZE9
M=?I^7B^T47@&?W656FL/NK7M<WFE"YK Q,$'3X-:@Q-_>.</O4]=A?\GL3T;
M^JT-_4/J\0R?*5 *#P(>Q.3QHKF]A)8FDXK]A;2K_%HSK#3MO\@Z]KWZ,W;7
MNZ4=$;B'/6BQ!Z=A%U21->4E=.'66J,="J_G>?XSUK>B]D##%C0\"#J5>8ZG
MZ11SPQ>>!5ZWN\=$[E$/6^KA"=0'O1T>Y>U;47N4HY9R=+JW3.NRV]?1"[=&
MH\M!$ ZC9[ =@>&E'PV&83=OU/)&I_-BW]6&BI2)51=T="QT1V WM+O32FP;
M_T;5B@E-."PQU>N-4$/5K;&>&%E4W64A#?:J:ICAVP0H&X#[2RG-=F(;5OM^
M$O\#4$L#!!0    ( /B#"55XO*O4N04  .P8   8    >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&ULK5EM;]LV$/XKA#<,*9#&XHLH*4L,-+:W=5BWHEG7SXI-
MVT(ET1-I)_OW.TJR;%&4D'7Z$EOR<P]YSQV/1^;N619?U4X(C5ZR-%?WDYW6
M^]OI5*UV(HO5C=R+''[9R"*+-3P6VZG:%R)>ET99.B6>QZ=9G.23V5WY[F,Q
MNY,'G2:Y^%@@=<BRN/CG0:3R^7Z")Z<7GY+M3IL7T]G=/MZ*1Z$_[S\6\#1M
M6-9))G*5R!P58G,_>8=OES@R!B7BKT0\JXOOR+CR).57\_!^?3_QS(Q$*E;:
M4,3P<11SD::&">;Q=TTZ:<8TAI??3^P_E<Z#,T^Q$G.9?DG6>G<_"2=H+3;Q
M(=6?Y/,OHG;(-WPKF:KR+WJNL($W0:N#TC*KC6$&69)7G_%++<2% ?"X#4AM
M0&P#UF- :P/ZVA%8;<!>.X)?&Y2N3RO?2^$6L8YG=X5\1H5! YOY4JI?6H->
M26X2Y5$7\&L"=GKVJ&,M(/!:(;E!?^Q%$9L *A3G:S27&63?SJ3%4:#?I%+H
MZG,>']:)%NLWZ"WZ_+A 5]^_N9MJF(HAG*[J81^J84G/L!1]D+G>*;3,UV+M
ML%\,VT<#]E.0H-&!G'1X((.$OQ[R&T2]:T0\0ASSF;_>'+O<^7^C+[]Y])88
MM$D*6O+1'KXZ#?(M$B]0D910K@A7',S-80K<K=K'*W$_@1Q2HCB*R>R'[S#W
M?G3).R;98DRRY4ADK4"P)A!LB'WVL\@A$FFY&.,U+/]$:1.9HW %I.+B)9?9
M((XSBD.?^9 2QTNMNSC"*,,D:.,675R$>>!SKXU;=G$<T] G88-K.>\WSON#
MSG\".>-BM2N]7XLC;&I[4ZE<KE=,_N5424 )CRS7N[@PXNQRJI7K71SA/F4D
MLC1:.H"48R\,>YSGC?-\T/D_I8:XRU<M1-Z9PUM,F!\&Q(K4W(7$- JY[UL"
M.)#4#SS()UL!!Q)D8A'#W"U!T$@0#%<AO1,%2O*5S 2Z.@G@W&R",4O1F&2+
M,<F6(Y&UHA$VT0B'2U$1Y[J.ABL$@];NN2&7^F$GG1@EH97(BY%&6W9'\QGV
M/'?B1HU4T3<5+J,>?)A>JE_'J#,C'D)Y)M9*[L(PY91SJ]8ONC@"<D(5MU9Q
M%T?]"(IXSQK&WKF_] ;%>)]K 3$XI<XURH6S@M<TK9F2*,)6N9D[<!@SGUI^
MN^@889[MMXLNPK@G _!%6XT'W893#)Q1<JC;JUV<;\55"MWS&[2%HUN_!+A;
M2F$3\YF]B[F L,S#SC)Q 9D'/0&V9>@"<0!"],A SC*0UVQC%Y6\WWOBF$(4
M>O8>YL(1/_ QLYWO @GFQ*>1[7P72'G(R,56UW;_W$?CP>YP]CN<]$W@T9.
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ME8X*R8-6&B2!$YE3C6]H2P=R<TRVQ:ALR['8VI$Z-]AXN,-^76YV>]H@8(Q
MO;33TX'T_##B]M7)PH7D/A1 9E^*.) \"+$'4[#R='IQ>YN)8EM>FRO8$0ZY
MKN[LFK?-U?R[\D+:>O^ ;^?8\7YAKO++V^(S??5_@ ]QL4URA5*Q@:&\FP"F
M6U17Z]6#EOOR[OA):BVS\NM.Q&M1& #\OI%2GQ[, ,T_.&;_ E!+ P04
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M^0A8QL"K'G%;TG!6CV"#O,,*][0$[G&)'R%H\$[0X*\(&A[5(QC*8[7 ;4F
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M@^(-A@Z?6(#[A)D;3Z?TJ&]3&$?RO[)PPWHY](7H\J]'0@0TE2 ,Z0:08^[
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MS+;&TP*\GSO$/'T@!?VO=%[^%U!+ P04    " #X@PE5^MD5RC(#  #Z!@
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M_GR1.*"&AV$PM&QM,]Y*3:W=#BMZ2U$9!UK?2;K"HV$"3*_SYA]02P,$%
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M;0+4M=5NXFT;6]G*>FZ,<5CSGP@I!/!^::T_3H+ Z=\V_1=02P,$%     @
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M<9D42CTZXTLU":@3! )*ZQ@8OI[@%H1P1"CCSYXSZ$(ZX/'ZP/[)YXZY%,S
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ML<(\4+O7,KVY^[YP#@\;>Y+P;>:Y28:N85(1=!9P*<'HA6#TYF4*>'IB=J_
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M@HT@2+,!WR^%T/<3TYM4K67T!U!+ P04    " #X@PE5\WE F+0$  #E$P
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M0@YZ^G CIWU@RD">7U$JGA8J0/__P>)?4$L#!!0    ( /B#"54KO,SYT@(
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M)G!4^PS1,LO1LA"%?$JJ721-%[UKGMK=X7;--BS#LKJ;#OV\SE;X1+<^J-L
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MR)+RXYK1D.5J@/Q^F67B^4 Y:%[9G/X/4$L#!!0    ( /B#"551#*BN, ,
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MM+FXS-F*Y9.FJ^=3UXQLPV9M+B <(M?N"B,8QV-A!# L#^8 XW@6EN=_FL\
MG8_',&^#(#) .0.4XUDA9.(^6)XP)[-7>*99EB1IBJWH9!)T,,'6+4WA&U;#
MO $#RP.9_FRM\=W&*^3I.L#V]*D*P6:*5R(V4WRM 0FO&S"R++S;6!Y@8+N
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M[MSRK[_=V[4P4MF#/^M^D,P^ 5!+ 0(4 Q0    ( /B#"54'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ ^(,)5=I>6<;N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ ^(,)59E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #X@PE5
M*@I_&_\%  "-(   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ ^(,)51) ;B*K!   VQ   !@
M     ("!0@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M /B#"56[Q8,1T (  *L(   8              " @2,3  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #X@PE5>+RKU+D%  #L&   &
M            @($I%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ ^(,)50/4VEC?"P  ;&(  !@              ("!&!P  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /B#"56Y/IZKK@4  +H5
M   8              " @2TH  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #X@PE5%(JF19 -  "Q(P  &               @($1+@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ^(,)5?K9%<HR
M P  ^@8  !@              ("!USL  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( /B#"54<Z3-24 ,  *D'   8              "
M@3\_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #X@PE5
MR!U6PN\"  !G!@  &0              @('%0@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( /B#"5747DC8KP8  -X/   9
M      " @>M%  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ ^(,)5<S,I& D#   9Q\  !D              ("!T4P  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #X@PE5>OXI!#8#  #G!@
M&0              @($L60  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( /B#"56S.^N(U0(  "0&   9              " @9E<  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ^(,)57":NMMD
M!@  61$  !D              ("!I5\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #X@PE5FN3)<9@"   ^!@  &0
M@(% 9@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /B#
M"54M0 [X:00  "8<   9              " @0]I  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ ^(,)59IKO+_U @  D @  !D
M         ("!KVT  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #X@PE5Q^@4KTD%  "Y'0  &0              @(';<   >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /B#"55H+V8BA@,  )X-
M   9              " @5MV  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ ^(,)5<-A;<?L @  9@H  !D              ("!&'H
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #X@PE5\WE
MF+0$  #E$P  &0              @($[?0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( /B#"55>#'6X_ <   %%   9
M  " @2:"  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M^(,)57VF-">0 P  2Q   !D              ("!68H  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #X@PE5*[S,^=("  #Q!P  &0
M            @($@C@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( /B#"55,6_+%/@8  +XI   9              " @2F1  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ^(,)55$,J*XP P
M[A(   T              ( !GI<  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #X@PE5EXJ[',     3 @  "P              @ 'YF@  7W)E;',O+G)E
M;'-02P$"% ,4    " #X@PE5F\C;\\@"   L$@  #P              @ 'B
MFP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ^(,)5?_DO>-" 0  11
M !H              ( !UYX  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ^(,)5:H=$+!V 0  *!$  !,              ( !4:
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "( (@ E"0  ^*$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>178</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Interim Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>Interim Condensed Consolidated Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Description of Business and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e3945_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e3945_10q.htm">e3945_10q.htm</File>
    <File>avxl-20220630.xsd</File>
    <File>avxl-20220630_cal.xml</File>
    <File>avxl-20220630_def.xml</File>
    <File>avxl-20220630_lab.xml</File>
    <File>avxl-20220630_pre.xml</File>
    <File>e3945_ex31-1.htm</File>
    <File>e3945_ex31-2.htm</File>
    <File>e3945_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="372">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>44
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e3945_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 92,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e3945_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 285,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20220630": 29,
    "http://fasb.org/us-gaap/2022": 36,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 70
   },
   "keyCustom": 42,
   "keyStandard": 136,
   "memberCustom": 18,
   "memberStandard": 7,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Accrued liabilities",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Recent Accounting Pronouncements (Policies)",
     "role": "http://anavex.com/role/RecentAccountingPronouncementsPolicies",
     "shortName": "Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Accrued liabilities (Tables)",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)",
     "role": "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
     "shortName": "Description of Business and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Accrued liabilities (Details)",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Equity Offerings (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2021-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2020-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 1)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 3)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-012022-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 4)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details 5)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "shortName": "Commitments and Contingencies (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:OperatingLeasesRentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:OperatingLeasesRentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2022-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Interim Condensed Consolidated Statement of Changes in Stockholders' Equity",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "Interim Condensed Consolidated Statement of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Interim Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://anavex.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3945_10q.htm",
      "contextRef": "From2021-10-01to2022-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "avxl_AccruedLicenseFeesPayables": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued license fees payables"
       }
      }
     },
     "localname": "AccruedLicenseFeesPayables",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ClinicalSiteCostsAndPatientVisits": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical site costs and patient visits"
       }
      }
     },
     "localname": "ClinicalSiteCostsAndPatientVisits",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesShares",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_CommitmentSharesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesValue",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DeferredGrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredGrantIncome",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncome",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20220630",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20220630",
     "xbrltype": "stringItemType"
    },
    "avxl_EarningPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_EquityOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingTextBlock",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrossProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "GrossProceedsFromIssuancePublicOffering",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncreaseDecreaseInDeferredGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInDeferredGrantIncome",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LessShareIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: share issue costs"
       }
      }
     },
     "localname": "LessShareIssueCosts",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LessShareIssueCosts1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LessShareIssueCosts1",
        "verboseLabel": "Less: share issue costs"
       }
      }
     },
     "localname": "LessShareIssueCosts1",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_MichaelJFoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "localname": "MichaelJFoxMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NetLossAndComprehensiveLoss": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetLossAndComprehensiveLoss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetLossAndComprehensiveLoss",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrants",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OperatingLeasesRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpense",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_OptionIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "localname": "OptionIssued",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ParkinsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parkinson [Member]"
       }
      }
     },
     "localname": "ParkinsonMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceForfeited",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareProceedsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Proceeds Receivable [Member]"
       }
      }
     },
     "localname": "ShareProceedsReceivableMember",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfWarrants",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of warrants, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfWarrantsShares",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering, net of share issuance costs"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCosts",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to registered direct offering, net of share issuance costs, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssuanceCostsShares",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementNetOfShareIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, net of share issue costs"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementNetOfShareIssueCosts",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales agreement, net of shareissue costs, shares"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementNetOfShareissueCostsShares",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUponExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of stock options, shares"
       }
      }
     },
     "localname": "SharesIssuedUponExerciseOfStockOptionsShares",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues1",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2022Member",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://anavex.com/20220630",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r265",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities (Note 4)",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r154",
      "r155",
      "r156",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r7",
      "r43",
      "r67",
      "r69",
      "r72",
      "r77",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r170",
      "r174",
      "r186",
      "r209",
      "r211",
      "r230",
      "r238"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r6",
      "r41"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r194"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r233",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r45",
      "r46",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding:77,942,568 common shares (September 30, 2021 - 75,918,465)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r44",
      "r160",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "avxl_NetLossAndComprehensiveLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r25",
      "r26",
      "r27",
      "r45",
      "r46",
      "r47",
      "r51",
      "r58",
      "r60",
      "r66",
      "r78",
      "r104",
      "r105",
      "r154",
      "r155",
      "r156",
      "r161",
      "r162",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange(loss) gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r67",
      "r68",
      "r70",
      "r71",
      "r73",
      "r229",
      "r234",
      "r237",
      "r244"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "avxl_NetLossAndComprehensiveLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r10",
      "r232",
      "r242"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r43",
      "r77",
      "r186",
      "r211",
      "r231",
      "r240"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r19",
      "r43",
      "r77",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r171",
      "r174",
      "r175",
      "r186",
      "r209",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r38",
      "r40"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r23",
      "r24",
      "r27",
      "r29",
      "r40",
      "r43",
      "r50",
      "r54",
      "r55",
      "r56",
      "r57",
      "r59",
      "r60",
      "r64",
      "r67",
      "r68",
      "r70",
      "r71",
      "r73",
      "r77",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r181",
      "r186",
      "r235",
      "r243"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r48",
      "r49",
      "r52",
      "r53",
      "r61",
      "r62",
      "r63",
      "r75",
      "r76",
      "r79",
      "r80",
      "r163",
      "r164",
      "r165",
      "r179",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r189",
      "r201",
      "r202",
      "r203",
      "r205",
      "r214",
      "r215",
      "r216",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r8",
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r153"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r23",
      "r24",
      "r27",
      "r35",
      "r43",
      "r50",
      "r59",
      "r60",
      "r67",
      "r68",
      "r70",
      "r71",
      "r73",
      "r77",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r169",
      "r172",
      "r173",
      "r176",
      "r177",
      "r181",
      "r186",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r106",
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r106",
      "r206",
      "r208",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r157",
      "r212",
      "r253"
     ],
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r105",
      "r211",
      "r239",
      "r248",
      "r252"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r51",
      "r58",
      "r60",
      "r78",
      "r154",
      "r155",
      "r156",
      "r161",
      "r162",
      "r180",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r117",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Share Purchase Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Share Purchase Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r22",
      "r25",
      "r26",
      "r27",
      "r45",
      "r46",
      "r47",
      "r51",
      "r58",
      "r60",
      "r66",
      "r78",
      "r104",
      "r105",
      "r154",
      "r155",
      "r156",
      "r161",
      "r162",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r204",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r66",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, shares",
        "verboseLabel": "Shares issued under Sales Agreement, net of shares issue costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Purchase shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r104",
      "r105",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued under 2019 Purchase Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r13",
      "r14",
      "r43",
      "r74",
      "r77",
      "r186",
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r254": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r255": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r256": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r257": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r260": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r261": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r262": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r263": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r264": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r265": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r266": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r267": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r268": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r269": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r270": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r271": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r272": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r273": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001731122-22-001301-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-22-001301-xbrl.zip
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M0/'J@/@!X/#9CUL4';>\:YGX\6]02P,$%     @ ^(,)54J_.2T^"@  %7,
M !4   !A=GAL+3(P,C(P-C,P7V-A;"YX;6S576UOVS@2_G[ _0>>#SAD/SB.
M[:2[39M;)$Y2&,@U0=)V[]N"D>B8J$SZ1,EQ_OT-*<G1NRC;,KG]D!>',YQG
MGN&0'%'LY]_7"P^MB"\H9Q>]X?%)#Q'F<)>REXO>]Z?^Y=-D.NTA$6#F8H\S
M<M%CO/?[O__^-P3_/O^CWT>WE'CN.;KF3G_*9OP3^HH7Y!Q](8SX..#^)_0#
M>Z'\A-]2C_AHPA=+CP0$_A!U?([.CH>G&/7[&GI_$.9R__OC=*-W'@1+<3X8
MO+Z^'C.^PJ_<_RF.';[04_@4X" 4&VTGZY/X7R3^V:/LY[G\\HP%0> O)L[7
M@E[T9+]QMZ_C8^Z_#$8G)\/!?_]S]^3,R0+W*9-^<T@OD9):RN2&'S]^'*B_
M)DT++=?/OI?T,1XDYFPTPU]I3?N4)8*>"V7>'7=PH&AO[ 95MI"_]9-F??E1
M?SCJCX?':^'V$N<K#_K<(X]DAN1W8&_3*V9X1=:2KH'\TV#"(1S!3B4T]\GL
MHH=7:P]TCT8G'\8G4O,_,XV"MR6$I: RJGIHL%6O4Q80GRXFG+F$">+"#X)[
MU,4!<:^P)WWW-"<D$$V6M59T4.L?L$]8,"<!=;"W-RBE6O>!2PY-L@#=XGYV
MOY3I!.)57#)7IA"?S,$LNB)W7#32TEY3U[QL++J?3>:8O1 Q94\!=W[.N>="
M7KSY7TB#MUTX:M?#P? " Q,LYK<>?]UI--4JW >::R(<GRYEI-S/KD)!&1$R
M9*ZPH-#G@T\$]*XBJ0G'%JKV@>"1.*#VTG%XR *8TA]\SN!')W);D]%ZTONP
M\QZ2AS^%=<>"-!E5TG0?%@!*/R3N'<7/U*,!)8W>J9;8ASW1V+R?S2#\V4NC
M,17-]V$)),@%#13E*EVJ4( UHH:+-$2[C_('R!<ZQK;3TDW,?<//WC:1EY7K
MF'4]([45'#A37Y, 4T]\Q;Y< ZP:\\T>5.\Y0[9%H"':333'O;4/YYQ@!_FT
MK0\UQ3L>>9H.U==P&'N'NQL\/*S%H]TM'AW6XO'N%H\/:_'I[A:?'M;BL]TM
M/CNLQ=KY;0M5=0@<[#FAIR;%._@](T'6 8'=G)OHD5#TBD$!#633N#HW1'U9
MR@NET?!CW+(C.]I7=3*VCL# S785?H[5H8T^E%:(8HTH4HF.OC,<NA3^\DM2
M4DL >MS)@/)D38_GRF=)?515[F98/*OR72CZ+Q@O!S(.!L0+1/*)B@P5%?$'
M?UX*D8+FX6?BJ:[^C!LD?Q\8L4[N_670PC<Y3:^PI\(XF$#$OD$8J[INM?&:
MXGELJ="Z]!W$?9?X%[W-/(5])Q-0Q<IIW&(@PL5"J>D#PXM$?N;S1:F/8W_R
M;3"DN8#N>^B5T)=YH,PVPUVT+/V&UT3(_1=8_NS5<%717(^;D1EN:B':Q 5L
M99:8NC?KI4Q)$$YJXQ!AFX2^+/%6,Z,EK,?3V Q/+>#;Q%IJV]1(4EE;,U;'
M91;Q@-_D<&BTO*J]Z:Q<[?U<=-4#MBF@BMMQ'7:J1$RGYC8$U<.VB:-K,B-@
MG!O-+8W\5#0WG8ZUN:F%:Q,OU4_7BJ24M34V\4?^528U+)=+&YM.PS5/-0N3
M?!54F^)(;L<YTZ&CV-)TQM7FH@JD341<NK#O!LC8>X"UX91-\)(&V$N97C,K
M:LB:3L':9.D[PB;Z'F7MBA'W!OM,UNUAD@\7TK_$A3F%.K1FTM21U:/OU#Q]
M^HZPB;[4 @'V8VTFUV9)TU.6+K8<D;NN3PVNO]O ;#JF5 7S\Z"L[FNX)EQ^
M/"Y3(![OJT",CC*]_=)917R+ W49Q*<YQ._Z$)^A=XT(,Q=E="*IU'Q1/#:1
MO<05HYKZ>$E3,PDU.I/M 4N7[H(R*H+HF4YL5S6"1D'3Z;22C5QBT?2 3;/@
M(Q$$+)$%_FNR(AY?RF'22%F#F.F)09<P+?0VT?65,YY@BPH6C535B&R%H?A\
M5WXB+;O/=G,+K'SQ,2M]N"=EZD5,#_I&5R>QU QE[W%4P4%Y.(,]\!724/9@
M:XX,35G3([L5*ZW\8=,P5RLT(H(,PJ^D9D-9+6&Z"J#-6",2^WBZY3Z8P*+-
MDO/V#<:[P([TR1?8$<NEY!6909MO>%U-72LEIHL";=G<PD,V$1Q!E&;*?!X=
M70H!^OL6(C(_]1S^9@VK/N"!,NR_3<&7 GSF@"2XV5->B^*[Z2!"1YV:GE8/
MX-%<"%8O!HN!UK>@JG%X#S4/ZLZ7+I#@)>*Z+7Y^]5@G82S*&RVKF/.ZI]RB
MK!H7%S=HXFB[@NWSK*YJWB1G;.1NQ[J>&QJRE"U%R9;O@V;*=6?M"I3O3?D,
MQ9TARE"ZNW_A)1>?4+X@;\(AI6^09O!_V!*_JF9*W4@I-U^VA#$@S7GP^8J"
M#Z_>O@MYL&(S U_"RF^5>9VQI%[10H>A(@P)WA-V+9!T,],+K_;<Y%<)9;!M
MFE:>YM@G5UB-PX5,I9E7GDL.R52T-[T W)FI>D?81!D$E$_ T&L2?9^R]H>V
M]108+X/L2FI+5VEN;DS1G#T0W8;?O*3QBLC^B2UWCN6,Y@XAMZ&T(*K'Z=E?
MB=,*]]B=C*NOH="DM2"MQ^R'OQBSM7=U=%DV*5J3'&=6SYYJG_AHRNHQ]JN%
MC+4 :=]@K(!]2QEFSFY;J5(=IDZ'<X<05Y6]ID*$\N 1;)=U3L!JB%JZY:KA
ML'"B7-,]-D4NS'!QV6,#=,)%W2N^U1*6;L5:,-C@#*L6=>EP^T.^DB_/PA#?
MH;4'T.JE+-UW;3<&JYQBU?!+V:MRQ+VZ7T@D1KMZ3%:(6KK;VH[.6O?8Q*F$
MG'O__I&(P*=.0-SX_?SL!ZF6#\2GW,TOA&[6CA>ZZJFHHTKHCS@@-[,9<>H>
MP!S8#M,3N!F_%^NN;1? 5I[6M]F9=?G#FG<"MKGG,_.<Z5=YJPT5CL=%Z!/Y
MR[M&^2@IT:F.Q2NM\M.LWHZ>I&E>!YJ!\UL>3J0$O6M!>34=65]V;VC&U(]Y
M4Y4$RN^Q]VQ6364B;=WP)&]=+(B\LM+-GHVLNETT8^$P;V$DA5)BG5T2U7S-
M:,;44=[4E(;X?9.,#B,#JG#C: ;"N.W 0D>)PN[>"6J\F#0#X50CI-%1I*$[
MF_7O*<T8?]8JA+J'L8]K2C, /^P\$:&CN">TZ:H[_#J7G&;P%2;:=+H_J.G-
M]Y]F#"],J:7#)E9AZL*X3N^0V:4:/X$F\L7()U@'JRH/C)$'(!$Z^D$%K7P1
M1D/.]$ZH^08;W@J/?7OL&.$59Z'0#ZE\<].;+&V>ZF$<ZOG5+5VK4W.!CYU
MV8*]JE%2T=9T@;'5R*C%V[V[-[8Z\F#!+2')X^@JG]<)F"X%MG)\,W*;<E%T
M.V#[>:Y)SO2YBK;92<\/]E1H=&]RSZRY"K6!_-[VH O&%O>[IU&,"C6$ACW+
M9@UI#LBP'$FAUJ"'! U-8AF58VE7C'C',C*)95R.I5"5T,0R-HGEM!Q+H3RA
MB>74)):S<BQMJQ4)EC.36.IS\JA0H-#$E$_0\>0CO\C_PQ ^^3]02P,$%
M  @ ^(,)560N=1SG%   >6P! !4   !A=GAL+3(P,C(P-C,P7V1E9BYX;6SM
M75]SVSB2?]^J^PX\;]56]L&1)=N9)#/9+<6.IWSEL5VV,WOWI())2&*%(K0
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MPBA=U("Z8FCI@))1R+A0S/WJV7/M^!@E>*@E>W<1UZKL*[6B:R9I9^B^9H
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MM;%UATF6\D!$3$A'1^X]A3%!D<TIDS 4LB$\C(^ #$FF$Q1'/NXT,R!JH"F
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MJ:$AS+]#GYI0'C5+QLZ"BIT$F!*]ALST\@DL"VN6ZJXI+D?N"4/U^#%N-7V
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MMS='W[U[ U 6Y7&2+?[VYN>[P]G=Z>7E&U"4,(MAFF?H;V^R_,V__LL__ ]
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MC?[>9Z._-S?Z^T ;_;U]H[]WV.@?K!K]@\]&_V!N] ^!-OH'^T;_X+#1-6>
M,BD?C:XZ]1-%@FMT_3E?I]''.]_;>?%TF47Y$C77*]0W)&D605H-EXL9"^CM
M18E&W#N7[#'V><4U0*,":IU0+KO@EZ*ELRR>Q<LD2V@T 77P/G^FBR=Y,/I
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M=5V!F7E D0F[9HL:<)\OHF10C%'"4W*&:8!*)1S:G#]1ZYR829:%;<G[)(\
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M=EG0E0F("5)@"C9L9-EU2EX8<4I&)@S3RRQ&S_^.7I3E$N3<<D(!LTN*GE!
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M719T!B7 U+O@6B7'QPL6!>@=,F@T J*>!4S5@0/3!$SU '!ET-+VM#XK-K<
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MZ3OW!?VUG9_WKE<Y2M.C6Q[G1"KD'.,<G^:87IEMX>TT+ FGL;Y;%*X3MSM
M/QBJ;P%:X3U/-S'JZ#?*8)8*:"43TASR&7W=P+[!>4;^&%6S:197Q6C"!Y@,
ML3(3L@@J3//&.$F[/1$;KS*Z9V6[IQM,1QFQ,/T.1(/ULA*T^E$W_8G6UIN)
MBCV_Q%=CBM';1L'9"MH*>+-HUDI[IY<U1,&J9]%REZ-X]2L(T@)C-INM-)Q1
MQ YZPQ&]>% A(590IR3+&!Z9+,J8#)LL] FF)IM1J^'8+],$O>>:J1+W/O#8
M8Q0\F"H-9N75.B$9=[V@3S$0CY25]8C63YN^=,H#D$UFWMB9>%CIC%Q!DK70
M2#F$,@!/6CI_8:$;:/QJV/I]+=6P;*ODP2 T%$!B%"HTO(_/@V *=\@R:="(
M3T2<+BBM9:@4=482 ]B&&@JY4,8@"XQ3LV%W+ZQ\N4S*9NW, M\6B*R6V\.D
MP28<F(93+ZMMBM=QG1F2@/>1:A?4PH'O)@UF7G92 9MD0C(W6YCM3Y=,2I[X
M:GGRH]<(D9'V:V4M!;V33;,->9.G2?3"_[O#)K4BF4 VI+6%M-Q\EJ81#&FW
M!"[?5$Y?P"S.5R6*I]M>WMVS,'I$\3I%UW-Q)75/%U@F-@])P*E_X>""=5P,
MK;6#X>Y@R(*C894 /?FN%\!7XRV 1Z0J6]_++["M8JE>!G)WBQ3]D'GKHLO9
M/3BY .F^;1ET_*]B0ZE:]=#TJGX:J8Y5!OGF09FIWJ5LRLB*5[_.5#]@V'K1
M1DOW'=-R]U;ECL7=O%JY94+>R3T&>AVM'5!YQ&&^'=I]FZ?I18X)XGC@T&Z9
MBI_A?% 1Y4.X51+>F;T;;AVG6]RMPO@;?H<2S]_KT<(TU:Z*+0V8[1/V1/P=
M*T+1%[9,-<3NL5M1E#WF>@Y8TM5;#M7-0&!&9X(%6Y0> )[! :AS"*@#G2]7
M:?Z"T!W"3TF$%&9?RF P+V'ZGLDB2_Y ,8^_9O<>V?>KT?/ST]TFJC9Y+QPY
MLP [YS0EU,UR"Y0A#%.V*PIC&GU%M^#9(P*=B]RIQSJI'A[6&J,GE.8KUL%K
MJ8#Z\J;:JE%H1@V ]A!'7[/E=5D4ZR7_;>N)<9=,?$^2NU>0:<+</H< ^^>(
MQ=)URJ\H63S2_5WX1#KG M&'$^K$6-3D'":8/^++-A4@Z9?<)@60 O+>%V=9
MF<1)NJ;CR!V*UICM]/$K25!,K]>B ]JZCK@YAYC>ET!O,F$U/%O276V5H\XX
M:3OUS1JS.CHN66,D'$P_&[,T_>Y%'YNCMRY46Q6T$ZWRDCZ7 ]/T!=39!G;1
MZ6;D.4/S)$/Q"9FNYTEY0\K6.O[D(XQQ]+)*P\^,-*!X\@G'(H%@>+X-:MUT
M4:4"JF0 2Z?E6%& WUA2_MTJQ/)N4%Z1+^RM2$6M6>JZY.^@XK1Y:Z48#%^'
MH)6\6"%PL^/S0Q, + 7_]+RM%CFS+#[;+'%:6QC4;X0Z*-WG9-*A]Z1<Y)@=
M$Q7M!1J=F)0WNHZ<ATNZ3U(][6XQ:@:A.'=.63C1042Q2D^:IP''>3-&<;#X
M.=\\$\(CDZC5QMZUD9U(:<6='0]:@&Y. #6RH?#-$F>?.C^.^**0*B;![F$J
MO\]0V3PZ%?H34YX?E%+=^T5$D@BF=TF)V#XEO7F#,)0,3+\D12+<Q6FKY.Z6
M+]L";"[W,FEXM_$&P13<:BL]0&2J%QW8S+/BNN")*7LWZRJGLY,\6Q>HJ$*U
M5'L0<EG'D7QJN+V /%'0.Z-LT*GBXMHOP#,F/?!EPU3!3A?),XIKNZL.>Y7U
M$(6@LZ%'"[09;J12W@EAA-9G Y,E7.#" %;2$W&@\6J-Z#G6!4)U"*B4"#II
M9VPP0VXHH18-@Q=&?.H06J8!YD2E?N/7_U3#UFNBG[1^SC$I.;UCSJH G1OC
MM!K>638(ID"V-*V>,(?#(K>G-P_L&D==8+>7<1M?0# #[;?-/4UR:+LX/K4Y
MS5,"(^<.%:VM'FI@DR5ZI/A\3_Y4P&AS>&P\2!@O(S_G/V-7E/R0:*Q<@AG4
M)BN:&$#9TF\[]?$+8UI_Y]<2E8\P UVE4,Z@1JBI*\-1U;A9N T;'K]RND'&
MXZ4?3"^<H%!3]+^K\4[:%$NI&X3I,0-<D 'I1YP71>=!/:A84MEH.5M:V1>A
M66*95;PS=1A.X7*P1I%YC&+F2M-Y\K" (2R^:!FJ^(_/Z^4#PI7#7D%?,J8O
MX[5ZG&I"'92$4UMIB\)UK* !^M[YN@-HX8U#IM=^PYK%\A1YNK.;I&(4%/I6
M_9#VS?HA3:+ZRAY9%[56=38>#BQ,,RA:ZGEGVA9@Q9-3<4!LWD[G*33W-'D?
M(V6EO,P2Z@:II><6^KX>)K8JENJ!8JVR=[9NBUC_8/%49%5%GU-CX7H^6V#$
M3%:IM[=6TEWDN!;J)BY<*N:=+69L@E<I%:9S):S% 63R$U&!1DO4817%-2'?
M I8HOL_KV'19@<PZSNAA"[\ABDDA#,I8HNR3YY<Z'H4[SX.\U@1EWL1.3^5X
MUK$.)9C)B$?6P9 ^P1))'::&)>#..6V;@FW<U89HAT&^;2!+IC= 9< #%0)9
MLP28DIF3F&;7F"^!^'6? ZR!OJ)O8TQ>$),5UM7R3M#!4"WMKAP#JDP9RM4]
M'2VRA39?6I^Q9[YY4''5%>G&HG1GP:CE^+#1PAE[ &;!1N)C2,*4P3J+$6^]
M C0VU@'(4-D:;Y@L]X\[&"FT3&5;R\O%IN;/Z"O[4AQ)[41+37>V]Z"B;&QQ
M*S7O0\EPK.J-K:+#2!K:"!>$BG2&V]Q9L\))A YXT+!;\O$.LQ7[1%7?]%,5
MQL2_OE[0!%2 '<+ J+EQU[M=9;K[IGUB=_(B#_&W\\+8.7W?UT'L5"U#KDZR
M3MQ[/YFJ1+J 7GZ1$E,'[3S:![T%>'CI"#8W+M&<@O&V,%:6JJZN##X68R3L
MM+N-5A&=?K9SJN%TL+&*(C78#;W)T)FN @I2WKJ>^-+R,BM*O&8C"%OGW#_"
MK+J[YG.>/:&B1#&?V,=NI^'Y[T7_W+9:1^G&0S-WVMM7W)@L(2ZU:W''A9>.
M#Z#>7@3U?;C@!*9T=^8 0#(\H$6291.>B4U6!ZUK?7^MKI6:\5NESOE=U.B&
MK@REJP/_H-PM]_R7M;^0](THI+$BJ!KI#R"U"JAT0*T$F-8K&4BJ8'*^0^"V
M>7I9OX)!05J9#KI^)U_OIK^'PMI._DP73>4BN/T6@EVAJ6LD+[8PG*T23%+<
M>LIW RR<'NZR(>S[OPM4>S(Z.*R*@?/^P5B#B+\M W:-$+MUJE^9=5%5UYQ-
MF^5>; P,J+Q1]@(L\G/3IS_R/IVQ$\AXDJ6_?5EM)_Q&;^\,<]V*1=5-PX 4
MSC3OIO(=&/A6>/9D:G=2"8,G]=$&BA"G]8L<SU%2TDN#9UG,;""6Z.BG<%M!
MV/-IWUBY$YL!ROS_!&:!J>RV9D*5SBLS$YI2A3-.MR"]<C-!J'S/9D*#Y\]L
M)O0K8;"98#50A#A_[==YMEO/<GY*=9Y-,WMM7?AM3K21\576_1ME]_>H-2 :
M!U8CNQRVFCD>]CJM?E.,]7ENMJ*(!</1GUHU.8W#UN#L]V)]MF6ECC*]#<S;
MNP'FJ<#R0(,_03\>X*$5"JC7U>=MS88P$/V)QH<MW+*ZAH'WT:.VPDDI;VE9
MVI;03["DKQV^G,%2U<_MU5WVR*&%:O<=6]U@6#X0L,C'58)? )7P3L9=.ZPK
MVW//C4PGUJ1?LW%J)W]#(?N=K!('+?E1W6Y#ZGD>K,57:19ZM/]"-/3<]^@)
M?.[_#/W_,BMQDA5)Q"Z,F+Z9^OGM:1^75]M$O;J;V2OOQ]+""F^J-'>3)+4X
MOY7D]?99Y@=<U([&[+[8B1I#FM,^]5--58W90R79!+/,G*YL*F-Y;_S4E<[^
MTJ)/81^/B2"H?CE^U0[JK^-EOS_]>/0R#S62]Z;?[U)1["/==+N "9[24AZ,
M(JC^/TT53S=G&R'LSS@P2;F-8P%_\)VJ JH+^/7-KV5(:/G[*F+6)\UIG[JV
MIJK&[+Z2;%Z-W[FQB"K+>S1W<O^VMZ3P/@SPP3""ZJH35?*HIOA #/LS#T]3
M\*%&N?<(D_&JH9C@GHFM080313)5!8]P?\26"+SW<:_%WM+4#FCNUUT#S3Y6
M%62\]6&+A)S.OUL7U/K! VDJP1FZVY9 9<?N45"T:1!HNKA/*W8@B+VR8;>J
MX%$MV$$(O,]M7HL]U'KU?HW*6)4PH>TZ%,+^6*[;5>YX=NNP_+WW;(^%WM)F
MW:-Y?FBMW><E3)VX5-EE'=2</F)ECKFG;).O]U[NH;#V/E=6'3I@YGGRL \H
M7GOZ0EKZV'NY4>!/Y /^NCDWR64 KY2A/CV87S<+%87=VH?YE=Q 474K^J38
MI.%^DGSVT P6JVD"FW>3R6LS<(62&3:=J?SK[&L> ORL<]_3?NG:N+/,^C7V
MX>EVET/L\0_F.GLPUUG7_N@_E>PB0^?]>M**$[KR)+F%U7NG+.+@C:40NZHP
MO/%S[]FZ?,QQ\@>*?\YBA%O'X#>DS$5G_+JE%7J5?T68_RE9)N6@$76L+/U/
MP^-6GGGN'2>_L+KLM(7L=UHF0-^91O7LNJ(I% <@I?J C18@I2F\K@[[\VKE
MNL,*6>YMAU54WF0=MI??Z^RP\D+:=]@UU;?ML &OT#P=X[P/G%5CE$U^F29E
M4][:J\QY,F&,]SM8L.H3A5NTA F]3N(T)Z8JC,HU3.\17AY/9$MOA62?5E\[
M5/68R[(M8(35Z[V47;GS JN=%UPG *)-"F2.F2/P39*!%P1Q\>W^SS:A'O:^
MRIG)JL1&9G:-H+V?L7YIO>AP/>=VY$3#A3RK?9IS=)4UYJ0BRR>L'CE-X=3&
M(G]X)"P[<8=127'CM-_#MUU!^=];<-T #NYB#_$$C^3_D!=H2J>846ICW^;R
MJ[PHJ,%,;!6410DJ[FE!%36L$G;9"_6 V[U#+AG,G*:%UZ<1%08=:? ;D_^O
M\!ATE63HLD1+E4VG4_#*) &XEDV-=+B,ZD.T8175 4S)/[5F*4L7Q?*AG8[3
M6:$:K&R575)N6(':]+/3#(:*@^#V:<FB/$!!-0&SZ$'4TO7.RJWMC.;"LEE1
MK)?<Z+A-BB\7&%'G T0:H;Q5OX?B(-^],*>'5N,H%K-MIL'T0%<E%4[NB.CA
MG,A2_Q@F#' P[[]LLX4@JX]FA8#P<G27-8L,]V(#R[KB1MG&,N865L^<LHB2
M9YB8##_+H,>@E3OY-^8SC?V;4>O2_I*G))DT*5]<S:FJG/=V5M57Y63SJCS;
ML/JOD[(*OJ=9MH8I=;8!3XW\Z^R]9\E3$J,L=MUWN_GN?<^55>/D_;:=Z>ON
MM9*2]OML+3**%:RX(NAZA4CJ2;:X0@1]<4N@R_=&C-+.+MXQ0V[NR%&+>B>7
M'3XQFJ]2 %SC % =4"EY'\]O" I"<N9&DSRL&>$5G4HNZG+4U(%M#W0R.>_T
ML0#7YTY;!L!EOL[\>ZR3 7699\SU]Q2NDA*F_(3]%A4(/Z'X(L<7:WK'*+U_
M$6;*P^0MTG%)M:V+V>;AX$2"(>FVR/L,_@D^)\OU$F2-HT7$4N8;O@7 57I@
MGF,P9RF"I$K2.]6WMB)JWY-9'"=4I:Z]C?_\V':+38Y[8=_:5]THEJTYNV"Z
MY/1E%%:@C4+=75O]EPX- #[!)&4QD+3_[G_'E3Y),Y$'2C^3O>B>V@J:[C6D
M_>^$NF+)+P !"SS*6T7*923-A%^2+5_HM+\[7"J*L%J+P\U'[Y10(5*T9L)D
M]G=H[/K3SNJ!GQB"C--335K*[/9BN+2LM%%-&45>WON+HP+VNQ^3/N2>)>T,
M02M'\/ "VG)5KH!E>P V7N(\:S#KF#TL]_WMV.=_7R?ERV56E'A-?RRNRT>$
M[Q]AUG&5]?;\Y/CX]F+HF*I91AEKQ@:W_X/31#5B]#!G1B*(Z14U<WJ/.;^=
MIG7LSP-;?$8R_CEC<-U&X=I&3'BJ!".-A2#<%H-;<?QAS+)")?;W4RQOQV@%
MFU1U/$E,OP=T_EW6O#6)>=QQ#BVLV368^E#=NXHV"7N:-B>/' AN<AJ(6[K(
M"S%\X'RY2O,7A.X0?B+$E9?N<YYQ*XU-MP6+B&A_/\V+\G->_B<J;U&4+S+:
M2=JOV"GJU%'>+L=ZI]79[E=.,@YFG'996B&DH+F8A1\Q#>O44VU+DU5;1.QA
M,JM<SW_$>5'<X#Q"*"XNB,P=3+O7-%BJ_![GD;/V)GFQA2FK0ME6MC5>L<56
M]!B?K'E!DLUSO.3[:QBE=$ '90Y63=+4KE_0Q,&J2AW06@8%3?\['RW+%^[7
M\SFB#X6R<LX6&+$5T4^H?U>;I4I8+6N-=WC+(I8T:56>-F]' .O4O;3H*<S(
M1'Z1E'\LB!V8TB#_TUS1E!K9L-K0#'1XXT4L33!O$@5DE4V&6B^MQG:]ZLW]
MZX<T8:_\WN<WI"H?H<13U*005OM9HNTWXJ6\Y9I=OMHOHTZ0C;95DJ39DS*!
M:?KBI4'KDC5#S9&B#ZH$PVI  TI-[RL?4:<'DMFPK$R<=FOY'32ODBS*T^P&
MXMKA[V*=Q5=7IXI&,\B'U79V8"W['L5)NUZ*%C %)%LR 7IILNYYJ&1,(08<
MAB4DEGL2"0TX2#NLYMP&NF7C;OQ4M2/KBF= %R=)Y*7Q>_MCQ^^.OE?T5*5D
M6(UJ@CFP=ZZ(L-=I[U>(F:^78=+KBH75)%J,PA8<BM:8K@7*1UB"1?*$^,SW
MF*<QZ5'TCYANSW;ZT<:ME"_VDPS *,IQ3-U(P=>D?&2*)<)+)L6GTOJ,]0"L
MBS6U;\!Z1>?5RFN#R$%0K%"4S!-ZQ,3B)OQTTLE.D[>XXC4,1&$Q/)3JL!S<
M"L4V-X!=7Z:V7-TK((5=K]<W?8AT*XJ<]MI,=N(*ONKOM'/=KYH#@Z) I72K
MEG]Q?,2AVTWM 1*\[-EG\-L9FL-U6@)V3**]CFO":KU*X ,--$]0<;K&&,E]
M%$6I@*I; TZX$FTC>@ J85^>,G3^XW-EP0<7Z8&R(/7[AV J7@-.,!9:HO\(
MN#"8E3S8D3E6DM&.+-?\M4>+&K,LMFL=DTZ8G40/5=-EV&XA%_?42$UL=74^
M+)T/!*& FD&-31U&7HMZJO//>9;76"XS8H4@C3N"4CB@-C!C%&X-;VD K@*^
MJ91\O1G!8= [/NEQ';_F<TWP5;PA5MT)(C8EXG+W\!D5Y\\EAF2ME600O[!+
M0$G!F"->GJ;\L7!VI9NL82?,+B!JN"BE:/IS/M%<O^6'HYN,P29G\,"RKOG'
M,C\ W<Q G9LG4E8F55,]51\Y01F:RY]8TVL$1 U+H,*-#ERMU6KU> Z^J71=
MCR!\2Q65E'#L5'&YPNB17E+QQ*@O[ARK90-H(&N(PJBNUO'1(KU=@]Z>]V:!
MSC:Y">BS)%V7DIC)+=,)I25WA:_R/!^8GL_XB38LZ:*P+Q3:ZTI2;%(73C*#
M7=MY^T]V#HJ*@D%A,;W4AZTX$OJ43"B4#J/%)JSF),*^UA6HW)A;TK5$6R"
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M/3*A/S>=A!^M-H^V5%B;+@146P7MGZ[(G\C/]4_D/_1^(O++_P-02P,$%
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MR?Y/H[W1&8F]((KG%/,_5BUR/_J\S1$*_9%HE7]::A=DXKFA$Q22/P0%JS
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MN>I8^\*]!0V4]+,+S3,2B-6D,>EKM=+M9+$(](G3U@ZR"L/FCNQR)-WQ I&
M&YG8DBITR^(J(^T1^@SMWFC7%-+F:N'Y/^<D>;T,XX3.A07T)GG"].$)A:5
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M0M/I\=&*1%*>)S^4H]%\4F2:R)M2O*7D>+Z81 ?\#* _A2!E F_[.:/'OER
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M"4B9P%LFG9?<+5E:,38['L#)85T,4)[J'K[64'Y(V@#@S^[Z:--6=0A,6;6
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M4GD;&K:DDNXEGBP)15+@$QGML@>A32+OGLOK <MKG.*Z\;5UODC2'$\6&?%
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M[&F7[@V8<(XZ25MJ1A1)BEO=)#!%KGE"2(VQ PE*A E",AU(?,-#%K=Z =H
MNK'*%6JTXD0DL^*MOSZ5?A7EIZ>ZFJBY#K]&&$'0O5T0';0-0L7[B+62(9[J
MA6UNC4;4'Q%O3I>XC6Y.;[&_+%W'7=*S*)(():LN.(XE2^SZU]$BW'U?G<^+
M7EK25!O-GNVH$:1.E"]B<\Q]O3KO@9M.D5=VY2ULJ%FFE09!AX"!E2AO2M.L
M/DF/R">[2RM2)"VRI+C!+:7HRN^0VQ!L2=,$2B<8LDB))"VL?Z\S>IN"3-<
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M59QPP?WP/0%%02)D*%8HCX.2)-!Q::E&ORO!D$X& YS?(=P@@P!Z!SZ VVG
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M^JJH.ART-:2-Y/NZ3&<^88M$K:4*3=FF9!#5QEL#06:Y 7EGN\W?.%":>;@
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M,9FMHI=+*GD_E;F[<>JNV?=S=A=#VPX/V:=ZS31#&'"PD<'=T;G1$VG.@CG
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M/$)'X[09(/NUR_^"MMJ*;VV,KNV?I\7K>NMBV(FA]$_(OL;B/R(G%JO^RX)
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MR<9<W'<D&YO)J_:4+XV=<H+Y4BY3C:KU3_E2,OE2?:/-.=8KTD@&"_(B"4+
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M38) LYQ:XW0989/\C8#AQO=)S(7"PMU 5I=[.T3TF1QHRZ>?7ZD16?S8$8J
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M$FN(O1!K#<F/&3).NLS@4C=L9""&_&V(>&-A5Z""KL:]XYFF H6(Q?AC50Q
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M<<0&"\IGRIU/*1X"*Z"C.RZ[MNZ)LV 6#S2)G(E3/LX9[;L=*QP@7:*#WP\
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M8ZD_&:C;#7;8R7,X^C([]U!;T7&C7[(A=*%OG)VDKAT&9NP]^B&<-O+[N&S
MVE GH:A;,/,&,HI25 ;C+%2,D8^0$%UZAC7$V#+ZT]KPS,3EM77CL>>!-[8-
MTI#>7W#V!^9/EP6:O4%$H@VT41ZYI@_6Q9FCU8;SJR/K6[J#^\[R08Q3%NH[
MO(A@^D*F7;.9\>/M2Z;1)_&?IQ#XR!%(!2N9DQ-*F2OZ"O,''0/2V.0VA@[S
M >'2'>++PW--V60:65G,=O5U]FP."!AQD)7Y8ODB(]!%^*<"#C--8H]()_]N
M6/ZC5L&-Y NT 'NP"VB_K2:T*I#SIHK"KA4=!Z:O8<+ @0V] ELCE=P^!2,F
MRB*P-YI *(&F"F>B_$+ZI2"S.;"(UP=,4)1&8+%F.IE.O?\N^9 E]PFVSQ+H
ML4QRC1Y; CV62:[18ZN!'OLG[>V?C_6N('F8!6YQ_=GTGBUSM))X;GH:\1I6
M\ $PH([$"97P0D,90CPR,6<*!!6FCDK7X))@:C^$1F5+J,G!#T-!&9Q.)K.8
M].&R(I$GBE?!C*MRF<T-(*.S(98P2+F%;5[+[R/XP;8MI)K#(YT#]80;!%X&
M'S4+[]UM^;-4F%,TZGB#B1*.KU@0/K'85FCDZ/F"J\N+HJX?<.)J/P!WDXV$
M79=B&P[*GV#H%KQ<5BP)2C K*HA-:@K'Y35!L]>V8*DI(C+RKXBI80\2=MEM
M0H_69T=-$^U(18&ID4%FT('@%'-3O(=? \UZ%X1F97F/GII"/#8.7[=UJ<0V
M M%/H?)I>9UM:%8=R^@RFI:8R.V74J/^-;H_VWCPF.@2BP+AY*SL:!=R8#@@
MB$AHQ+,&U#8=LVL%?&@0)ALZVY=^X!K,?]!]KD+'[D\C D(W\/XG20]<3F@>
M96"8\X+1]XB%#GY4DX&<'0M?W+$IWB#[6FA#=$(,W3KR[4"&#\BUG1X*4L2?
M/-;<,7\=K=;F7\'3_@B9US@=GHIL>S:C12NL /3SQ5=F(OH09E7# /)!8+N[
MQ(H*JQK<!X,OE6@C3JT^;GEP]^M<?IL?(^.I+:&.:=&F(/#YO*T 8R;N.0K"
MXQ.PN2&?=D>KO_EH\1&K6Y[VKOR%@B7 / "=G23P"OL#25FCU#7L?C_T\$/B
M&NSOS%20>%>S?JM<)S%_BGDB7FR[1#PEC\:4LHM AOAL A<M35\D,RMZN_ +
MD;6/3,:\)<13=--3M][A[^\!EV!)>I8/613!4H-0;3PP !\V8-_J^\Q6=]AB
M080SU!5!IP\_ ]F6E?.<5]<5.T3WAOCLEGY1F.87<M74?\.%I$T'V$A%1S:<
MO.7;4OGLK%PKE;$8X!'L&9IW^X"/3^]FF*$'.B(/NM?C8A.1&KJ'.K8!M;U+
M'\8*3,DHPIOF3]G3=-P!/@65?M>[_H/ %:1I(OIPW1#20NR8@I+ZT-8-L^UN
M1W2UXO6WV?L'7W0L2RFQGO[Y32G(,PZ, :)("R698'-CI(N4-RP'DS#YO)$B
MG<8HE&KWN&P=QX6T.?!L:(A>[>B!+HAD]( /C2\QCG?KZW87+HK76ZDWM8J+
M2Q3Y ;B.G&[1RT5&BZ>0A4:<L7)Z/9 WHJQ-^%AV?WMDFH_@!SKL.VWFZ$6(
M%7YH\>4IC0W(T5.E,E*T\R73\R$6Z*RUK7GO(1>EJVJ/$VRS3QQ#7NC,?*M^
M% =.K:+B=;%5;/"=+NK'BG6:;X+P*^M7_OZ^53T*V,K<R_\@1^O]N[Y;J*L1
M)<-B06X@&Q^%F0/NX:[E@_N#+C/*5O^92D>:U@D*"SU3BFA&E/+BFO0)+-Q,
M7EZ+KIX"XOGYHR.G$5S%;705(6"WW,Y,SYZ&F<DI6M:Q4:8+RE]BH I^469W
MU8'1&_G<"W<%]]I2*1K^+G?24R^, HA%<0-WSJ+W/F-QQE8D1I&Q)=FDCC7
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M+86'01(A*.C;8TZ F'J* SHV(*1O@!0#V+XI4 3802[=-/$WKM[TE>QE27>
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MGIH&)9Q7:V5VBE7*[/!24#SK]?T^ZSL&S/G=;?J/\*5FU\#S98#GV37P?#6
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M6BYM.D+]S^'>^Q^YT5RGJN_D;K42DH4P1,HGJB= )1:8JG,2#61NG[^$T^V
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M[P:[;=-A]2_ :G#/!5O:4%0P)7#*3(#>=Q7'$H_..3W&M7 P@%OE,!$N: F
M;YA(,Z;A-"P%V1'AT7.$U")1IL \HD&M$H<'<JL*181VPS[ _Y$ H+R/NW?A
MF&>H:CJ@.JIQ#-L[X%M9! @=[QU^$-MNE;W#:+G--TK*VC(/2EJ,$2,M8=5#
M!XHA/+YLU7C%JC%6G8?M93AC'(7_[RJ'<C\'NSN_4 F\3E4_\.UZ+1(&PN I
M%ZB> !5;8"J@(!KRPCQ_"H7;H6#52CX\JD)# ,AH(@U1G MY(G."*$]>1.9E
MBM4BX80R5L;'!3B"DGZI4X(IH8RK_+EUF@Z-C"37DG8@?1AWI)^1I,(@LM9K
M[A4U+A [1E1&0",+"J99.7),&18))RK'QIP6BQ"-&3[B+V<J^&TH:""X%O-%
M]#Z0\9Y /'P$XF=3U2,L/WOF TC7:ZLQ3</P'DQD1$CE1F6<N)T;H)Q218(O
MU]$<20"WY$.92#NC6+YJ77JS'.@<GOP[H>)Z;57"XF/(7;FEO- Y &U<]A&&
M2D=. Y=UCD2&G"(!KM$C<GIC: A2:H]=O%DR!W&_#TB\)_2&0*^8\*1P-$6>
M%7&,5%!.X!*S(J6K\HEG\*Y_7)WD.:QB(BB3H(ITD ]589]6X3FA@5>C!:7*
M\?\O8=BP3,+K-?<&EK: 1L<D_5TX\3WA+2*V])Y\# DJH\M<S?6LQ-T+.)*B
MN K#0I/?%Q&S7ELA-E7&8BZ=#D*8"2'IBS_5\7+&W%09 ?&4@ZB('(6['93L
M.D-A?BOPY>KW!^.#)Y=_]JZ^9UBN5[_#5]=*[@2P0G%0<8CCM&4@+=B$R.BA
MCY'P/9D8/$HO*]TX4DRKM*E"L6N S#25U@KQ%<H>*@1[ZH\D%"0A*): 7S"D
MH7(>WY3ISM,!\:60V(![(XHL="7_]H_29VVE#XB!4?XF@2VJ+JEF=2>]LHR=
M504R%?R68J'/GEPT=)F?.U"<'\>L@MC3Y.AJ!>B@Q6KNXA%F&E%1UY-P+/-%
M3 &FD-4%/B(;;-84*4PI__*'WB7)KSRZ.H8FWRVMO6UM0D$UUB") #X7CMB
M&G?V6\(K\!%.9A.53 2%N8R/RC-L77*A2/-$S01ZIV/E"9#? R_ ]I6H7:\]
M&YD[[\*TJU$PZ)SVN^RLV^_?7'7.>I>?/C9V&^[YJG-^/G]^\7:6K@Y4]PQ"
ME20\-^*(S7^C>Q7MP?5<_(2B%]*8^8ZMROV(\_F(4NPA2<UY1&7@@I,E"DK2
M;[=Q<@Z<'+%.,8+-V+_]GZC:K<'YZZ2MQ^!8'1_7+]WR-U'LVZ_X&E,\N*\R
M?'A?Y0T4;YG6@S]-OS^SO8%BC_Y<?W;5P<>GS@_K0+$K?_J#$'%1!8O//AW'
M4,I=4/OK'Z:B>+_*5I1Z=1:'::7IMC?#8"T7,5?'^?V7%Q*5JCN',GOC#.\?
M4^^A8G_K(N3!VN]!KO>>XX:#X)^[ 4DO#]V^]==QZ=;N_P!02P,$%     @
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M_]5NMI%]T[O3HYV_.MW1J]'_/,RWE@&MD?2:/'MO3J_7_P502P,$%     @
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M@QK;W(;-0<DBS2 W.$M $@&(/FPJ,>MWU(7-7!HB LN,(-D+[/V]?\$?J*N
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M4N')OSF?-G4@R19MIZUSQ+Y7:/-P721>WM3U^2<YL=6:DDU:XT[BI2?QH&H
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M4>@S!*(!>>(?@IU.DA1ETB[SW&,,P[<<7&6F=U^=NRW-4U52:!$T#D+W84!
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M,JGMURVU3K6"O2<VJAUXE;&M8^'II>7W..!NYD,8<.>3=H=>N/)/$S\+ _H
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MZM=/,YHU#5V3BI/M5 XH!,DH_"(>8A,*E@J'3RK+7E-[Q13[UF/5<6:/7W'
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M9BI$Y]>-A\9_BT;V3I)O[7HW7^ C'Y.I\<\+]?)842S]* CP]=< &YG=4L.
M:(UT\ 0A#!@.^Z=<0Q7)[D$/Z<?TQ&UP%>7U50P,D.*3*;4U.J88!>^LJ]PA
MCY$ ?QX$_#M2Y@;V\OTY$>\RBV>09Q'9/+S),Z3ES9C^9,_!OLCBI&C?HB:>
M: $MD)0B 1^51X3 @K7/65Z(#OK'5?U?Y5552V,9NQW[1@TW^P3G3PW'4\%M
MYB8\0+/Z@F=JH&)&A0Z78RZ:@;EM4UI:&A#7R:Z-74N4C985LG2G*SNC&_DO
MOD_+^@SL98M7IC<WB.:")A?U4U/PE,JMX%1-$G?:<&Y2P;RB/G%>BO\@2"KX
M%T0N"];V. :ZU-//_[!L_BJ/(VKF_3[M&MFF[2;5>%&83*49-/%H;?Z+GGZC
M]Q\3)%^[_SA:DN15#XJ42/\P&OM\X*!FWAC=EF@)=!N,,"=JT*MR9%8OQ'QP
M:_E1RQTJ2?S=%2]<CYJ!T2T+!^E#UE26#UZ(D?WK+Y)DV?AC,. O^O];]W_K
M_F_=_ZT+U_,?]@?M/HG#HD:'AUVA,QL&^"OYJ1SV*C5"Q<FLJH4#&V;FI%&?
MT#@%J1M\'%R4!MPJ_W]P$/5OB[;$LEZ3PL".C*W(EXRJN'M&>[RNNE4TITK<
MU@A#GM,2T$7[]%AVAA']%IO_A9,7!PE>Y?$Z=F$I\96,AST=CH\J4K;:*W^*
MNH<\R[!U?6T_,&P((K2*0AR;(=MF!^"@1B6[=KQI3#+09%=\Y'VM"K^98Q]S
M[P4#5D;_+(%KIJ0L&) *OCPC_:,$Q"$66Q(;:?=B<F9NQ%Q']V> O#2/:]K)
M( R@R/RC3$<:?CG'<'L" [KR_BSA3C4$Y&& * PXVO[;"\ /G^3G+C?MRMVV
M 10\*''K'4#Y;[:F^5J6[BVERGF^Q]\;P^O_O9&P?]666@(9EFBSRHUFPS]1
MDOF]D,3,2*A7N=IX2+C4_B@?K),W+:L60WDOIOCWM_Z'!BL7 5[X4I[G/5)@
MPHL6(KJUMOKM9N;_K)08M5,PU!^>EY$,6N+5NQY&,-V/H;$_1?/@.##P0+/;
M&CDJR6C<:/?.HCR,G;N+E*7OT65K:C6RNB!$+JS[R57.(=3]<W/2T),7;A-T
MS#M^U'/$R[Y-U-F.\R'\PSO951N%OL-=FH4V;S-F=D#QU2CJAZFGCR(:FR)J
M;$;2D7.KWFW*,(30':_B/%U**1+&WF?^,L0;Y>+A=)=BMSZ7KQC$]7Z=Z>;[
MG2//3KBM# 0H-,G5V7+/F.Z<%Z1&T[-!,TO-ND[SCGVPVCK'A=ZU9A7NP[CV
M&>W7G*8_L?HC5F.*A@&%$FJW6Z?=X+&TO'M7X*]_F4^,>?U5)>?Y?9[&YI\V
M@0NY+U?)N]>\?@TNBMF6B!7_FS+1P@[N4>X(Z=UK?][KOP6#9BW;@Z-@83]N
MHS/+;8F4OZNCF!EMQZ6]_'2G/@2_^3^(+O\S87EWE!6&T40X_56 'ZH+ S*E
M[[ZQ5BMD?^(D?>L0[] _,.N3>&#[[@B4X)-WF54=?G17/3X@$@):GC.308$B
M#\N[47])X+F58!P0"7#U)TC33)*J)FFJD'8CLPJC3J$_:5:+?^RYNEY=R-#V
M:,R7)9LMYN=Y!I0+5X&SPSW4S%V\M2H/*')93L%2<<,UZBRV*1?-CGT7\ &I
M#3MH6@X)83$9U.&5=8\V;EG72(.G@ZHO9^Z3W"%D#9(;%X0!:W'N0!>\Z(:[
MBR3%VUP;]\3B!A5+CB^0=8''"N6<V\2O'F'2OA.!)/PYCB"5X-T#FC3-EJ8
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M95?I/K<=?NH\5(?ZYZ Y:-M0H_]3(O38 .'-F17;2_Z%AXT\ZHL=IM^&L5L
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M%WT1W*=5)RC\M4%3XJCBY;B7&#O;'7(@"%VOZHTD1FTSJRX&E[*H0S6,K^=
MY3GP02>VHM/8?_+%\68:L6^8F+51>J??V59HA>NCM;WOY!SJ3#R!C^ :JAH^
MJ@UFDRE?PZ=]>XY.]J$U6N.=Z&@FW+?-#&@7,:@\/>FFN/KL3-XE2_83E!-/
MM_:< _;G@+!(T_[L;OZ@$K:'+[II13;A;/+LU06"37MV['@X>&G'!18.8MVE
M.DS?S3_\*24ECGHKYD=]V4K_4Q1Q 9__2P]7R"-6?)..PL^&SX&?L_ZFNA?M
M([N3/P#Z-6+VY? ^9$#_K^;?+^@"YDL.GFV+66[.I%]V3_B3>?(!^/ZKO1($
M__)&5[^K8?+*!A[W#[O]N+3PDDSZ3VJ_C<F3IC=]EG0AE?QSN\O 847R1+^&
M0G]_Z;C=U JE6'(M. TOG0Y4##@-I._-&$ZM[M^V:N.K10<)A'XL:,:J(XB6
M8PAS@?6OGC%Y]9,]M0YS@-ADOBUN=K!P[R2]2U>9H";ZX@*1$=#CPT*E8E"4
M/^ZU6#/'7I=#40@9 K+=&=%7_*A2A[@#[$-)I9T*9J8\*M];X'O8EC/;=Y.Q
M^5V#;&K:>SO?1Q)!W#ACG9[JU5C-SRCT7(W,JA;7,I9]WK@ <TF_WIA0HJO'
M7-OE\%5YO;W46,>1Z[;HRQ,O0!G0'_86M80T'!N*M*)'0ZQORH!L MK(%]\D
MB$<66&Y]H2R;QE^K"WG/5?2Z_7ZP#4F2:;4]@'W87P4"OS]1L"_B7RV9UTI7
MB!KKUNY/SGTL)5N'#5I+AE T%?9_4LR+'^),FS8FR1GB<7-3^T)L]D(8#T@^
M;NDI>%]_^O1$="0#6N?>9F,IH1LQ=_CZV&?*LD&_?JN]8>HH)J7PW<)P\>M^
M9SQ[Y+A&9@OC+3^QZM5V+3&66IH*JW135?0SF,D3IW%[S\/#[Y,[B\<GKY8A
MD^[93Q+:^_.AUWT2ONR,2#S<(;JV@$VU#U< IF):1U\>!$WJ6R2@*;82M4#>
M86,$,@^,J9O%PJUK'0)>00*0*$')=KUICG>28-UH"?NZR@!YD(B/4,'M$1<#
MW^OZJ\A0"@OVX:1Y@;[VK)WM'SL/,.\MF>*$[^5"?*T/K4\3[5I75H[5GO.@
M*_W(H>,&^LIJ%8==#J/SSCMH"^T[:W'D%R[ID5>QH8TK,G<Z#![).=FE.\X;
MQ"'DXO!25:&[:FPO))U(&I(P6!RWE$!J*+=&VI$3:'Q-_![UTA;/:"WA[<,]
M49KN,T6W2J]W)-IOCS(9A>X#T:M.RA#=V2ZF("^AI3!A8')_*2J\B745S/_P
M*@P7T^E9O_4PS_OK;R!4-X,UV/;(,/I;Y^7L<ORA:,F=+I(9=FN2V\&]<@=*
M\1J/6A@9J1F"2."?M?<%]\>N^K@.ZO?>']W_\N3Y_;HJL[=3L^Z+3 NU-*R@
MVXC6RG@GJVTX4YNU0@_1@IA=IFI*N+MHF?*PB!@W]U)#U; CAT7R=<SE\?Q-
M-1(9M[NMA+U!5"*G[!9@H+=\8/W[\?@&YYL,<"_'D,A)(0V);*/'7C';/]SQ
M6DWHVJ,IQE83HE@_9AFO^"I9+KLQ"/>Y1A^@W"G_ $<LU;FSY*Q^;(%T@OM=
MD3BTN(B$)(3&T'"<O\5G\@?0FO>9&(V:;"@ -0ZA>RNCK.V^H4S?JL?K>8]B
M$A ;'$0T>2IR,B@AS*(5"86'1BZ<BNZ 1,$SE,1R]@"-]M9^*D*?,R</*3J*
MRI62M3J4$ GUI(_+OECY.J0?#S[I#'&7F$3?H!Z7VBAMKQ.8B-(@9;?$\;";
M V2(^ *L0)4%Z7]H&XMOGF'34[5A'[8"IW6G<)/ER#[*X;%#@.A'K<:A:7'9
M?Y% ?NRV##L$OC\6SX&!T2)5/G9<$XP\DPY/UCVQV;Y2;W4O)Y)6 N,<^UU!
MR,UM?<_'W4A/91'5E:Z>,M1,>NX+#C.;!>:W8&NXV]DSCX%O0AI:3[\T$+!?
ML<>,5M&+T!;+R\GS"#[S:%J53?1=23F+FXH&E]^SKW(52_H-\B/NG0/]@J=W
MHVM87\N@1$6MWR6#+7^)QO[6^YF56V8X7#X'<NE-SH$TQU\E!__:9RSP,^A
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M[CU%U3SI,X@5QO?_[2G!98HH&WV=]\^'@X-@$(?&";?]M<1D 8-$W:I8@)?
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M2]":SX8Y+%0-YNIRSH5OM' [6'Y@MLJ<KL*O(?/_$<'I=X^]<LWP%!YHGX]
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M9C#KB'HZA0[@//HWYZ_^-P_.^<3_ 5!+ 0(4 Q0    ( /B#"54<?>>Q4@L
M ))O   1              "  0    !A=GAL+3(P,C(P-C,P+GAS9%!+ 0(4
M Q0    ( /B#"55*OSDM/@H  !5S   5              "  8$+  !A=GAL
M+3(P,C(P-C,P7V-A;"YX;6Q02P$"% ,4    " #X@PE59"YU'.<4  !Y; $
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M,3!Q+FAT;5!+ 0(4 Q0    ( /B#"55#U[4[?0<  .\J   0
M  "  8^G 0!E,SDT-5]E>#,Q+3$N:'1M4$L! A0#%     @ ^(,)529$^WU[
M!P  O"L  !               ( !.J\! &4S.30U7V5X,S$M,BYH=&U02P$"
M% ,4    " #X@PE5<F A9B8&  !E'P  $               @ 'CM@$ 93,Y
M-#5?97@S,BTQ+FAT;5!+ 0(4 Q0    ( /B#"56+B\0:(&H  $&&   -
M          "  3>] 0!I;6%G95\P,#$N:G!G4$L! A0#%     @ ^(,)5=*U
MV(FF7   _FX   T              ( !@B<" &EM86=E7S P,BYJ<&=02P4&
2      L "P"V @  4X0"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
